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Abstract 
Background: 
Clinical response to therapeutic B-cell depletion by anti-CD20 antibody in rheumatoid arthritis 
(RA) is not associated with robust depletion of disease specific anti-citrullinated protein 
antibodies (ACPA). This suggests pathogenesis mediated predominantly by short-lived antibody 
secreting cells or an antibody independent role of B-cells or both in RA. The persistence of 
ACPA post B-cell depletion is consistent with secretion from long-lived plasma cells (PC) and 
could be linked to non-response to B-cell depletion. The aim of this thesis was to delineate 
populations of B-cells and plasma cells linked to RA disease activity.  
Results: 
Autoreactive citrullinated protein-specific B-cells were detected using ELISA from supernatants 
of B cell culture but not by flow cytometry or ELISpot. RA patients relapsing following B-cell 
depletion showed an increased proportion of a memory B-cell subset in the peripheral blood. 
The in vitro stage of B-cell differentiation closest to this relapse associated subset secreted 
multiple proinflammatory mediators. A novel mode of contact-dependent B-NK cell interaction 
was noted, likely to be due to EBV latency in B-cells or a novel mode of B-cell regulation by NK 
cells. CD19Neg PCs had a longer recovery time following depletion and had a longer life span in 
an in vitro PC differentiation model system but were generated early, which suggests that CD19 
negativity is a marker for potential to be long-lived rather than PC age.  
Conclusions: 
Memory B-cell subset distribution is skewed during clinical relapse in RA which reflects on-going 
B-cell activity/differentiation generating inflammatory mediators or pathogenic short-lived 
antibody secreting cells which explains response to B-cell depletion or anti-TNF therapy. In 
those patients where B-cell depletion does not achieve clinical response, CD19Neg long-lived 
PCs may have a pathogenic role. Agents targeting certain stages of B-cell differentiation or 
long-lived PCs can be therapeutic options in carefully selected patients.  
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1 Glossary 
7-AAD – 7-Amino-actinomycin D 
ABC – Activated B-cell 
ACPA – Anti-Citrullinated Protein/Peptide Antibodies 
ACR – American College of Rheumatology  
ADCC – Antibody-dependant cell-mediated cytotoxicity 
ANA – Anti-nuclear antibody 
APC – Allophycocyanin 
ASC – Antibody-secreting Cell 
BAFF – B-cell Activation Factor 
BCDT – B-cell Depletion Therapy 
BCR – B-cell receptor 
BSA – Bovine Serum Albumin 
CCP – Cyclic Citrullinated Peptide 
CD – Cluster of Differentiation 
CD40L – CD40 Ligand 
CEACAM – Carcino Embryonic Antigen Cell Adhesion Molecule 
CFFCP2 – Chimeric Fibrin-Fillagrin Citrullinated Peptide  
CFFCP2-Mimo/ESP – Chimeric Fibrin-Fillagrin Citrullinated Peptide synthesized by Mimotopes 
or Spanish collaborator 
Cit Fib – Citrullinated Fibrinogen 
CST – Cytometer Setup and Tracking 
CVID – Common Variable Immunodeficiency 
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CV – Coefficient of Variation 
DMARD – Disease Modifying Anti-Rheumatic Drugs 
dsDNA – Anti-double stranded DNA antibodies 
EBNA – EBV Nuclear Antigen 
EBV – Epstein Barr Virus 
EDTA – Ethylenediaminetetraacetic acid  
ELISA – Enzyme-Linked Immunosorbent Assay 
ELISpot – Enzyme-Linked Immunosorbent Spot 
EULAR – European League Against Rheumatism 
FCS – Foetal Calf Serum 
Fib – Fibrinogen  
FITC – Fluorescein isothiocyanate 
GO – Gene Ontology 
HMDS – Haematological Malignancy Diagnostic Service 
ICAM – Intercellular adhesion molecule 
IFN – Interferon  
Ig – Immunoglobulin 
IgA – Immunoglobulin A 
IgD – Immunoglobulin D 
IgG – Immunoglobulin G 
IGHV – Immunoglobulin heavy chain - variable region 
IgM – Immunoglobulin M 
IL – Interleukin 
IMDM – Iscove’s Modified Dulbecco’s Medium 
    21 
 
 
ITIM – Immunoreceptor tyrosine-based inhibitory motif 
LEAF – Low Endotoxin, Azide Free 
LFA – Lymphocyte Function-associated Antigen 
LMP – Latent Membrane Protein 
mAb – Monoclonal antibody 
MALT – Mucosa Associated Lymphoid Tissue 
MCF – Median Channel Fluorescence 
MFI – Mean Fluorescence Intensity 
mRNA – messenger ribonucleic acid 
NK cells – Natural Killer cells 
OD – Optical Density 
PADI – Peptidyl Arginine Deiminase 
PBLM – Plasmablast Like Memory B-cell 
PBS – Phosphate Buffered Saline 
PCR – Polymerase chain reaction 
PCs – Plasma Cells 
PE – Phycoerythrin 
PI – Propidium Iodide 
PMT – Photomultiplier Tube 
QDot – Quantum Dot 
RA – Rheumatoid Arthritis 
RAMB – Relapse-associated memory B-cell subset (CD24Neg CD84Neg CD95Pos LAIR1Neg) 
SDS – Sodium Dodecyl Sulphate 
SLAM – Signalling Lymphocyte Activation Molecule 
    22 
 
 
SYK – Spleen Tyrosine Kinase 
TBE – Tris Borate EDTA buffer 
TMB – Tetramethylbenzidine 
TNF – Tumour Necrosis Factor 
UDMB – Usual-dominant memory B-cell subset (CD24Pos CD84Pos CD95Neg LAIR1Pos) 
XLA – X-linked Agammaglobulinemia 
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2 Background 
Rheumatoid Arthritis (RA) is a chronic inflammatory polyarthritis where the primary target tissue 
within the joint is the synovium. The definitive diagnosis of RA is based on a score of >= 6/10 in 
the ACR-EULAR classification criteria which is based on the number of joints involved, positivity 
for autoantibodies, acute-phase reactants and duration of symptoms (1). 
2.1.1 Epidemiology of RA 
The estimated prevalence of RA is between 0.5-1% from North European and North-American 
studies with a mean annual incidence of 0.02-0.05% (2). RA is considered to be a multifactorial 
disease secondary to interaction between genetic and multiple environmental factors including 
age, sex, ethnicity, socioeconomic status, hormonal, dietary, infections and smoking, all 
considered to increase its risk. HLA-DRB1 genotype (shared epitope) and smoking are the most 
strongly associated risk factors (3). 
2.1.2 Burden on self and society 
RA is the most frequent cause of inflammatory joint pain with a female predominance of 3:1. 
The incidence is highest during the fourth and fifth decades of life (4). It causes severe joint 
pain, restricted functionality and mobility. Up to 40% of the patients lose their job within 5 years 
of disease onset, which is a significant personal economic burden. The health care costs are 
also significantly high in terms of number of hospital visits, time spent in hospitals and treatment 
costs. The recent NRAS report estimates the cost of RA to the UK economy at 8 billion GBP (5). 
There is also slightly increased mortality with a reduction in life span by 3-10 years (6).  
2.1.3 Pathogenesis of RA 
The presence of shared epitope – amino acid motif QKRAA in the HLA-DRB1 region confers 
increased susceptibility to auto-antibody positive RA (7) with a relative risk (RR) of 2.8 (3). The 
risk is enhanced with smoking (RR=7.5), other forms of bronchial injury like silica exposure and 
periodontitis. The peptidyl arginine deiminase enzyme (PADI) family which is released during 
bronchial damage or directly by P.gingivalis converts positively charged arginine residues on 
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self-proteins to neutrally charged citrulline. The recognition of such citrullinated proteins is 
enhanced by the presence of the shared epitope (8).  
Single nucleotide polymorphisms in genes involved in lymphocyte signalling, co-stimulatory 
molecules, transcription factors, cytokines and their receptors have been linked with RA. The 
combination of environmental factors, epigenetic changes and presence of susceptibility genes 
induces post translational modification of self-proteins (citrullination and carbamylation) with 
resultant loss of tolerance to the modified proteins (9).  
The adaptive immune system mounts responses to these modified proteins in the secondary 
lymphoid tissues and localises to the synovium through poorly understood mechanisms and 
initiates synovitis. The synovitis is perpetuated and maintained by positive feedback loops 
involving innate inflammatory cells, cytokines and other soluble pro-inflammatory mediators 
causing tissue damage locally with some systemic effects (8). Studies have shown that the 
inflamed synovial environment directly contributes to this by favouring the development of 
functional ectopic lymphoid structures that support autoantibody production which exacerbates 
disease chronicity (10). 
The genetics of RA and presence of autoantibodies is suggestive of a key adaptive immunity 
component to the pathogenesis. Additionally, the remarkable clinical response to anti-TNF 
agents and anti-IL6 would imply a key role for cytokines and innate immunity. Cytokines also 
have systemic effects like release of acute phase proteins (IL6), cachexia (TNF- α) and 
accelerated vascular disease (11). Thus the clinical manifestations of RA represent a combined 
manifestation of adaptive and innate immune responses. 
 
2.1.4 Role of autoantibodies in RA 
Various autoantibodies have been described in RA and the first RA-associated antibody, 
rheumatoid factor (RF) was identified in 1937 (12). RF causes differential agglutination of 
normal and sensitised sheep RBCs which formed the basis of Rose-Waaler test (13). It was 
later found to be directed against the FC portion of IgG. IgM-RF is the commonly measured 
isotype and depending on the chosen cut-off value has a sensitivity of 60-80% but is limited by 
poor specificity (14). Transiently elevated IgM-RF is part of a normal immune response and 
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elevated RF is seen in a variety of other autoimmune disorders, infections and healthy people 
(15).   
Anti-citrullinated protein antibodies (ACPA) are highly specific (98%) RA associated 
autoantibodies present in two-thirds of patients (16) and can precede disease onset by 4-5 
years or occasionally longer (17). The diagnostic ACPA assays mostly detect IgG isotype using 
cyclized versions of citrullinated peptide (CCP) sequences from various proteins including α–
enolase, vimentin, fillagrin, fibrinogen, collagen and keratin (18). The presence of ACPA 
positivity is associated with more severe disease and joint destruction (19). Therefore, RA could 
be perceived to be an autoantibody driven disease. However, a direct pathogenic role for ACPA 
remains unproven in humans so far as clinical remission is achieved without ACPA depletion 
although induction of ACPA has been shown to cause joint damage in mouse models (20).  
2.1.5 Treatment of RA 
Immunosuppression to down-modulate inflammatory cells and soluble mediators is the main 
stay of treatment for active RA. Disease modifying anti rheumatic drugs (DMARDs) including 
methotrexate (MTx), sulphasalazine, anti-malarial agent hydroxychloroquine and leflunomide 
alone or in combination with or without steroids are used as first-line agents. Anti-TNF agents, 
anti-Il6, B-cell depletion and co-stimulatory blockade in the form of monoclonal antibodies and 
fusion proteins have been used as the next step-up in therapy in case of DMARD failure. All the 
anti-TNF agents and biologic therapy are comparable in efficacy, but the IL-1R antagonist 
Anakinra is less effective (21). 
2.1.6 Therapeutic B-cell depletion for RA 
The clinical response achieved by B-cell depletion with therapeutic monoclonal anti-CD20 
antibody (rituximab) for treatment of DMARD and anti-TNF failures in RA points towards a key 
role for B-lineage cells in the pathogenesis of RA (22). Rituximab directly depletes all B-lineage 
cells except plasmablasts, plasma cells and pre B-cells that do not express CD20.The B-cell 
depletion is mediated through 3 different mechanisms: complement mediated killing by 
activation of classical complement pathway, ADCC (Antibody-dependent cell mediated 
cytotoxicity), direct apoptosis by ligating CD20 (23). However, the mechanism by which B-cell 
depletion improves clinical symptoms remains unclear. ACPA levels decline initially, then 
plateau and continue to persist, and the change in ACPA levels does not predict clinical 
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response (24). This along with correlation of clinical response with B-cell depletion (25) implies 
a key role for B-cells which may or may not be related to the generation of ACPA secreting 
short-lived cells. 
2.1.7 Other B-cell modulating agents for RA 
There are other antibodies under clinical trials targeting pan-B cell molecules including 
anti-CD22 and anti-CD19 for treatment of RA. Belimumab is an antibody targeting the B-cell 
activation factor (BAFF) licensed for lupus and undergoing clinical trials for RA. Tocilizumab, an 
anti-IL6 antibody has been licensed for RA recently and is effective (26). IL-6 is required for 
plasma cell survival and Tocilizumab alters the peripheral blood memory B-cell compartment as 
well (27). Oral small molecules blocking the cytoplasmic tyrosine kinase SYK, which is a 
mediator of immunoreceptor signalling in B-cells, neutrophils, macrophages and mast cells have 
shown significant clinical response compared to placebo (28). Another small molecule targeting 
Janus Kinases (JAK) involved in signal transduction for multiple cytokines has been shown to 
be of comparable efficacy to the anti-TNF monoclonal antibody, Adalimumab for RA (29).  
2.1.8 Rituximab – Mode of action 
The mechanism of action of rituximab in RA and other autoantibody driven autoimmune 
diseases is still poorly understood. Potential mechanisms include: 
• Depletion of pathogenic B-cells that mediate disease in an antibody independent fashion 
which could be antigen-specific secretion of inflammatory cytokines (TNF, IL6 (30)), co-
stimulatory activity, increased antigen presentation or antigen independent. 
• Depletion of short-lived plasmablasts that secrete potentially pathogenic short-lived 
autoantibodies including rheumatoid factor and ACPA and also have some B-cell 
functionalities including cytokine secretion and co-stimulatory activity (31). 
• Depletion of short-lived plasma cells by depleting the B-cells and plasmablasts from 
which they originate. 
• Depletion of non-B lineage cells like sub-populations of T-cells expressing CD20 with 
pro-inflammatory properties (32). 
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2.1.9 RA – Unmet needs   
The response rate for anti-TNF agents is 60-70% and it is similar for rituximab. Recent EULAR 
recommendation advocates the early use of biologic agents (33) and combining biologics with 
DMARDs is more effective than DMARDs alone (34). Anti-TNF agents are preferred for 
seronegative RA, but currently there are no biomarkers to guide the choice between rituximab 
and anti-TNF for seropositive RA. However, it has been noted that use of multiple anti-TNF 
agents prior to rituximab reduces its efficacy (35). Therefore, it would be beneficial to identify 
markers that would predict response to B lineage targeting for seropositive RA. The levels of 
citrullinated protein-specific B-cells might be one such marker in predicting response to BCDT. 
Poor response in the form of early relapse or lack of response to rituximab therapy could be 
secondary to multiple reasons: 
1. Lack of depletion or early return of the pathogenic subset (antigen-specific or antigen 
independent) 
2. Presence of cells which are unaffected by rituximab (CD20 negative plasmablasts or 
plasma cells) 
Various predictors of better response to rituximab prior to commencement of therapy have been 
proposed and include low levels of type1 interferons, circulating BAFF levels and favourable Fcγ 
receptor III genotype (36). Chemokines such as CXCL13 are able to predict return of B-cells 
following B-cell depletion (37) and baseline circulating levels of miRNA-125b predicted good 
response (38). Recent studies have shown the levels of IgM RF, soluble CD23 and serum free 
light chains as markers of plasmablast differentiation correlate with B-cell depletion and 
response (39). One of the best available predictors of response to rituximab is the level of B-cell 
depletion in the initial 2 weeks after the first dose of rituximab. The persistence of plasmablasts 
or B-cells at this time point is a predictor of poor clinical response (25). Relapse is unlikely 
without return of B-cells once clinical response is achieved with B-cell depletion. However, in 
patients who have started regenerating B-cells, the clinical relapse is variable, which might 
theoretically relate to the re-emergence of ACPA-specific clones, but this is unproven. A 
proportion of patients reconstitute with high proportion of plasmablasts, which is likely to be due 
to incomplete depletion and predicts poor response (25). Currently there is no way of predicting 
relapse in the major proportion of patients who reconstitute their B-cell compartment in a 
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physiological manner with predominant naïve and transitional B-cells and low proportion of 
plasmablasts. Some centres have therefore resorted to administering rituximab regularly every 
6 months even though most patients would not have needed any treatment at that point (40). 
2.1.10 B-cell subsets 
Naïve B-cells are generated from the differentiation of B-cell precursors in the bone marrow 
(BM) through an intermediate transitional stage, which can also be seen in peripheral blood. 
Transitional B-cells are the earliest stage of B-cells seen in peripheral blood under physiological 
conditions (41). Naïve B-cells recirculate between peripheral blood and secondary lymphoid 
organs (lymph nodes, spleen, mucosa associated lymphoid tissue (MALT), BM) and die in the 
absence of antigen encounter. When the naïve B-cells recognize an antigen they can respond 
by generating extrafollicular plasmablast foci generating short-lived antibody responses, or in 
the context of a T-dependent cognate interaction start the germinal centre (GC) reaction in the 
secondary lymphoid organs (42). In germinal centres, B-cells express high levels of BCL6, 
undergo multiple rounds of proliferation and somatic hypermutation of rearranged 
immunoglobulin genes (43). This is coupled with antigen-dependent affinity maturation to 
generate memory B-cells and antibody secreting plasmablasts with enhanced affinity for 
antigen, and in some cases class-switched immunoglobulin (44). Plasmablasts migrate to 
survival niches in the BM or MALT and complete differentiation into plasma cells whereas the 
quiescent memory B-cells continue recirculating or migrate to antigen draining tissues.   
During the process of B-cell activation and differentiation distinct combinations of surface 
proteins are regulated by underlying genetic programmes. These allow characterisation of B-cell 
subsets and functional states. The surface marker profile of major subsets is given below:(45) 
• Transitional – CD19PosCD20+CD27-CD38++CD24+ 
• Naïve – CD19PosCD20+CD27-CD38+/- 
• Memory - CD19PosCD20+CD27+CD38+/- 
• Plasmablasts - CD19PosCD20-CD27++CD38++ 
• Plasma cells - CD19Pos/-CD20-CD27++CD38++CD138+ 
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2.1.11 Long-lived plasma cells 
Evidence for the existence of long-lived PCs comes from animal models that have shown 
persistence of antigen-specific PCs in the absence of B-cells (46-48). The presence of long-
lived PCs in humans is supported by the persistence of anti-viral antibodies including small pox 
(49, 50) and also the stable antimicrobial antibody levels in the absence of B-cells following 
therapeutic B-cell depletion for B-lymphoid neoplasms and autoimmune disorders (24). The 
therapeutic anti-CD20 monoclonal antibody rituximab, does not affect PCs since CD20 
expression is lost during differentiation to plasmablasts and plasma cells. The levels of vaccine 
antibodies do not fall after treatment with rituximab where as there is a steep fall in levels of 
rheumatoid factor (24), which are good examples of antibodies secreted by long and short-lived 
PCs respectively. Since, there are no definitive phenotypic markers of short or long-lived PCs, 
identifying PCs secreting vaccine-specific antibodies in the absence of recent vaccination or 
infection is a potential way of identifying a long-lived PC. 
Multiple factors have been described as determinants of PC longevity. Although plasmablasts 
can be generated from naïve, memory, germinal centre, marginal zone or follicular B-cells 
whether all of these heritages could generate long-lived PCs is not known. The nature of signals 
received by these cells in terms of the antigen, T-cell help and TLR stimulus also play a role. 
According to the model described by Radbruch et al., the heritage and instructions determine 
the competence of plasmablasts to become a long lived PC (51).  
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Figure  5.1-1 Competence of becoming a long-lived plasma cell 
Plasmablasts can be generated from naïve, memory, marginal zone, germinal centre or 
follicular B-cells, but whether cells of all heritages can give rise to long-lived PCs is not 
known. This heritage along with instruction in the form of nature of antigen, T-cell help and 
TLR stimulus determines the competence to be a long-lived PC. Pictures of the cells – 
courtesy of Dr.R.Tooze. 
 
The PCs reside in bone marrow niches that support their survival. The niche is constituted by 
molecular components such as SDF1, APRIL, BAFF etc. and cellular components such as 
stromal cells, eosinophils, DCs, neutrophils etc. To maintain the competence once differentiated 
to PCs, they should be able to home to the niche, reside there against competition and respond 
to the niche components (52).     
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Figure  5.1-2 Maintaining competence of long-lived plasma cell 
To maintain the competence of long-lived PC, the cells should be capable to homing to the 
niche, reside there against competition and respond to the niche. Pictures of the cells – 
courtesy of Dr.R.Tooze. 
 
 
2.1.12 In vitro methods for generating plasma cells 
The direct comparison of human and mouse plasma cells is difficult due to significant 
phenotypic differences, such as the lack of CD38 expression in mouse. Investigating the biology 
of human plasma cells in vivo to derive precursor-product relationships and establish lifespans 
is not readily feasible. Furthermore human plasma cells do not survive well in xenotransplant 
models, although these issues have been addressed with some modifications (53).   Multiple in 
vitro model systems have been developed in the past as alternatives. One of the earliest 
developed models developed using CD40L transduced fibroblast established that exposure 
followed by removal of CD40L is essential for PC differentiation (54). Mouse stromal cells and 
IL6 were able to maintain viable plasma cells for short periods (55). Differentiation of B-cells to 
PCs has been achieved with plasmacytoid dendritic cells (DCs) due to their secretion of IFNα 
(56). IL21 was identified as a key cytokine to induce B-cell differentiation to PCs and also class-
switching but not somatic hypermutation (57). TLR9 agonist unmethylated CpG DNA can induce 
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Winter et al. 2012 J Immunol
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PC differentiation of naïve and memory B-cells in the absence of CD40L and BCR stimulus (58). 
A method using a 3-stage process to generate PCs with detailed characterisation has also been 
reported (59). However, none of the methods were able to maintain viable, functional plasma 
cells in vitro long-term. A recently described method uses the key essential factors identified 
from the above methods and is able to generate plasma cells with an estimated potential 
lifespan of 40 years (60).        
2.1.13 Myeloma and long-lived plasma cells 
Intuitively it may be considered that long-lived PCs that are linked to autoimmunity may share 
characteristics with PCs from malignant conditions given the longevity of the latter. Multiple 
myeloma is a monoclonal PC disorder that is preceded by a premalignant condition, monoclonal 
gammopathy of undetermined significance, MGUS. The MGUS PCs share phenotypic and 
genetic abnormalities of myeloma PCs and the key distinguishing factors are the tumour load in 
the bone marrow and end organ damage. Clear progression from the indolent MGUS to 
aggressive myeloma state is demonstrable. The normal counterpart of myeloma PCs is the 
post-GC, long-lived bone marrow PC but the cell of origin for these neoplastic PCs is still not 
completely understood (61, 62). Myeloma PCs subvert the survival factors of normal long-lived 
PCs which depend on bone marrow survival niches (51). While the presence of long-lived PCs 
is supported by observations related to antimicrobrial immunity (50) and also the stable 
antimicrobial antibody levels in the absence of B-cells following therapeutic B-cell depletion for 
B-lymphoid neoplasms and autoimmune disorders (24). However the phenotypic identification of 
this population has remained elusive. Direct evidence for extended PC lifespan in humans is 
lacking. While human PCs with extended lifespan can be generated in vitro (63), the mode of 
maintenance and regulation of long-lived PCs in vivo is not known (64). Animal studies support 
extended lifespans (47, 48) but comparisons are complicated due to the phenotypic differences 
with human PCs such as the lack of CD38 in murine PCs and maintenance of CD19 on many 
but not all human PCs. In vitro systems for generation of human PCs that can survive for 
prolonged periods provide tractable models (63) but cannot fully recapitulate in vivo biology. 
Thus in vivo correlative studies are an essential component of understanding human PC 
biology. 
The PCs in myeloma are characteristically CD19 negative and show aberrant expression of 
CD56, CD45, CD27 and CD38 in addition to their clonality. Normal PCs are predominantly 
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CD19 positive but also include a proportion of CD19 negative polyclonal PCs (65). While the 
normal counterpart of myeloma PCs, the long-lived PC may share some characteristics it is not 
known whether normal CD19Neg PCs share extended similarities with myeloma PCs and how 
they differ from normal CD19Pos PCs.  
2.1.14 B-cell subsets in autoimmunity 
Flow cytometric phenotyping of peripheral blood B-cells has been successfully employed in the 
past to identify markers associated with autoimmune diseases and subsets correlating with 
response. Complement receptor 1&2 have been shown to be down-regulated on B-cells of RA 
and lupus patients (66). In lupus patients, an autoreactive population based on levels of CD19 
expression and CXCR3 has been identified (67).The surface expression and function of 
leucocyte associated Ig like receptor (LAIR) 1 which mediates down modulation of various 
kinases and cell activation via its cytoplasmic tail containing ITIMs has been shown to be 
reduced in lupus B-cells (68). BCDT has helped to identify a previously undescribed late stage 
of transitional B-cells which would have been classified as mature naïve B-cells in the past but 
differ from naïve B-cells in terms of increased CD24 and IgM expression, reduced CD23 
expression and functional immaturity demonstrated by increased apoptosis susceptibility (69). A 
recent study has shown that levels of CD95+ non-class switched memory B-cells is predictive of 
clinical response to rituximab (70). Thus several recent and prior studies point to alterations in 
peripheral blood B-cell populations as a means of identifying disease associated B-cell subsets 
and potential biomarkers of disease activity. 
2.1.15 Identification of antigen-specific B-cells 
The ability to robustly isolate antigen-specific B-lineage cells in RA has considerable potential 
for defining the cellular hierarchy in ACPA production. Identification of Ag-specific cells has 
been technically challenging so far irrespective of the techniques used and one of the main 
reasons is the low frequency of Ag-specific cells (1 in 10000 B-cells) (50). The limiting dilution 
method, which was used to determine the initial frequency of Ag-specific cells, employs 
culturing of serial fold dilution of cells followed by evaluation of the supernatant for secreted 
antibodies by ELISA (71). This method is limited by the inability to phenotype the antigen-
specific B-cells, sensitivity of ELISA, lack of reproducibility and labour intensity. 
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Flow cytometry can also be used to detect Ag-specific cells by using a fluorescent-tagged 
antigen (71). This offers the chance to phenotype the antigen-specific cells using surface 
markers, isolate the cells by sorting for further analysis such as gene expression and 
sequencing the immunoglobulin gene but could be limited by sensitivity issues and non-specific 
binding. ELISpot is another technique where the antibodies secreted by the cells are captured 
on the surface, which are detected with a colorimetric agent as a spot. The number of spots 
roughly equals the number of antibody secreting cells and from the number of input cells, their 
frequency can be calculated. While this technique can be linked to phenotypic characterisation 
of the input cell population, it does not allow the subsequent functional evaluation of the 
secreting cell, unless modified in a fluorescent capture approach. 
Another novel approach employed single cell sorting of B-cells with a chosen phenotype from 
synovial fluid or plasmablasts from peripheral blood of RA patients with active disease and 
sequencing their immunoglobulin gene. The sequence was then re-expressed in a hybridoma 
setting and the secreted antibody was tested for ACPA specificity (72). While this technique 
provides a gold standard definition of antigen specificity linked to a known rearranged 
immunoglobulin gene pair, it is limited by the expertise required for sequencing from single cells 
and the hybridoma setting required to express the immunoglobulin sequence. 
2.1.16 Summary 
Several lines of evidence point to a central role for B-cells and their plasma cell progeny in RA 
pathogenesis. However the definition of disease associated B-cell and plasma cell populations 
is incomplete. The overarching theme of this work was to undertake detailed phenotypic and 
functional characterisation of B-lineage cells associated with relapse and resistance to 
treatment with rituximab in RA, and assess the relationship to ACPA secretion and plasma cell 
longevity to build toward a more comprehensive view of B-cell populations in RA.  
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3 Aims and Hypothesis 
Anti-citrullinated protein antibodies (ACPA) are highly specific (>95%) for diagnosing 
rheumatoid arthritis (RA) and correlate with disease severity. However, the direct pathogenicity 
of ACPA is unproven. Of note, ACPA typically precedes clinical symptoms of RA by a few years. 
Clinical responses in RA are achieved with B-cell depletion, indicating a central role for this 
lineage in RA pathogenesis, but ACPA persists although there may be some reduction in levels. 
This could be suggestive of an antibody independent role for B-cells, which could either be 
antigen-specific or independent of their specificity. Alternatively, short-lived plasma cells and 
plasmablasts or their secreted autoantibodies are pathogenic whereas the long-lived PCs and 
their secreted antibodies are not. Due to their lack of CD20 expression neither PCs nor 
plasmablasts are directly affected by anti-CD20 therapy, however the B-cells giving rise to the 
short-lived cells will be depleted, thus potentially arguing for a more important role for 
plasmablasts and short-lived PCs in disease pathogenesis. 
Hypotheses: 
I. Antigen-specific B-cells correlate better with clinical response than the levels of 
autoantibodies. 
II. Pathogenic B-cells responsible for disease process in RA are enriched within B-cell 
subpopulations as characterised by flow cytometry. 
III. Short-lived and long-lived PCs have different roles in RA pathogenesis.  
The key aims of this work were: 
I. To identify ACPA-specific B-cells to correlate with clinical relapse and response. 
II. To phenotypically characterise the B-cell subsets during clinical relapse following 
rituximab to identify potential pathogenic and/or autoreactive B-lineage cells as markers 
of disease relapse and response to therapy. 
III. Establishing a phenotype for long-lived PCs to assess the nature of PCs generated by 
above B-cell subsets from RA patients. 
IV. To identify functional differences between normal & RA B-cells in generation and 
survival of plasmablasts and plasma cells. 
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4 Overview of Thesis 
RA disease specific ACPA depletion is not required for clinical response and incomplete 
depletion of B-cells is associated with poor clinical response. Therefore, it was hypothesized 
that citrullinated-protein specific B-cells are pathogenic in RA. In the first section of the results 
various methods were employed to detect the citrullinated-protein specific B-cells from 
peripheral blood. Although autoreactive B-cells are unlikely to exhibit a distinct surface 
phenotype, it was hypothesized that the B-cell subsets that are expanded during relapse 
following rituximab are likely to contain the autoreactive cells. The second results chapter 
discusses data from extensive phenotyping of peripheral blood B-cells to identify subsets of B-
cells that are altered during relapse post-rituximab. The third results chapter attempts to define 
the functional role of the subset identified from the B-cell phenotyping such as antigen-
specificity, pro-inflammatory mediator secretion and fluctuation during a normal immune 
response. The fourth chapter describes the unexpected finding of B-cell interaction with other 
cell types particularly NK cells which can have potential relevance to RA pathogenesis and was 
initially observed with RA B-cells. The clinical response to B-cell depletion with maintenance of 
disease specific autoantibodies suggests that pathogenesis could be potentially mediated by 
short-lived antibodies and short-lived PCs that are indirectly depleted. The distinction between 
short- and long-lived PCs is that of a functional one so far and the final chapter aims to identify 
phenotypic markers for long-lived PCs.   
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Figure  5.1-1 Overview of the sections of the thesis 
The first results chapter aims to identify antigen-specific B-cells from peripheral blood. The 
second results chapter describes alterations in B-cell subsets during relapse post-
rituximab which could be due to recruitment of pathogenic B-cells into the synovium or 
egress of pro-inflammatory cells from the joints. The third results chapter evaluates the 
functional role of the subsets identified in the previous chapter such as pro-inflammatory 
mediator secretion. The fourth results chapter describes B-cell interaction with NK cells 
which was an unexpected finding but might have relevance to RA pathogenesis. The final 
results chapter attempts to identify a surface phenotype to distinguish short and long-lived 
PCs which are likely to be differentially involved in RA pathogenesis. CCP – Citrullinated 
protein specific B-cells, B – B-cells, T – T-cells, NK – NK cells and LR1 – LAIR1. 
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5 Materials & Methods 
5.1 Patients and Ethics 
Samples were collected from RA patients managed at Leeds Teaching Hospitals NHS Trust and 
controls after informed written consent and was approved by Leeds (East) Research Ethics 
Committee (Ref: 04/Q1206/107). The use of waste clinical samples at HMDS from anonymous 
patients and controls was approved by the Leeds Teaching Hospitals Research Ethics 
Committee (Ref: 04/Q1107/40). 
The MRC Myeloma IX trial was a multicentre, randomised phase III trial approved by the 
relevant institutional review boards. All patients provided written informed consent. Patients 
included in the analysis received high dose melphalan followed by autologous stem cell rescue. 
The detailed protocol of the trial has been described elsewhere (73). A six-colour panel of 
antibodies was used to analyse the PCs: CD138 APC (Miltenyi Biotec), CD45 APC-Cy7 (BD 
Pharmingen), CD38 PE-Cy7 (BD Pharmingen), and CD19 PerCP-Cy5.5 (BD Pharmingen). 
A series of clinical trial studying the efficacy of Campath-1H for refractory CLL (74-76) were 
approved by the institutional review board and informed written consent was obtained from the 
patients 
5.2 FACS staining 
A volume equivalent of 1 million white cells from peripheral blood or bone marrow aspirate 
collected in EDTA tube was used. The required sample volume was calculated as follows:  
𝑉𝑉𝑉𝑉𝑉𝑉 (µ𝐿) = 1000
𝑊ℎ𝑖𝑖𝑉 𝑐𝑉𝑉𝑉 𝑐𝑉𝑉𝑐𝑖 (× 10^9 𝐿)⁄  
For example, to obtain 1 million leucocytes from a sample with white cell count of 10X109/L, 
100 µL of sample would be required. The sample was treated with 8.6 g/L solution of 
ammonium chloride (Sigma Aldrich) for 10 minutes at 370C to lyse the red blood cells. Then 
cells were washed with 0.1% BSA in Facsflow (BD Biosciences) twice in 15 ml tubes (2000 rpm 
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for 4 minutes). Cells were then transferred to microtitre plates and incubated with the antibody 
cocktail for 20 minutes. For tests using a biotinylated antibody, 10 µL of Streptavidin pacific 
orange (50 µg/ml) (Invitrogen) was added at the end of 20 minutes and incubated for a further 
5minutes. The samples were then washed twice with 0.1% BSA in Facsflow and resuspended in 
300 µL of Facsflow in a tube. 500,000 – 1 million events were acquired on an 8-colour BD FACS 
Canto II or 11-colour LSRII Fortessa.  
FACS Diva (Version 6.2/7, BD Biosciences) was used to analyse the data files. Data was 
analysed using Excel (Microsoft Office 2007/2010) and statistical analysis was performed with 
Graphpad Prism 5/6. Significance of difference in subsets between different patient groups was 
calculated using 1 way ANOVA (Analysis of Variance). 
5.2.1 Antibody titration for flow cytometry 
Antibodies were used at manufacturer recommended concentrations or the concentrations 
validated at the diagnostic HMDS laboratory. For antibodies which are not routinely used in 
HMDS, titration experiments were performed to establish the optimal dilution. In this example, 
CD19 PE-CF594 antibody was tested undiluted, 1 in 5 dilution and doubling dilutions till 
1 in 640. An unstained sample was also included in the dilution series. CD20 antibody was used 
to identify B-cells and the level of fluorescence on B-cells and non-B lymphocytes were 
measured. The aim of titrating the antibodies is not only to achieve the best fluorescence signal 
in the cells of interest but also reduce the levels of non-specific fluorescence in the negative 
population. Signal to Noise ratio was calculated as follows: 
𝑆𝑖𝑆𝑐𝑆𝑉 ∶ 𝑁𝑉𝑖𝑁𝑉 𝑅𝑆𝑖𝑖𝑉 = 𝐶𝐶19 𝑀𝑀𝑀 𝑉𝑜 𝐵 − 𝑐𝑉𝑉𝑉𝑁 
𝐶𝐶19 𝑀𝑀𝑀 𝑉𝑜 𝑐𝑉𝑐 − 𝐵 𝑉𝑙𝑉𝑙ℎ𝑉𝑐𝑙𝑖𝑉𝑁 
The dilution at which the fluorescence of the positive cells intersect the signal to noise ratio i.e, 
the dilution that provides the highest signal to noise ratio with the highest fluorescence was 
chosen. For CD19 PE-CF594 antibody in the example below, the optimal dilution is 1 in 5, which 
is 1 µL. 
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Figure  5.2-1 Titration of antibody for flow cytometry 
Lymphocytes, monocytes (Yellow) and granulocytes (Purple) were gated based on their 
scatter profile and B-cells (Black) based on CD20 positivity. Inverse of the CD20 gate 
defined the non-B lymphocytes (Blue). 
Histograms of B-cells and non-B lymphocytes at undiluted and maximal dilutions shown. 
CD19MFI plotted on the left Y-axis (Circles) and signal to noise ratio on the right Y-axis 
(Squares) with dilutions shown on the X-axis.   
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M
FI
Signal:Noise
Neat 1/5 1/10 1/20 1/40 1/80 1/160 1/320 1/640Unstained
0
2000
4000
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0
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200
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CD19 MFI
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5.2.2 Cell counting 
Absolute cell counts of different lymphocyte subsets were obtained by dual platform 
methodology, the two platforms being – automated haematology cell counter and flow 
cytometer. Cell count of peripheral blood samples was performed on Sysmex K-1000 
automated haematology analyser. This measured various parameters including – haemoglobin, 
platelet count, red cell count and white cell count with percentages and absolute counts of 
neutrophils, lymphocytes and monocytes. The absolute counts of various lymphocyte subsets 
were calculated from the proportion of that subset obtained by flow cytometry with the counts 
generated by sysmex as shown below: 
𝐵 − 𝑐𝑉𝑉𝑉 𝑐𝑉𝑉𝑐𝑖 =  𝐵 − 𝑐𝑉𝑉𝑉𝑁 𝑆𝑁 % 𝑉𝑜 𝑉𝑙𝑉𝑙ℎ𝑉𝑐𝑙𝑖𝑉𝑁 × 𝐿𝑙𝑉𝑙ℎ𝑉𝑐𝑙𝑖𝑉 𝑐𝑉𝑉𝑐𝑖 𝑜𝑓𝑉𝑉 𝑆𝑙𝑁𝑉𝑉𝑆100  
Plasmablasts, naïve and memory and B-cell counts from the diagnostic assay was used where 
available to calculate the absolute count of the B-cell subsets from RA patients. 
For calculating the absolute counts of cells from tissue culture experiments CountBright 
absolute counting beads (Invitrogen) were used. 25 µL of CountBright beads were added to 
300 µL of cell suspension and acquired on the flow cytometer. 5 µL of propidium iodide was 
added few minutes before sample acquisition to exclude dead cells. When the available sample 
volume was less than 300 µL, rest of the volume was substituted with FACSflow. The absolute 
cell count was calculated using the formula below: 
𝐶𝑉𝑐𝑐𝑉𝑐𝑖𝑓𝑆𝑖𝑖𝑉𝑐(𝐶𝑉𝑉𝑉𝑁 µL⁄ ) =  𝑁𝑁.𝑁𝑜 𝐶𝐶𝐶𝐶 𝐸𝐸𝐶𝐸𝐸𝐸
𝑁𝑁.𝑁𝑜 𝐵𝐶𝐵𝐵 𝐸𝐸𝐶𝐸𝐸𝐸 × 𝐴𝐸𝐸𝐴𝐴𝐸𝐶𝐵 𝐵𝐶𝐵𝐵 𝐶𝑁𝐶𝐸𝐸 𝑁𝑜 𝐸ℎ𝐶 𝐶𝑁𝐸 (𝑏𝐶𝐵𝐵𝐸 25⁄ µL)𝑉𝑁𝐶𝐶𝑉𝐶 𝑁𝑜 𝐸𝐵𝑉𝑠𝐶𝐶 (µL)         
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Figure  5.2-2 Gating strategy for cell counts 
The cells were gated based on their scatter profile and dead cells were excluded based on 
propidium iodide positivity. The beads were gated on their positivity in FITC and PE 
channels and bead doublets and triplets were identified based on their forward scatter 
profile. Thus the bead events were verified by both their fluorescence as well as scatter 
profile. 
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5.2.3 Flow cytometry panel for B-lineage cells during in vitro differentiation 
For routine phenotyping of cells from the cell culture experiments, the panel shown in 
Table  5.2-1 with respective isotype controls were used. Non-specific binding was blocked with 
25 μL of blocking buffer (50 μL normal mouse serum, 16.6 μL human IgG and 933 μL of 
0.1% BSA in Facsflow to make 1 ml of blocking buffer) for 10 minutes before the antibody 
staining. Samples were washed with 0.1% BSA in Facsflow and then with annexin binding 
buffer (eBioscience). Samples were re-suspended in 100 μL of annexin binding buffer with 5 μL 
of Annexin-V FITC (eBioscience) along with 5 μL 7AAD (eBioscience) or propidium iodide 
(eBioscience) and incubated in the dark at room temperature for 10 minutes. Further 100 μL of 
annexin binding buffer was added and samples were kept at 40C till they are acquired in the 
flow cytometer.  
 
Table  5.2-1 Antibody cocktail used for flow cytometric phenotyping of B-lineage cells 
during in vitro differentiation 
Antibody cocktails were made up in multiples of 10 and 10 µL of the cocktail was used per 
test.  
 4-colour Cocktail (μL) Isotype Cocktail (μL) 
CD19 PE 20 20 
CD20 eFluor450 25 12.5 
CD38 PE-Cy7 1 10 
CD138 APC 20 30 
0.1% BSA in Facsflow 34 27.5 
Total for 10 Tests 100 100 
 
The gating strategy for classifying the B-lineage cells during in vitro differentiation is shown in 
Figure  5.2-3. Live cells identified based on their scatter profile and annexin V and 7AAD 
negativity were subdivided CD19PosCD20Neg, CD19PosCD20Neg and CD19NegCD20Neg. 
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CD20NegCD38Pos cells were further subdivided into CD19 positive/negative plasma cells/ 
plasmablasts based on their expression of CD19 and CD138 respectively.   
  
Figure  5.2-3 Gating Strategy for classification of B-lineage cells during in vitro B-cell 
differentiation 
Live cells were identified based on their scatter profile and annexin V & 7AAD negativity. 
Live cells were subdivided into CD19 positive (Blue) and CD19&CD20 negative (Purple) 
cells which in turn were classified into plasma cells or plasmablasts based on CD138 
expression. B-cells (Brown) were defined as CD19 and CD20 positive plus CD38 and 
CD138 negative. PB – Plasmablasts, PC – Plasma cell.  
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5.2.4 Plasma cell phenotyping 
A 9-colour panel was used for evaluating surface expression of plasma cells: CD81 FITC (JS-
81, BD Pharmingen), CD28 PE (L293; BD Biosciences), CD19 PerCP-Cy5.5 (SJ25C1; BD 
Biosciences), CD117 PE-Cy7 (104D2; BD Biosciences), CD138 APC (B-B4; Miltenyi), CD38 
AF700 (HIT2; Biolegend), CD45 APC-H7 (2D1; BD Biosciences), CD56 BV421 (HCD56; 
Biolegend) and CD27 BV605 (O323; Biolegend). 
 
Table  5.2-2 Antibody panel for surface phenotyping of plasma cells 
27µL of the above antibody cocktail was used to stain one million cells.  
 
Flurochrome Antigen Volume (µL) 
FITC CD81 5 
PE CD28 5 
PerCp-Cy5.5 CD19 2.5 
PE-Cy7 CD117 5 
APC CD138 1 
AF700 CD38 2.5 
APC-H7 CD45 2.5 
BV421 CD56 1 
BV605 CD27 2.5 
Volume per Test 27 
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Figure  5.2-4 Gating strategy for identifying CD19Pos and CD19Neg plasma cells 
Plasma cells were identified based on the expression of CD38, CD138, CD45 and their 
scatter profile as shown. Cells that met criteria P1, P2 and P3 were designated as plasma 
cells and were divided into 2 subsets based on their CD19 expression. 
 
and and
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A six-color panel of antibodies was used to analyse the PCs from the Myeloma IX trial: CD138 
APC (B-B4; Miltenyi Biotec), CD45 APC-Cy7 (2D1; BD Pharmingen, Oxford, United Kingdom), 
CD38 PE-Cy7 (HIT2; BD Pharmingen), and CD19 PerCP-Cy5.5 (HIB19; BD Pharmingen). 
Plasma cells were gated using CD38/CD138 and scatter profile. The level of CD19 staining by 
CD19Neg lymphocytes was used as threshold for CD19 expression by PCs. 
Plasma cells from Campath trials were analysed retrospectively using markers from the panel 
designed for detection of residual CLL, comprising CD19 PE-Cy5 (FMC63, prepared in-house), 
CD5 APC (UCHT2, prepared in-house), CD20 FITC (B9E9, Coulter) and CD38 PE (HIT2, BD 
Biosciences). Plasma cells were gated using CD38/CD20 and light scatter characteristics and 
the CD19 threshold was set using CD20NegCD5Pos lymphocytes as a negative control. 
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5.2.5 Memory B-cell Phenotyping 
The initial memory B-cell panel consisted of 8 surface markers which included four gating 
markers CD19, CD20, CD27 and CD38 and four markers for subset classification – CD24, 
CD84, CD95 and LAIR1. Subsequently, the antibody cocktail was modified to include IgM and 
IgD to identify class-switched B-cells as shown below. 
  
Table  5.2-3 Antibody cocktails used for memory B-cell phenotyping 
21.5 µL of the version 1 (V1) or 29 µL of version 2 (V2) of the antibody cocktail was used 
to stain one million cells. Residual antibody cocktails left after a week of preparation was 
not used for staining 
Fluorochrome Antigens V1 Volume (µL) V1 Antigens V2 Volume (µL) V2 
FITC CD24 5 CD24 5 
PE CD84 5 CD84 5 
PerCp-Cy5.5 CD38 0.5 CD38 0.5 
PE-Cy7 CD19 1 CD19 1 
AF647/APC CD27 5 IgM 5 
AF700   IgD 5 
APC-H7 CD20 2.5 CD20 2.5 
BV421 CD95 1 CD95 1 
Pacific Orange LAIR1 1.5 LAIR1 1.5 
BV605   CD27 2.5 
Volume per Test 21.5  29 
. 
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Lymphocytes were gated based on their scatter profile. CD19 and CD20 were used to identify 
the B-lineage cells. CD27 and CD38 were used to divide the B-cells into naïve, memory and 
plasmablast subsets. High levels of CD24 and CD38 expression was then used to distinguish 
the transitional B-cells from naïve B-cells. 
 
Figure  5.2-5 Gating strategy for defining B-cell subsets  
Lymphocytes were gated based on their scatter profile and the B-cells were sub-classified 
as follows: Transitional B-cells (Red) – CD19PosCD20+CD27-CD38++CD24+, Naïve B-cells 
(Green) – CD19PosCD20+CD27-CD38+/-, Memory B-cells (Blue) - 
CD19PosCD20+CD27+CD38+/-, Plasmablasts (Purple) - CD19PosCD20-CD27++CD38++ 
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Plasmablasts (24-84-95+LAIR1-) and transitional B-cells (24+84+95-LAIR1+) were used to guide 
positive gating for 24, 84, 95 and LAIR1. With the help of two markers memory B-cells could be 
subdivided into 4 subsets. Each of these four subsets could be further subdivided into four 
subsets each based on the other 2 markers yielding 16 different subsets as shown in 
Figure  5.2-6.    
 
 
Figure  5.2-6 Gating strategy for defining Memory B-cell subsets 
Plasmablasts (in purple) known to be CD24-84-95+LAIR1- and transitional B-cells (in red) 
known to be 24+84+95-LAIR1+ were used to guide the placement of the quadrant gates to 
separate the positive and negative populations for the respective markers 
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5.2.6 Flow cytometry panel for detection of NK cells 
For detection of NK cells and other non-B lineage cells noted during the in vitro differentiation of 
B-cells, an antibody panel was designed that could reliably detect NK cells and also identify B-
cells, terminally differentiated antibody secreting cells which have reduced levels of CD19 
expression and T-cells. A combination of CD16 PE (3G8, BD Pharmingen), CD56 V450 (B159, 
BD Horizon), CD19 V500 (HIB19, BD Horizon), CD27 FITC (M-T271, BD Pharmingen), CD3 
PE-Cy7 (SK7, BD Biosciences), CD4 PerCp-Cy5.5 (SK3, BD Biosciences), CD8 APC (SK7, BD 
Biosciences) and CD45 APC-H7 (2D1, BD Biosciences) was used at the concentrations 
specified below.    
Table  5.2-4 Antibody panel for detection of NK cell expansion during in vitro B-cell 
differentiation 
24.1 µL of the antibody cocktail was used to stain up to one million cells. 
Flurochrome Antigen Volume (µL) 
FITC CD27 5 
PE CD16 0.1 
PerCp-Cy5.5 CD4 5 
PE-Cy7 CD3 1 
APC CD8 0.5 
APC-H7 CD45 2.5 
V450 CD56 5 
V500 CD19 5 
Volume per Test 24.1 
 
 
    52 
 
 
 
Figure  5.2-7 Gating strategy for detection of NK cells 
Lymphocytes were identified based on their scatter profile and further sub-classfication 
was performed based on the following markers as shown in the table:  
• B-lineage: CD19Pos/Wk, CD3Neg CD16Neg CD56 Neg CD4-Neg CD27Pos/Neg 
• NK-cells: CD16/CD56Pos CD3Neg CD19Neg CD4Neg CD27Neg 
• T-cells: CD3Pos CD19Neg CD16Neg CD56Neg 
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5.2.7 Intracellular staining for flow cytometry 
Intracellular staining was performed with BD Intrasure kit (BD Biosciences). Red cells were 
lysed using ammonium chloride and the cells were stained with surface antibodies as above. 
Once surface staining is completed further steps were carried out in FACS tubes. The cell pellet 
was resuspended in 100 µL of reagent A and incubated for 5 minutes in the dark at room 
temperature to fix the surface staining antibodies. 2ml of BD FACS lyse was added and 
incubated for 10 minutes in the dark at room temperature. Cells were pelleted and resuspended 
in 50 µL of reagent B which permeabilises the cell membrane for intracellular staining. 
Fluorochrome conjugated antibodies were added for intracellular staining at this stage and 
incubated for 15 minutes in the dark at room temperature. Cells were washed with 0.1%BSA in 
Facsflow and resuspended in 300 µL of Facsflow in a tube. 500,000 – 1 million events were 
acquired on an 8-colour BD FACS Canto or 11-colour LSRII Fortessa. The fixed and 
permeabilised cells were smaller in size compared to the surface stained cells and therefore the 
gain for forward scatter was adjusted accordingly.      
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For evaluation of intracellular expression of BCL2 and kappa/lambda ratio, surface staining was 
performed with CD95 PE (DX2, BD Pharmingen), CD4 PerCP-Cy5.5 (SK3; BD Biosciences),, 
CD19 PE-Cy7 (SJ25C1; BD Biosciences), CD138 APC (B-B4; Miltenyi), CD38 AF700 (HIT2; 
Biolegend), CD45 APC-H7 (2D1; BD Biosciences), CD56 BV421 (HCD56; Biolegend) and 
CD27 BV605 (O323; Biolegend). 
 
 
Table  5.2-5 Antibody panel for intracellular staining of plasma cells 
The antibodies marked as I/C (Intracellular) were used for intracellular staining after initial 
surface staining with rest of the antibodies in that panel.  
 
Fluorochrome 
Tube 1 Tube 2 
Antigen Volume (µL) Antigen Volume (µL) 
FITC BCL2 (I/C) 2 Lambda (I/C) 5 
PE CD95 5 CD95 5 
PerCp-Cy5.5 CD4 5 CD4 5 
PE-Cy7 CD19 1 CD19 1 
APC CD138 1 CD138 1 
AF700 CD38 2.5 CD38 2.5 
APC-H7 CD45 2.5 CD45 2.5 
BV421/Pacific Blue CD56 1 Kappa (I/C) 1 
BV605 CD27 2.5 CD27 2.5 
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For intracellular stained cells, plasma cells were identified based on the surface expression of 
CD138, CD38 and CD45 as before, and subdivided further based on CD19 expression. 
 
Figure  5.2-8 Gating strategy for evaluation of intracellular antigens expressed by plasma 
cells 
Plasma cells were identified based on the expression of CD38, CD138, CD45 and their 
scatter profile as shown. Cells that met criteria P1, P2 and P3 were designated as plasma 
cells and were divided into 2 subsets based on their CD19 expression. Expression of 
intracellular kappa and lambda light chains by CD19Pos (Blue) and CD19Neg (Purple) 
plasma cells shown. 
and and
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5.2.8 Choice of fluorochrome for antibodies 
The fluorochrome conjugate for the different antibodies were chosen in such a way that rare 
channels were used for the backbone antigens (CD19, CD20, and CD38) and common 
channels like FITC, PE were allocated for rarer antigens. Antigens with high expression levels 
were chosen for conjugates with weaker fluorochromes and vice versa to achieve better 
resolution and reduce the levels of spectral overlap. Consideration was also given to allow for 
key markers to be allocated to a channel with good signal-to-noise ratio. For example, CD27 
resolution is key to identify the major B-cell subsets and therefore placed on a common channel 
although it would occupy the potential space for a rare antigen.  
5.2.9 Flow cytometry quality control 
Polychromatic flow cytometry is a complex technology which requires various components to be 
optimized for reliable measurement of signals from multiple fluorochromes which can have a 
high degree of spectral overlap. Laser output, alignment, laser delay, photomultiplier tube (PMT) 
efficiency and optical filters are key components and need to be monitored regularly. 
Consistency is essential to ensure results are comparable between different samples and the 
same samples at different time points. Flow cytometry could be used to influence clinical 
decisions and therefore results should be precise and accurate. Two main methods were used 
on a daily basis to monitor the performance of the flow cytometer and thereby quality control. 
BD cytometer setup and tracking (CST) beads (BD Biosciences) was used for the automated 
setup and tracking of cytometer performance. It contains equal quantities of dim, midrange and 
bright intensity beads. The dim beads are of 2 micron size and midrange and bright beads are 3 
micron in size.  The beads contain dyes covering the range of excitation and emission 
wavelengths of the cytometer. One drop of the CST bead mixture was added to 350 µL of 
FACSflow and acquired with the CST setup of BD FACSDiva software in the low flow setting. 
The MFI and robust CV of each bead is measured for all detectors in an automated fashion. The 
software calculates the optimal baseline PMT voltage for each channel based on the known 
fluorescence intensity of the beads. This baseline PMT voltage was used for setting up of all the 
experiments. On a day-to-day basis the software tries to adjust the PMT voltage to attain the 
target MFI of the beads and monitors for the change in PMT required to attain the target MFI. 
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When the CV is more than 6% or there is a change in PMT of more than 10% warnings are 
triggered.  
Sphero rainbow calibration particles (Spherotech) were used, which contains mixture of 3µm-
sized beads with 8 different fluorescence intensities. Each bead contains a mixture of 
fluorophores that enable excitation by laser wavelengths between 365nm to 650nm. The Beads 
fluoresce in all channels, which allows monitoring of the entire fluorescence range. One drop of 
the bead mixture was added to 350 µL of FACS buffer and acquired in the low flow setting. 20 
minutes were allowed after switching on the flow cytometer before acquiring the sample. The 
PMT voltage that provided good resolution of the 8 different fluorescence intensities was set as 
baseline for each channel. CV and the MFI values of the highest peak for all the channels were 
monitored on a daily basis. The CV was maintained below 5% and change in MFI of more than 
10% prompted further action. This method was used as a third party control to provide unbiased 
performance assessment and monitoring. 
 
5.2.10 Flow cytometric compensation 
Multiple fluorochromes excited by the same laser can be used in the same experiment. Most 
fluorochromes generate signals of wide wavelength. The signals generated by the 
fluorochromes are filtered to specified wavelength by band pass filters targeting the peak 
wavelengths before detection by photo-multiplier tubes (PMTs). However, since most 
fluorochromes have a wider wavelength spectrum than the respective filters, there is spillage of 
signals to the adjacent detectors. This can be established by running single fluorochrome 
stained samples and measuring the levels of signals detected by the other PMTs. This 
phenomenon is called spectral overlap when the fluorescence of one fluorochrome is detected 
by a detector which is dedicated to measure signal from a different fluorochrome.  
To account for spectral overlap, signals detected from other fluorochromes are subtracted from 
the total signal detected by the PMT and this process is called compensation. This can be done 
in an automated fashion with FACSDiva software by running single stain tubes for all the 
fluorochromes to be used. For non-tandem conjugates like FITC, PE and APC, a generic 
antibody such as CD3 FITC can be used to calculate compensation values and does not require 
separate compensation for the other antibodies conjugated with the same fluorochrome, for 
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example, CD27 FITC or CD45 FITC. However, for tandem conjugates like PE-Cy7 and APC-H7 
separate compensation setup tubes need to be performed for all individual antibodies even if 
they are attached to the same tandem conjugate due to variations in the ratio of components of 
the tandem conjugate. Compensation values are obtained by inverting the measured spectral 
overlap values of all fluorochromes in all detectors by matrix algebra which calculates 
simultaneous contributions of the spectral overlaps of each fluorochrome into every detector 
(77). The software then applies the compensation values to correct contributions from other 
fluorochromes into a given detector. 
New compensation settings were created whenever there was any manipulation of the 
cytometer in the form of servicing of the equipment, changes to laser settings or alignment.  
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5.3 B-cell Selection  
B-cells were purified using memory B-cell isolation kit (Miltenyi), according to manufacturer’s 
instructions which enables purification of untouched B-cells by depletion of non-B lineage cells 
and plasmablasts. The kit contains a cocktail of biotinylated-antibodies against CD2, CD16, 
CD14, CD36, CD43 and CD235a to label T-cells, NK cells, monocytes, dendritic cells, 
granulocytes, platelets and erythroid cells. The labelled cells are depleted by passing through a 
column under a strong magnetic field after secondary labelling with anti-biotin microbeads. 
5.3.1 Isolation of PBMCs by density centrifugation 
• 20- 50 ml peripheral blood was collected in EDTA (EK3) purple tubes or crossmatch pink 
tubes   
• 50 ml of blood was mixed with equal volume of sterile PBS at room temperature  
• 17 ml of Lymphoprep at room temperature was placed into 3 x 50ml Falcon tubes 
• 34 ml of blood/PBS mix was layered on to top of the Lymphoprep (NB: ratio 1 volume 
Lymphoprep to 2 volumes blood/PBS mix) 
• Centrifuged at 2400rpm for 20 minutes at room temperature ~180C (acceleration 5, 
brake 0). 
• The cloudy lymphocyte layer was removed gently with a plastic 3ml pastette (usually 2 
times to get whole layer) and divided between 2  x 50 ml falcon tubes containing 10 ml 
cold PBS. (If the PBS is warm then clumping of sample may be noticed - probably due to 
the platelets. If this is the case then it was passed thru a 70 micron cell strainer at this 
point or later*). 
• The volume was made up to 50 ml in each tube with cold PBS. 
• Centrifuged at 1800rpm for 15 minutes at 40C. 
• PBS was removed with stripette or decanted gently without disturbing the pellet. 
• The cells were combined into one tube and washed with 50 ml cold PBS. (*passed 
through cell sieve if clumpy). 
• Centrifuged at 1500rpm for 10 minutes at 40C. 
• PBS was removed with stripette or decanted gently without disturbing the pellet. 
• Cells were washed with 50 ml PBS at 40C.  
• Centrifuged at 1500rpm for 10 minutes at 40C. 
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• PBS was removed with stripette or decanted gently without disturbing the pellet. 
• Cells were washed with 15 ml ice cold MACS buffer (19 ml MACS rinsing solution + 1 ml 
MACS BSA stock solution). At this point cells were transferred to a 15 ml falcon tube and 
10 µL was removed for counting before spinning. 
• The 10 µL sample for counting was diluted 1:10 in PBS then 1:1 in trypan blue. 
• Centrifuged at 1500rpm for 10 minutes at 40C. 
• MACS buffer was removed with stripette then P1000 tip. 
• The cell pellet was stored on ice until ready to label. 
• Approximately 5-10 x 107 cells were isolated from 50 ml of blood. 
5.3.2 Magnetic labelling of cells 
The following protocol was used for selection with memory B cell isolation kit for 1x 108 cells or 
fewer (scaled up accordingly if greater than 1x108 cells): 
• The cell pellet was resuspended in 400 µl of cold MACS buffer (same as above). 
• 100 µl of the B cell Biotin-Antibody Cocktail was added and mixed well. 
• Incubated for 20 minutes in the door of the fridge (not on ice).  
• 300 µl of cold MACS buffer and 200 µl of Anti-Biotin Microbeads were added and mixed 
well. 
• Incubated for 20-30 minutes in the door of the fridge (not on ice). 
• Cells were washed by adding 10 ml of cold MACS buffer and centrifuged for 10 minutes 
at 1500rpm (whilst doing this step the column for MACS separation was prepared as 
below) 
• The supernatant was completely removed and resuspended in 1 ml cold MACS buffer 
5.3.3 Magnetic separation of cells 
• The LD Column was placed in the magnetic field of a suitable MACS separator. 
• The column was prepared by rinsing with 2 ml of cold MACS buffer. 
• The cell suspension was applied onto the column. 
• The unlabelled cells that pass through were collected in a clean 15 ml falcon tube.  
• The column was washed twice with 1 ml of cold MACS buffer and flow through (effluent) 
was collected in the same tube.  
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• The 15 ml falcon tube now contains a pool of negatively selected (unlabelled) memory 
and naive B cells (total volume approximately 3 ml). 
• The cells were counted with haemocytometer and resuspended in IMDM at the requisite 
concentrations. 
• Approximately 2 – 8 x 106 total B cells (naïve + memory) were isolated from 50 mL of 
blood. 
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5.4 Tissue culture 
24, 48 or 12 well flat-bottomed tissue culture plates (Corning) and IMDM supplemented with 
glutamax (Gibco) and 10% heat-inactivated FBS (HIFBS; Invitrogen) was used for tissue 
culture. For transwell experiments 24 well or 12 well transwell plates (clear polyester 
membrane, 0.4 µm pores, Corning) were used. The B-cells were cultured as per recently 
published protocol which is described below (60).  
5.4.1 Reagents 
The following reagents were used for in vitro studies: 
Cytokines: Human IL-2 (Roche); IL-6, and IFN-α (Sigma); IL-21 (PeproTech).  
Stimulation agents: Goat anti-human F(ab’) 2 fragments (anti-IgM & IgG) (Jackson 
ImmunoResearch). R848 (Mabtech). Histidine-tagged recombinant human CD40L (R&D 
Systems); Monoclonal mouse IgG1 polyhistidine antibody (Clone AD1.1.10, R&D Systems).  
Nutrients: Hybridomax hybridoma growth supplement (Gentaur); Lipid Mixture 1 chemically 
defined (200X) and MEM Amino Acids Solution (50X) (Sigma).  
5.4.2 Preparation of irradiated CD40L (L-cells) 
Day 0 - 1 vial of CD40L L-cells was thawed and seeded in 30 ml of IMDM with 10% HIFBS in a 
T175 flask. 
Day 2 – The cells were trypsinized (6 ml of 1X Trypsin, neutralize with 14 ml of IMDM 
10% HIFBS) and split and seeded in 4 x T175 flasks at a ratio of 1:6 (5 ml of trypsinized cells + 
25 ml of IMDM with 10% HIFBS). 
Day 4 – The cells were trypsinized (6 ml of 1X trypsin, neutralize with 14 ml of IMDM with 10% 
HIFBS) and passed through a cell strainer to avoid clumps into two 50 ml Falcon tubes. 
The cells were counted and resuspended in 40 ml of fresh IMDM with 10% HIFBS in each tube 
at no more than 108 cells per tube. 
The cells in falcon tubes were irradiated on ice twice at 25Gy for 45 minutes with gentle mixing 
in between. 
Two 100 µl samples were tested by FACS (Unstained+anti-CD154) for CD154 expression. 
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The rest of the cells were frozen in aliquots (1.5 x 106/vial) in freezing media (90% IMDM 
10% HIFBS, 10% DMSO). 
Seeding 24 well plates to stimulate B-cells - 1 vial of CD40L L-cells was thawed and washed 
with 10 ml of IMDM with 10% HIFBS. The cells were resuspended in 12 ml of media, and plated 
0.5 ml/well, 24 hours in advance and incubated at 370C. The L-cells adhere to the plate and the 
media can be removed before adding the B-cells for stimulation. 
5.4.3 Preparation of irradiated mouse bone marrow stromal cells (M2-10B4) 
M2-10B4 cells were grown in IMDM with 10% HIFBS in a T175 flask, split 1:10 twice a week 
and used up to passage 30.  
M210B4 were irradiated in a flask when they are between 50-100% confluent at 57Gy for 57 
minutes the day before plasmablast co-culture. 
The media was removed from M210B4 and washed with 10ml of PBS. 
3 ml of trypsin was added and left for 2-5 minutes. 
7 ml media was added and the cells were transferred to 50 ml Falcon tube. 
The cells were washed and plated at 1x106 cells / 24 well plate (0.5 ml media / well). 
The plates were incubated at 370C until plasmablasts were ready. 
M2-10B4 cells adhere to the plate and the media was removed before adding the plasmablasts. 
 
5.4.4 B-cell differentiation of purified B-cells 
The culture conditions for various stages of differentiation are as follows: 
Days 0-3:  For a 24 well plate, B-cells were cultured at 2.5×105/ml with IL-2 (20 U/ml), 
IL-21 (50 ng/ml), F(ab′)2 goat anti-human IgM and IgG (10 μg/ml) on gamma-irradiated CD40L-
expressing L cells (6.25 × 104/well). The number of cells and other reagents were reduced by 
half whilst using a 48 well plate. In experiments using soluble hCD40L, histidine-tagged 
recombinant human CD40L (50 ng/ml) was multimerised with monoclonal mouse IgG1 
polyhistidine antibody (5 µg/ml) before or after adding to the rest of the culture media as 
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specified. In certain experiments, the TLR 7/8 agonist R848 (1 μg/ml) was used instead of 
CD40L stimulus.  
Days 3-6: On day 3 cells were removed from CD40L layer and reseeded into fresh plates at 
1×105/ml in media supplemented with IL-2 (20 U/ml), IL-21 (50 ng/ml), HybridoMax (11 μl/ml), 
Lipid Mixture 1 and MEM amino acids solution (both at 1× final concentration).  
Day 6 onwards: Cells were reseeded into fresh plates at 2.5–5 ×105/ml in media 
supplemented with IL-6 (10 ng/ml), IL-21 (50 ng/ml), IFN-α (100 U/ml), HybridoMax (11 μl/ml), 
Lipid Mixture 1 and MEM amino acids solution (both at 1× final concentration).on gamma-
irradiated M2-10B4 cells (4.16 × 104/well).  
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Figure  5.4-1 In vitro B-cell differentiation – schematic representation 
B-cells are stimulated with BCR stimulus, CD40L and cytokines shown on day 0. Activated 
B-cells generated on day 3 are removed from CD40L and transferred to the shown 
conditions and differentiate to plasmablasts by day 6. With stromal cell and cytokine 
support majority of the plasmablasts mature into plasma cells by day 13. Pictures of the 
cells – courtesy of Dr.R.Tooze. 
Day 0
B-cells
CD40L coat (L-cells)
+ IL-2 + IL-21 + Anti-(Fab’)2 IgG/IgM
Day 3
Activated B-cells
+ IL-2 + IL-21 + Supplements
Day 6
Plasmablasts
Stromal cell (M210B4) coat
+ IL-21 + IL-6 + IFNα + Supplements
Day 13
Plasma Cell
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Long-term culture in transwells: For long-term culture, day 6 cells were seeded at 1.5 
or 3×105/well into the upper chamber of 24 or 12 well transwell plate with the same day 6 
conditions as above. The lower chamber was seeded with gamma-irradiated M2-10B4 cells 
(4.16 × 104/well and 8.32× 104/well for 24 and 12 well plates respectively). IL-21 was withdrawn 
after day 13 and cells were re-fed by replacing half of the volume of media from the lower 
chamber twice a week with fresh media. 
5.4.5 B-cell differentiation of whole PBMCS  
For ELISpot to be used for routine diagnostic purposes, quicker turnaround time and the option 
to use PBMCs rather than selected B-cells is beneficial. Therefore stimulations of B-cells were 
performed according to ELISpot kit manufacturer’s protocol (Mabtech, Sweden) which induces 
antibody secretion in 48-72 hours.  PBMCs separated by density centrifugation were 
resuspended in 24 well plates at 1 million cells per well and stimulated with R848 (1 μg/mL) and 
rhIL2 (10 ng/mL) for 48-72 hours. The cells were then washed and used in ELISpot.  
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5.5 Synthesis of Citrullinated antigens 
5.5.1 Citrullination of fibrinogen 
Citrullinated fibrinogen (CitFib) was synthesized as previously described (10). Briefly, 
plasminogen-depleted human fibrinogen (Calbiochem) was incubated at 0.86mg/ml with 10 
units of rabbit skeletal muscle peptidyl arginine deiminase (PADI) (Sigma-Aldrich) in 0.1 M 
Tris-HCl (pH 7.4), 10 mM CaCl2, and 5 mM DTT for 2 h at 50°C. The reaction was stopped by 
inactivating PADI with 2% sodium dodecyl sulphate (SDS) and heating for 3 minutes at 100°C. 
CitFib was then purified using a 100kDa Amicon filter (Millipore) following manufacturer’s 
instructions. CitFib was then biotinylated using NHS-LC biotin (Pierce Biotechnology) as per kit 
instructions. Human unmodified fibrinogen was also biotinylated to be used as control for CitFib. 
5.5.2 Citrullinated cyclic peptides 
The sequence of the peptides used in the second-generation CCP2 assay, which detects ACPA 
specific for RA is under patent, and not revealed by the manufacturers. It is thought to contain a 
mixture of peptides for improved sensitivity. Dr.Haro’s lab (Unit of Synthesis and Biomedical 
Applications of Peptides IQAC-CSIC, Barcelona, Spain) have synthesized and evaluated a 
series of citrullinated peptide sequences from fibrin and fillagrin for their sensitivity and 
specificity for ACPA detection. From the best available fibrin and fillagrin sequences, a chimeric 
cyclic peptide CFFCP2 (Chimeric Fibrin-Fillagrin Citrullinated Peptide) was synthesized which 
was comparable if not slightly better than the commercial CCP2 diagnostic assay (78). This 
sequence was used to synthesize the peptide commercially (Mimotopes). 
Synthesized CFFCP2 amino acid sequence:  
Biotin-Ahx-HSTKRGHAKSXPVXGHQCHQESTXGRSRGRCGRSGS-acid 
Ahx = Aminohexanoic acid spacer, X = Citrulline, C = Site of cysteine residue used for 
cyclization 
 
Biotinylated and direct Alexafluor647 conjugated versions of the citrullinated and arginine 
peptides synthesized by Dr.Haro’s lab were used for ELISpot and flow cytometry (78). 
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5.6 Flow cytometric sorting of cell subsets 
5.6.1 Plasma cell sorting 
Clinical waste bone marrow samples which had been analysed at the Haematological 
Malignancies Diagnostic Service (HMDS) at Leeds and found to contain no malignant cells were 
chosen. Red blood cell lysis was performed by using 8.6 g/L ammonium chloride solution at a 
ratio of 10 ml for 1 ml of bone marrow. Plasma cells were then enriched in the sample by using 
CD138 microbeads (Miltenyi) following manufacturer’s instructions. The enriched samples were 
stained with CD45 FITC (BD Biosciences), CD38 PE (BD Biosciences) and CD19 PE-Cy7 (BD 
Biosciences). Plasma cells with high expression of CD38 were sorted into CD19hi CD45hi and 
CD19lo CD45lo fractions with a high-speed MoFlo (Beckman Coulter) cell-sorter for further 
analysis.  
 
Figure  5.6-1 Gating strategy for Plasma cell sort 
Bone marrow cells enriched by CD138 microbeads were initially gated on scatter 
properties followed by gating for cells positive for CD38 and weak CD45 to identify plasma 
cells. The PCs were sorted into CD19Pos and CD19Neg fractions.  
 
5.6.2 Sorting of plasmablasts and memory B-cell subsets 
Peripheral blood from patients and controls was subjected to treatment with 8.6 g/L ammonium 
chloride solution for 10 minutes at 370C at ratio of 10 ml per ml of blood. Ammonium chloride 
method was preferred to lymphoprep due to differential size and density of plasmablasts 
rendering them susceptible to loss during the density centrifugation. The cells were then stained 
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with CD19 PE-Cy7(BD Biosciences), CD38 PerCP-Cy5.5 (BD Biosciences), CD20 APC-H7 (BD 
Biosciences), CD24 FITC (BD Biosciences), CD84 PE (BD Biosciences), CD27 AF647(AbD 
Serotec), CD95 BV421 (Biolegend), LAIR1-biotin (Abcam) followed by streptavidin pacific 
orange (Invitrogen) for 10 minutes. The stained cells were sorted on BD influx cell sorter (BD 
Biosciences) platform into 4 fractions – Naïve B-cells, plasmablasts and 2 memory B-cell 
subsets. The sort compensation and setup was performed using BD FACS Sortware.  
 
Figure  5.6-2 Gating strategy for flow sorting plasmablasts and memory B-cell subsets 
Lymphocytes were gated based on their scatter profile and B-cells were defined as CD19 
and CD20 positive. Naïve B-cells (Green) – CD27 negative, Memory B-cells (Blue) – 
CD27 positive, Plasmablasts (Purple) – CD19 positive, CD20 negative, CD27 and CD38 
strong positive were gated subsequently. Memory B-cells were gated into CD24+CD84+, 
CD24-CD84-, CD95+LAIR1- and CD95-LAIR1+ subsets. Two of these gates were 
combined to sort the target memory B-cell subsets. 
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5.7 Next Generation Sequencing 
Next generation sequencing of IGHV@ region from RNA of sorted CD19Neg & CD19Pos PCs was 
performed by Dr.Darren Newton using the Roche 454 GS Junior platform following 
manufacturer’s instructions. RNA was extracted with TRIzol and reverse transcribed using 
Superscript II Reverse Transcriptase (Invitrogen). Ig H chain V (IGHV) regions were amplified 
from the cDNA with proofreading Phusion Flash polymerase (Finnzymes) using modified 
BIOMED-2 primers for framework 1 and common JH (79), with an incorporated 5′ M13 
sequence. Purified amplicons generated by first-round PCR were amplified with a unique MID-
tagged, M13-containing 454 amplicon sequencing primer. Libraries were quantified with Quant-
iT pico-green (Biorad), mixed, and sequenced using the standard Roche 454 GSJunior 
sequencing protocol (GS Junior Titanium Series; Roche Applied Science). Resultant processed, 
split, trimmed data were analyzed using IMGT HighV-Quest software (80). 
5.8 ELISA 
ELISA was performed as per the standard protocol provided by the human IgG ELISA 
quantitation set (Bethyl laboratories, USA). 96 well plates (Nunc) were coated with 100 µl of 
antigen solution at concentration of 10 µg/ml for one hour. Wells coated with buffer alone or 
non-citrullinated version of the peptide were used as controls. The plate was washed and 
incubated with 200 µl of blocking solution (PBS + BSA) overnight at 40C. The wells were 
incubated with 100 µl of plasma or supernatant at described dilutions with appropriate positive 
and negative controls for 1 hour and the bound IgG was detected with anti-human IgG 
conjugated to HRP (Bethyl laboratories, USA). Tetramethylbenzidine (TMB) substrate was used 
for detection and the reaction was stopped with 0.18M H2SO4. The plate was read on a 
spectrometer (Dynex Revelation 4.04) at 450nm and also at 570nm as control.   
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5.9 ELISpot 
ELISpot for antigen-specific B-cells was performed according to the kit protocol (Mabtech, 
Sweden). Briefly, PVDF membrane of the ELISpot plate was activated by 70% ethanol and was 
coated with 100 µl of 15 µg/ml of CFFCP2 or vaccine overnight at 40C. Anti-human IgG or anti-
TNFα at the same concentration was used instead of CFFCP2 for detecting IgG or TNFα 
secreting cells. 200 µl of 10% FCS in IMDM was used for blocking followed by incubation with 
appropriate number of cells up to a maximum of 1 million in 100 µl of 10% FCS in IMDM per 
well. The cells were allowed to secrete for 8-12 hours and then removed by washing. 
Biotinylated anti-human IgG was used to identify secreted IgG and combination of Streptavidin-
HRP and TMB substrate was used to detect the spots. When streptavidin (Invitrogen) was used 
to fix the biotinylated CFFCP2 peptide to the ELISpot plate, direct HRP conjugated anti-IgG 
(Bethyl laboratories, USA) was used. When anti-IgG was used as capture antibody to detect 
ACPA, the biotinylated peptides were used for detection with streptavidin HRP (Biolegend). 
Plates were read with AID Elispot reader version 5.0 (AID GmBH, Germany). 
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5.10 Polymerase chain reaction for detection of EBV 
DNA was extracted using QiAamp DNA blood mini kit columns according to the manufacturer’s 
protocol from day 6 plasmablasts that generated NK expansion. GM12878 and Raji cell lines 
were used as positive controls and HeLa was used as a negative control. 200 µl of sample 
containing 100,000 cells in PBS was added to 20 µl of Qiagen protease in a microcentrifuge 
tube. 200 µl of buffer AL was added and incubated at 560C for 10 minutes after vortexing. 200 µl 
of 96-100% ethanol was added and mixed by vortexing. After each vortexing step, the sample 
was briefly centrifuged to remove droplets from the lid. The mixture was transferred to the 
QIAamp mini spin column in a 2 ml collection tube and centrifuged at 8000rpm for 1min. The 
collection tube with the filtrate was discarded and replaced with a fresh tube. 500 µl of buffer 
AW1 was added and centrifuged again at 8000rpm for 1min. This step was repeated with buffer 
AW2 and the column was placed in a clean microcentrifuge tube after discarding the filtrate. The 
DNA from the column was eluted with distilled water. 
EBNA2 (Epstein Barr Virus Nuclear Antigen) was detected by using nested PCR using the 
primers (Sigma) described before (81). The first round of PCR targets the common region of 
EBNA2 and generated an 801bp product. The product from the first PCR or primary DNA was 
used in the second PCR reaction which included two nested reactions targeting unique regions 
of EBV type 1 and EBV type 2. 
 
Figure  5.10-1 Primers used for EBV EBNA2 PCR 
The primers used for detection of EBV EBNA2 are shown. The first reaction generated 
801bp product and the PCR product generated was used in the second nested reaction 
which generated a 250 or 300bp product depending on the EBV type. 
801bp expected
250bp expected
300bp expected
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1.5 mM and 3.5 mM concentrations of magnesium chloride and annealing temperatures of 
560C, 580C, 600C and 620C were tested. The final reactions were performed with 1.5 mM 
magnesium chloride and annealing temperature of 600C.  
 
Figure  5.10-2 Optimisation of conditions for EBV EBNA2 PCR 
DNA from control day 6 plasmablasts, 2 positive control cell lines (Raji, GM12878) and a 
negative control cell line (HeLa) was tested at 2 different magnesium chloride 
concentrations (1.5 and 3.5 mM – shown at the bottom) and 4 different annealing 
temperatures (560C, 580C, 600C and 620C – shown at the top). The primers used in the 
PCR reaction generated an 801bp product which was run on a 2% agarose gel and the 
PCR products were visualised with Gel Green.   
10 µL of 2X Phusion Flash High-Fidelity master mix (Life Technologies) which contains Phusion 
Flash II DNA polymerase, deoxynucleotides and 2X reaction buffer which includes magnesium 
chloride was used per reaction. Each primer at 0.3 µM final concentration and 100 ng of DNA 
was added to the master mix and water was added to make up 20 µL reaction volume in 0.2 ml 
tubes. Thermocycler (Applied Biosystems) Cycling conditions: First reaction: 980C for 10 sec, 
followed by 35 cycles of 980C for 1 sec, 600C for 5 sec and 720C for 20 sec, followed by 720C 
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for 1 min. Second nested reaction: 980C for 10 sec, followed by 35 cycles of 980C for 1 sec, 
600C for 5 sec and 720C for 10 sec, followed by 720C for 1 min.  
The PCR products were run on 2% agarose gel in TBE and Gel Green (Cambridge 
Biosciences) was used for DNA staining. DNA bands of the appropriate size were excised from 
the agarose gel and purified with Zymoclean gel DNA recovery kit according to the kit protocol. 
Agarose dissolving buffer (ADB) at 3 times the volume of the gel containing DNA was added 
and incubated for 10 minutes at 500C. Once agarose melted, the contents were transferred to a 
Zymo-spin column in a collection tube. The column with collection tube was centrifuged at 
8000rpm for 1 minute and the filtrate was discarded. This step was repeated with DNA wash 
buffer. After discarding the filtrate DNA was eluted into a clean tube using 20 µL of distilled 
water. Sanger sequencing of the PCR product was performed by Source Bioscience, 
Nottingham. 
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6 First Results Chapter: Detection of Antigen-specific B-lineage cells 
Anti-citrullinated protein antibodies (ACPA) are highly specific for RA and correlates with severe 
disease and joint destruction. However, the direct pathogenic role for ACPA is not proven in 
humans and the lack of symptoms in the pre-clinical phase of RA characterised by positive 
ACPA remains unexplained (17). Baseline ACPA titre or drop in ACPA titre following BCDT 
does not correlate with clinical response. Baseline levels of B-lineage cells and their depletion 
have been shown to predict response to therapy. Therefore, the levels of autoreactive B-cells 
could be a better marker of response to and relapse following B-cell depletion for RA. 
Identification of this autoreactive anti-citrullinated protein-specific B-cells would allow direct 
monitoring of the pathogenic process at baseline and follow-up and offer a new mechanism to 
study antigen-specific B-cell dysregulation in RA. Specifically, detection by flow cytometry would 
also allow further phenotypic characterisation, which would shed light on the functional 
properties as well. Although ACPA-specific B-cells are unlikely to have a distinct surface 
phenotype compared to all other B-cells, they are likely to be enriched within subsets of B-cells 
with an activated phenotype particularly during active clinical disease and relapse post-BCDT. If 
ACPA-specific B-cells can be identified by surface phenotype with commercially available 
antibodies, that would allow better standardisation of the assay, since standardisation of 
antigens for universal access is much more complicated. The ultimate aim of this study to 
identify the autoreactive B-cells is to use it as a biomarker of response to B-cell depletion and 
predict relapse following rituximab. 
If the frequency of antigen-specific cells is too low to be reliably detected by flow cytometry, in 
vitro expansion to generate PCs could be employed followed by a technique to detect antigen-
specific plasma cells. ELISA allows quantification of ACPA secreted by PCs and ELISPot allows 
numerical enumeration of the ACPA secreting cells. Developing the technique to identify the 
antigen specificity of PCs could also be useful in differentiating short and long-lived PCs since 
RA pathogenesis is likely to be mediated by short-lived plasmablasts and PCs. There might also 
be a pathogenic role for long-lived PCs in a proportion of RA patients who fail to respond even 
after total B-cell depletion and in other autoimmune conditions. In the absence of recent 
vaccination or infection, vaccine specific antibodies are secreted by long-lived PCs and this fact 
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can be exploited for their identification. The purpose of the work presented in this chapter was 
therefore to address these interlinked questions. 
 
Antigens used in commercial assays for detection of ACPA are not readily available. The 
citrullinated proteins cannot be generated by recombinant protein expression methodologies 
since citrulline is a non-standard amino acid which is not incorporated into proteins during 
protein synthesis as it is not encoded in the genome. The in vivo citrullinated proteins are 
derived from post-translational modification and can be generated in vitro by enzymatic 
citrullination of proteins. The alternative is to chemically synthesize peptides from the 
sequences available in the public domain, similar to the peptides used in commercially available 
ELISA for ACPA detection. The citrullinated fibrinogen synthesized in-house (as described in 
methods section  5.5.1) and commercially synthesized CFFCP2 peptide were initially evaluated 
by ELISA as shown in Table  6.1-1. The sensitivity of citrullinated fibrinogen was lower than that 
of the CFFCP2 peptide. ACPA can be directed against multiple other citrullinated proteins such 
as vimentin, enolase and fillagrin. The peptide contains an epitope that is common between 
multiple proteins and therefore likely to have a wider detection range. Due to the lower 
sensitivity and the multiple quality control steps required when every single batch of the protein 
is citrullinated and biotinylated, the synthetic peptides were preferred. The commercially 
synthesized CFFCP2-Mimo peptide gave a false positive result for one of the samples tested. 
Therefore, a series of ACPA negative samples from patients with other autoantibody positive 
conditions were tested with the peptide. Samples which were positive for certain autoantibodies 
such as anti-dsDNA showed a higher degree of non-specific binding as seen in Table  6.1-2. The 
CFFCP2-Mimo peptide identified all the 13 ACPA negative samples. 
After the sensitivity and specificity of the CFFCP2 peptide was established, it was tested by flow 
cytometry by using streptavidin-pacific orange for detection. The streptavidin-pacific orange was 
used after the cells were exposed to the peptide and was also tried by pre-incubation with the 
peptide before exposure to the cells. The peptide was used in excess to ensure adequate 
tetramerisation. Non-specific binding was observed when streptavidin-pacific orange without 
peptide was used as a negative control. The non-specific binding could be due to streptavidin or 
pacific orange.  
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To avoid this non-specific binding, directly fluorochrome-tagged peptides were obtained from 
Dr.Haro’s lab for testing by flow cytometry. When tested by ELISA, the sensitivity and specificity 
of the peptide was not affected by flurochrome (AF647) tagging, lyophilisation for long-term 
storage or indirect binding of the biotinylated peptide to the ELISA plate with streptavidin 
(Figure  6.2-3). There were a higher proportion of positive B-cells by flow cytometry in the ACPA 
negative patient compared to ACPA positive RA patients, which is suggestive of non-specific 
binding by the AF647 tagged peptide (Figure  6.2-4). This was also apparent when the AF647 
tagged citrullinated and arginine versions of the peptide were tested in parallel as they showed 
similar proportions of positive cells. A similar level of positivity was noted with lower 
concentration of the AF647 tagged peptide which suggests that the non-specific binding was not 
concentration related (Figure  6.2-5).  
The lack of citrullinated protein specific B-cells could be multifactorial. ACPA specific B-cells can 
be detected from peripheral blood as proven by ELISA from culture supernatants (Table  6.3-1) 
but their frequency can be variable as evidenced by the lack of detection in a significant 
proportion of the samples. The frequency of antigen specific B-cells could be below the level of 
detection by flow cytometry since it is reported to be 1 in 10000 during steady state for vaccine 
antigens (50). The frequency could be higher during an active immune response due to 
expansion of the antigen-specific cells or reduced due to their recruitment to secondary and 
tertiary lymphoid organs depending on the stage of the immune response. To assess this 
further, samples from bone marrow and synovium of RA patients with active disease have to be 
analysed. Bone marrow sampling and synovial biopsy require expertise and although low, 
carries a higher risk of complications compared to peripheral blood sampling. It also causes 
significant morbidity to the patients. The results cannot be reliably interpreted in the absence of 
a positive control. If detection of antigen-specific cells requires bone marrow or synovial tissue 
sampling it will preclude the use of the assay as a routine biomarker to predict response and 
relapse. However a technical explanation such as the possibility of non-specific binding masking 
the underlying specific binding cannot be entirely excluded. The non-specific binding could be 
peptide or flurochrome related or a combination of both.  
Simple tetramerisation of the peptide with streptavidin was not effective for flow cytometric 
detection of the antigen-specific cells (Figure  6.2-1). However this concept has been 
demonstrated in mice to be efficient in detecting antigen-specific B-cells after multiple 
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modifications (82). This method utilises pre-enrichment for B-cells to improve the sensitivity and 
titration to identify the optimal concentration where the unbound peptide is minimal. Steps were 
also included in that study (82)to remove unbound peptides and peptide-free streptavidin and 
pre-incubation with unconjugated streptavidin was used to prevent non-specific binding to 
streptavidin. Although these methodologies can be performed, they require multiple validation 
steps and requires considerable time and expertise to setup. This would not be easily 
transferable to a robust diagnostic assay. The method ultimately required sequencing of the 
immunoglobulin genes of the positive cells and their re-expression to synthesize 
immunoglobulins to prove their specificity. This methodology requires considerable expertise 
which was not available locally and requires setting up. Therefore, flow cytometric detection was 
not pursued further and other methods of detection of antigen-specific B-cells were sought. 
ELISpot was pursued as an alternative method for detecting citrullinated protein specific B-cells 
since the antigen is likely to be in a similar conformation to ELISA. In vivo generated antibody 
secreting cells can be directly assayed for their antigen specificity. Antigen-specific B-cells from 
the periphery can be expanded in vitro and the antibody secreting cells generated can be 
assayed thereby providing an option to circumvent their low frequency. The ELISpot technique 
was validated by detection of IgG and vaccine specific antibodies by plasma cells (Figure  6.3-1). 
ACPA secretion by PCs generated in vitro from RA patients B-cells was not detectable by 
ELISpot using two different biotinylated CFFCP peptides (Figure  6.3-2). For this assay to be 
useful in the clinical setting it has to have a lower turnaround time and be less resource 
intensive. Since the standard B-cell differentiation protocol requires 10 to 14 days to generate 
plasma cells and also requires B-cell purification, other alternatives were sought that can be 
quicker and would not require cell selection strategies. The ELISpot kit protocol recommends 24 
– 48 hour culture of PBMCs with R848 and IL2 to generate antibody secreting cells (described 
in detail in methods section  5.4.4). ACPA secretion by the antibody secreting cells generated by 
this shortened protocol was not detectable by ELISpot (Figure  6.3-3). The citrullinated peptides 
were also tried as detection agents by capturing the secreted IgG with anti-IgG on the ELISpot 
plate. When tested for the presence of peptides bound to the ELISpot plates using an ELISA 
type technique, IgG was detectable but not ACPA from positive control serum. This raises the 
possibility of lack of binding of the peptide to the ELISpot plate. This could potentially be 
circumvented by using streptavidin to attach the peptides to the ELISpot plate. Analysis of the 
supernatants by ELISA revealed ACPA secretion by one out of the three RA patient samples in 
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each of the above two experiments (Table  6.3-1). This confirms the presence of citrullinated 
protein specific B-cells in the peripheral blood but their frequency is quite variable as evidenced 
by the lack of ACPA secretion in 4/6 samples.       
The key issue that affected optimal quality control of the flow cytometry and ELISpot assays 
was the lack of a positive control. Dr.Malmstrom’s group have sorted class-switched memory B-
cells from synovium of active RA patients and generated monoclonal ACPA secreting cells (72). 
Such hybridoma cells can provide an ideal positive control. The other option is to EBV transform 
B-cells from RA patients to immortalise them and continue maintaining colonies that exhibit the 
appropriate antigen specificity. Robinson’s lab at Stanford school of Medicine have generated 
citrullinated peptide tetramers which have been used to flow cytometrically sort B-cells. They 
have proven the sorted B-cells to be citrullinated protein specific by re-expression of the 
immunoglobulin mRNA (Verbal communication 2015). In a collaborative project Robinson’s lab 
have agreed to provide samples of the peptide tetramers for evaluation of putative autoreactive 
B-cells by flow cytometry.    
In summary, this chapter describes the various methodologies that were employed to identify 
the citrullinated protein specific B-lineage cells that are likely to play a key role in RA 
pathogenesis.  
6.1 Generation and evaluation of antigens for ACPA detection 
Antigens used in the commercial second generation CCP assay (CCP2) are not readily 
available due to patent restrictions. Therefore citrullinated fibrinogen was synthesized in house. 
The PADI enzyme used for citrullination is not cost-effective since it is able to citrullinate only 
small quantities of fibrinogen. Therefore attempts were made to synthesize peptides similar to 
CCP2 which has better sensitivity than fibrinogen. A biotinylated version of CFFCP2 was 
synthesized commercially by Mimotopes and non-biotinylated CFFCP2 was provided by 
Dr.Haro’s lab in Spain. Further direct fluorochrome labelled, biotinylated and non-biotinylated 
versions of the citrullinated and arginine peptides were synthesized by Dr.Haro’s lab.  
6.1.1 ELISA of commercial CFFCP2 & citrullinated fibrinogen 
Eight patient samples including 4 high positives (>300), 2 negatives (<0.5) and 2 moderate 
positives (50-100) were assayed on a diagnostic platform (Immunocap, Phadia). These samples 
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were used to compare commercially synthesized CFFCP2 (CFFCP2-Mimo) and CFFCP2 
obtained from the collaborator (CFFCP2-Esp) by ELISA. The same samples were used to verify 
the in vitro citrullination of fibrinogen performed in house using previously described technique 
(10). Blank wells coated with buffer were used as negative controls for the peptides and non-
citrullinated fibrinogen was used for citrullinated fibrinogen. ELISA was performed according to 
the kit protocol (Bethyl laboratories, USA) as described in detail in the methods section  5.8. 
Both peptides were comparable in their optical density (OD) values for all the samples except 
one. Although, the citrullinated fibrinogen was quite specific and identified both negatives, the 
sensitivity was 83.3% of the commercial CCP2 assay and missed a strong positive sample. 
Therefore, citrullinated fibrinogen has lower sensitivity compared to the chimeric peptide.  
    81 
 
 
 
Table  6.1-1 Comparison of 2 Cyclic citrullinated peptides and citrullinated fibrinogen 
The CCP value was determined by a commercial diagnostic assay for the 8 RA samples 
and the values are given in arbitrary units determined by the manufacturer (Immunocap, 
Phadia). CFFCP2-ESP is the synthetic peptide obtained from our collaborator in Spain 
(Dr.Haro’s lab) and CFFCP2-Mimo is the commercially synthesized peptide. Avg OD is the 
average of the duplicates in ELISA. Binding to the blank well (Blank OD) was used to 
account for non-specific binding for the CFFCP2 and non-citrullinated fibrinogen (Fib) was 
used for the citrullinated fibrinogen (Cit Fib). The biotinylated versions of the proteins and 
peptides were tested in this ELISA since those were the versions to be used in flow 
cytometry. a) Raw ELISA data from the samples. b) Average optical density with the 
baseline signal subtracted. 
 
 Sample 
 
CCP Value 
(Units/mL) 
CFFCP2 - ESP 
(Avg OD – Blank) 
CFFCP2 - Mimo 
(Avg OD – Blank) 
Biot Cit Fib 
(Avg OD – Fib) 
1/100 RA1 >300 3.03 3.03 1.01 
1/100 RA2 >300 2.90 2.88 1.46 
1/100 RA3 >300 2.79 2.97 0.70 
1/100 RA4 >300 2.48 2.54 -0.02 
1/100 RA5 <0.5 0.18 0.29 -0.05 
1/100 RA6 <0.5 -0.18 1.10 -0.17 
1/100 RA7 59 1.13 1.40 0.27 
1/100 RA8 95.9 2.61 2.81 0.16 
.  
a)
b)
CCP Value
1/100 RA1 >300 0.202 0.228 3.236 3.251 3.299 3.186 1.296 1.265 0.28 0.268
1/100 RA2 >300 0.245 0.247 3.156 3.128 3.182 3.076 1.789 1.812 0.349 0.34
1/100 RA3 >300 0.104 0.097 2.811 2.971 3.108 3.027 0.855 0.834 0.149 0.144
1/100 RA4 >300 0.594 0.606 3.073 3.092 3.189 3.091 0.66 0.653 0.635 0.71
1/100 RA5 <0.5 0.532 0.579 0.734 0.744 0.855 0.839 0.523 0.502 0.575 0.559
1/100 RA6 <0.5 0.653 0.659 0.472 0.474 1.756 1.749 0.513 0.502 0.683 0.669
1/100 RA7 59 0.127 0.11 1.302 1.193 1.535 1.502 0.45 0.42 0.163 0.165
1/100 RA8 95.9 0.262 0.434 2.989 2.92 3.214 3.094 0.479 0.456 0.317 0.302
Biot FibrinBuffer CFFCP2-ESP CFFCP2-Mimo Biot Cit Fib
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6.1.2 Evaluation of negative controls for CFFCP2 ELISA 
There was disparity between the two peptides in identifying a known negative sample with 
commercially synthesized Mimo peptide showing false-positivity. Therefore further negative 
samples from different clinical settings were chosen to evaluate the CFFCP2-Mimo further. 
ELISA was perfomed according to the kit protocol (Bethyl laboratories, USA) as described in 
detail in the methods section  5.8. Anti-nuclear antibody (ANA) negative samples had a lower 
OD value compared to ANA positive samples since they are less likely to have other 
autoantibodies and proteins with non-specific binding. Anti-dsDNA antibodies in particular 
caused higher non-specific binding whereas Anti-Ro antibodies were less so. The CFFCP2-
Mimo was less sensitive towards the lower end of the reference range.  
Table  6.1-2 Evaluation of specificity of the citrullinated peptide CFFCP2-Mimo 
Luminex value was determined by a commercial diagnostic assay (BioRad) for the RA 
samples and the values are expressed in arbitrary units/ml. Levels above 3 are considered 
positive. OD-Blank was calculated as the difference in average of optical density of the 
wells coated with CFFCP2 and blank wells. ND = Not done, ANA = Anti-nuclear antibody, 
dsDNA = Anti-double stranded DNA antibodies, Ro = Anti-Ro52 antibodies. 
 
Sample OD-Blank Luminex value
Diluent 0.008 0.007 0.013 0.015 0.0065 N/A
RA 1 0.159 0.159 3.361 3.326 3.1845 >300
RA 5 0.584 0.586 0.853 0.839 0.261 <0.5
RA 8 0.141 0.148 2.831 2.807 2.6745 95.9
RA 9 0.192 0.191 0.283 0.317 0.1085 <0.5 ANA ND
RA 10 0.092 0.092 0.165 0.168 0.0745 <0.5 GP Sample
RA 11 0.074 0.068 0.139 0.129 0.063 <0.5
RA 15 0.093 0.087 0.124 0.123 0.0335 <0.5 ANA Neg
RA 16 0.107 0.097 0.131 0.13 0.0285 <0.5 GP Sample
RA 17 0.13 0.124 0.127 0.125 -0.001 <0.5
RA 21 0.089 0.089 0.152 0.148 0.061 <0.5 ANA Neg
RA 22 0.132 0.135 0.162 0.168 0.0315 <0.5 Clinic
RA 23 0.171 0.167 0.364 0.364 0.195 <0.5 dsDNA 
RA 24 0.294 0.271 0.485 0.464 0.192 <0.5 Pos
RA 25 0.216 0.224 0.276 0.293 0.0645 <0.5
RA 26 0.125 0.14 0.32 0.304 0.1795 <0.5 Ro Pos
RA 27 0.265 0.297 0.289 0.307 0.017 <0.5
RA 28 0.225 0.233 0.22 0.238 0 14.2
RA 29 0.133 0.138 1.161 1.291 1.0905 26.2
RA 30 0.173 0.173 0.374 0.399 0.2135 8.5
Blank Coat OD OD
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The lower sensitivity of CFFCP2-Mimo peptide could be peptide dependent or sample 
dependent. Patients with higher ACPA titre possibly have a wider coverage of epitopes whereas 
those with lower titres may have a restricted repertoire, which is not covered by the peptide.  
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6.2 Detection of antigen-specific B-cells by flow cytometry 
Flow cytometry can be used as a quick tool to identify cell populations of interest. If ACPA-
specific B-cells can be identified by FACS, it would allow easy monitoring and quantification of 
their levels in peripheral blood and could present a biomarker to predict relapse and response to 
therapy. This would also allow for further functional evaluation of these cells following flow 
sorting.   
6.2.1 CCP-specific B-cells were not detectable by FACS using citrullinated 
fibrinogen or commercially synthesized CFFCP2 peptide 
PBMCs from 2 RA patients with active disease and 1 RA patient relapsing after rituximab who 
were all known ACPA positive were selected along with a control sample. The relapsing 
patient’s peripheral blood contained only plasmablasts from the B-lineage. The PBMCs were 
surface stained with CD19 PE-Cy7, CD20 APC-H7, CD38 PerCP-Cy5.5, CD27 AF647 and then 
prepared with intrasure (BD Biosciences) for intracellular staining. 5 μg of biotinylated-CFFCP2 
peptide (1 mg/ml) was incubated for 20 minutes and 0.05 μg of Streptavidin-Pacific orange (10μl 
of 50 μg/ml) was added or pre-incubated mixture of CCP/ Streptavidin-Pacific orange was used. 
Streptavidin-Pacific orange without CCP was used as a negative control. No positive staining 
was detected by either method with intracellular staining. The molecular mass of the biotinylated 
peptide is 4224 g/mol. Therefore, 5 μg contains (5 μg) / (4224 g/mol) X 6.022 X 1023 molecules. 
The exact molecular mass of streptavidin pacific orange is not provided by the manufacturer but 
similar flurochrome-tagged streptavidin’s molecular mass is 60000 g/mol. Therefore, 0.05 μg 
contains (0.05 μg) / (60000 g/mol) X 6.022 X 1023 molecules. Streptavidin has four biotin binding 
sites and the peptide was in excess to saturate all the binding sites.     
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Figure  6.2-1 Intracellular staining with CCP  
Patients 1&2 are active RA patients with no previous BCDT; patient 3 was relapsing post-
BCDT with predominantly plasmablasts. For “CCP then tag” the cells were incubated with 
5 μg of the biotinylated peptide before adding 0.05 μg of the Streptavidin pacific orange 
tag. For “Pre-tag CCP”, the cells were incubated with pre-mixed peptide (5 μg) and 
streptavidin pacific orange (0.05 μg). For negative control streptavidin pacific orange 
without the peptide was used. B-cells were defined based on their scatter profile and 
CD19 and CD20 dual positivity. The level of CD27 expression was used to subclassify B-
cells into naïve (Green) and memory (Blue). Plasmablasts (Purple) were gated based on 
their scatter profile, CD19PosCD20NegCD27Hi and CD38Hi. 
  
Patient 1 Patient 2 Patient 3 Control
CCP then
tag
Pre-tag
CCP
Neg
Control
    86 
 
 
For surface staining, 5 μg of biotinylated-CFFCP2 peptide was added at the same time as other 
surface staining antibodies followed by 0.05 μg Streptavidin-Pacific orange or the pre-incubated 
biotinylated-CFFCP2 (5 μg) / Streptavidin-Pacific orange (0.05 μg) mixture. Streptavidin-Pacific 
orange without any CFFCP2 used as a negative control showed equivalent or higher binding 
than with CFFCP2 in the 2 RA patients with active disease. The presence of CCP-binding to 
surface of plasmablasts is likely to be non-specific since there was no binding detected by 
intracellular staining. The non-specific binding was worse with pre-tagging the peptide with 
Streptavidin-Pacific orange. 
 
Figure  6.2-2 Surface staining with CCP 
Patients 1&2 are active RA patients with no previous BCDT; patient 3 was relapsing post-
BCDT with predominantly plasmablasts. For “CCP then tag” the cells were incubated with 
5 μg of the peptide before adding 0.05 μg of the Streptavidin pacific orange tag. For “Pre-
tag CCP”, the cells were incubated with pre-mixed peptide (5 μg) and streptavidin pacific 
orange (0.05 μg). For negative control streptavidin pacific orange without the peptide was 
used. CCP positive cells shown as a percentage of total B-cells. B-cells were defined 
based on their scatter profile and CD19 and CD20 dual positivity. The level of CD27 
expression was used to subclassify B-cells into naïve (Green) and memory (Blue). 
Plasmablasts (Purple) were gated based on their scatter profile, CD19PosCD20NegCD27Hi 
and CD38Hi. 
0.5% 0.7% 12.8% 0.7%
Patient 1 Patient 2 Patient 3 Control
5.3% 3.4% 7.4% 1.1%
3.5% 3.5% 30.8% 3.2%
CCP then
tag
Pre-tag
CCP
Neg
Control
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6.2.2 Detection of CCP-specific B-cells using fluorochrome-tagged CFFCP2 
peptide 
CFFCP2 peptide directly conjugated with the fluorochrome AF647 was synthesized by Dr.Isabel 
Haro’s lab in Spain. The detailed methodology for synthesizing the peptide has been previously 
described (78). The peptide was also generated with biotin tag to allow for a choice of 
conjugates and can also be used in ELISA. Non-citrullinated versions of the peptide with native 
arginine instead of the citrulline were also generated to be used as negative controls. The 
CFFCP2-AF647 peptide was validated by ELISA before using it for flow cytometry. The 
biotinylated peptides were bound to the ELISA plate with a streptavidin coat to test whether this 
additional protein binding interferes with the binding of the peptide when used in other 
methodologies like FACS and ELISpot. Serum from RA patients with very high levels, moderate 
levels and no ACPA were used as controls along with commercially sourced positive and 
negative controls used in the diagnostic laboratory. ELISA was performed according to the kit 
protocol (Bethyl laboratories, USA) as described in detail in the methods section  5.8. The optical 
density values (OD) of non-citrullinated version (Arg-CFFCP2) was subtracted from those 
obtained with the citrullinated version to calculate the final OD shown in Figure  6.2-3. Results 
obtained with AF647 conjugated CFFCP2 peptide was satisfactory for all the controls and 
correlated with those obtained with streptavidin-tagged CFFCP2 peptide. The OD for AF647 
tagged CFFCP2 was lower which is likely to be due to the inherent fluorescence of AF647. The 
peptide solution was aliquoted and lyophilised for long-term storage. The lyophilisation process, 
fluorochrome tagging or streptavidin binding did not affect the sensitivity or specificity of the 
peptide for ELISA.  
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Figure  6.2-3 ELISA of AF647 fluorochrome and streptavidin-tagged CFFCP2 peptide 
Optical density values obtained by subtracting the arginine peptide values from the 
citrullinated peptide are shown. Commercially available positive and negative ACPA 
controls and samples from RA patients were used. The values in brackets are arbitrary 
units of level of ACPA antibodies detected on a diagnostic platform (Unicap). 
Peripheral blood mononuclear cells from 4 RA patients with active disease, one patient stable 
on anti-TNF and one SLE patient were stained with 5 μg of CFFCP2-AF647 and 5 μg of 
biotinylated Arg-CFFCP2 + 0.05 μg streptavidin pacific orange. The arginine peptide served as 
a negative control to exclude non-specific binding to the peptide. Therefore, cells which were 
positive for both peptides were excluded as false-positives. 1-2% of the B-cells from the RA 
patients showed positive staining with CFFCP2-AF647. The lupus patient whose serum had 
been tested to be negative for ACPA had the highest proportion of positive B-cells (2%). The 
positive staining noted therefore is likely to be non-specific. 80% of the CFFCP2 positive B-cells 
were IgD positive in all samples except the SLE patient which was 75%. This reflects the higher 
non-specific binding by naïve B-cells rather than presence of higher proportion of autoreactive 
B-cells within the naïve B-cell compartment.  
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Figure  6.2-4 Detection of citrullinated protein-specific B-cells by flow cytometry 
Lymphocytes (grey) were gated based on their scatter profile and B-cells (black) were 
identified by their expression of CD19. Intensity of staining with the citrullinated peptide is 
represented on the X-axis and the native arginine peptide on the y-axis. Cycle number of 
rituximab therapy for the active RA patients is given. The SLE patient was ACPA negative. 
CCP positive B-cells as a percentage of total B-cells shown.  
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Since there was high degree of non-specific binding with the fluorochrome-tagged peptide, cells 
were stained with increasing dilutions of the peptide. There was little change in the proportion of 
positive cells between 5 and 0.5 µg concentrations. 
 
Figure  6.2-5 Titration of the AF647-tagged citrullinated peptide 
Lymphocytes (grey) were gated based on their scatter profile and B-cells (black) were 
identified by their expression of CD19. Intensity of staining with the citrullinated or arginine 
versions of the cyclic peptides tagged with AF647 is represented on the X-axis. 
Biotinylated version of the arginine peptide with streptavidin pacific orange as the 
fluorochrome was used as additional negative control and is represented along the y-axis. 
CCP positive B-cells represented as percentage of total B-cells.   
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One of the active RA patient’s samples with positive ACPA was stained with citrullinated and the 
arginine versions of the direct AF647 tagged peptide to assess the specificity. Both versions of 
the peptide showed similar levels of positivity in B-cells as shown in Figure  6.2-6. The non-
specific binding could be due to the fluorochrome conjugate or directed against other amino 
acids in the cyclic peptide. 
 
 
Figure  6.2-6 Non-specific binding by the AF647-tagged citrullinated peptide 
Lymphocytes (grey) were gated based on their scatter profile and B-cells (black) were 
identified by their expression of CD19. Intensity of staining with the citrullinated or arginine 
versions of the cyclic peptides tagged with AF647 is represented on the X-axis. 
Biotinylated version of the arginine peptide with streptavidin pacific orange as the 
fluorochrome was used as additional negative control and is represented along the y-axis.   
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Citrullinated fibrinogen and the CFFCP2 peptides were able to identify ACPA by ELISA. 
Modifications to the peptide in terms of biotinylation, direct fluorochrome tagging and 
biotin-streptavidin tag did not interfere with its activity in ELISA. The cyclic citrullinated peptides 
were not reliable in detecting CCP-specific B-cells by flow cytometry. It is possible that the 
peptides are not sufficiently sensitive to detect the CCP-specific B-cells at all, and the staining 
seen was non-specific. Alternatively, the peptides might need binding to a solid phase for their 
optimal conformational state for binding and being in liquid phase when used in flow cytometry 
is suboptimal. The autoreactive B-cells might have higher degree of non-specific binding limiting 
their detection. The high degree of non-specific binding by the peptides could be related to 
folding pattern, ionic or hydrophobic interactions. Unfortunately, a positive control for flow 
cytometry is not available which makes quality control of the assay challenging. Due to these 
issues, flow cytometric detection of CCP-specific B-cells was not pursued further. The only 
definitive way to confirm the detection of autoreactive cells by this assay is to single cell sort the 
positive B-cells, sequence the whole immunoglobulin gene and re-express in a hybridoma (83). 
The immunoglobulin secreted could then be analysed for ACPA. However this highly technical 
process was not established locally, and was not pursued as an option in this work. 
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6.3 Detection of antigen-specific B-cells by ELISpot 
The detection of antigen-specific B-cells by flow cytometry was unsuccessful and therefore 
alternative techniques were sought. One such technique is ELISpot which is more sensitive than 
ELISA. ELISpot also allows for quantification, and the frequency of secreting cells can be 
calculated from the input cell numbers. However, it does not allow selection of cells for further 
analysis although novel techniques using photodegradable hydrogels have been developed to 
capture the secreting cells (84). ELISpot can be used to define the antigen specificity of 
peripheral blood antibody secreting cells like plasmablasts or bone marrow plasma cells. 
Alternatively, B-cells can be expanded and differentiated in vitro to generate antibody secreting 
cells and assayed by ELISpot. If B-cells predominating during relapse can be identified based 
on surface phenotype, they can be sorted by flow cytometry and antibody secreting cells 
generated in vitro could be assayed. 
6.3.1 ELISpot for detection of vaccine specific plasma cells 
To establish the technical ability to detect antigen specific B-cells by ELISpot, plasma cells 
enriched by CD138 magnetic beads (Miltenyi) from clinical waste bone marrow samples were 
tested for secretion of antibodies against two vaccines. In the absence of recent vaccination or 
infection, the vaccine specificity is also a useful marker of long-lived PCs. Trivalent vaccine 
Revaxis (Diphtheria, Polio, Tetanus) and pentavalent vaccine Pediacell (Diphtheria, Polio, 
Tetanus, Pertussis, Haemophilus Influenzae type b) were coated onto the ELISpot plates at 15 
mg/ml. Blank wells and CFFCP coated wells were used as negative controls whilst anti-IgG 
coated wells were used as positive controls. The spots were developed as described in the 
methods section  5.9. The positive control IgG spots were discrete when numbers of cells plated 
were optimal as in the case of control in vitro derived plasma cells and BM PCs1. When the 
number of cells is higher, the spots tend to merge in BM PCs 2 and 3 as shown in Figure  6.3-1. 
There were more spots in the pentavalent vaccine wells for BM PCs 2 and 3 compared to the 
trivalent vaccine wells (10 Vs 7 and 20 Vs 12) as expected in triplicates. There were no spots 
seen in the uncoated wells, which excludes non-specific binding. 
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Figure  6.3-1 ELISpot for vaccine-specific plasma cells 
In vitro generated PCs (Using protocol described in Figure  5.4-1) from a control (Row 1) 
and magnetically selected CD138 positive PCs from surplus bone marrow samples of 
patients (Rows 2-4) investigated for haematological malignancies were incubated for 8 
hours. The spots were detected with anti-IgG biotin and streptavidin HRP (as described in 
the methods section  5.9). The labels at the top represent the primary coating of the well 
and the labels on the side represent the samples added. The average number of spots in 
triplicates is shown in the graph for the 4 samples. Revaxis - Trivalent vaccine (Diphtheria, 
Polio, Tetanus), Pediacell - Pentavalent vaccine (Diphtheria, Polio, Tetanus, Pertussis, 
Haemophilus Influenzae type b). These findings demonstrate ability to detect antigen-
specific PCs.  
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6.3.2 ELISpot for CCP-specific plasma cells 
Peripheral blood B-cells from one healthy control and 3 ACPA+ RA patients were differentiated 
using standard protocol as shown in Figure  5.4-1. An alternative condition using TLR 7/8 
agonist R848 instead of CD40L stimulus was also included. The rest of the culture conditions 
remained the same. The cells differentiated into plasmablasts by day 6 and on day 10 consisted 
of a mixture of plasmablasts and plasma cells. These day 10 cells were plated on to ELISpot 
plates coated with the citrullinated peptides as shown in Figure  6.3-2 and incubated for 8 hours. 
The spots were detected with anti-IgG and streptavidin-HRP as described in methods 
section  5.9. IgG secretion was detected in all samples but there was no evidence of ACPA 
secretion in any of the samples by ELISpot. The supernatants were tested for ACPA by ELISA 
and only RA2012 was positive. CCP coated beads used in the diagnostic assay (Biorad) was 
also tried as the capture agent by coating it on the plate which did not detect ACPA secretion 
either. 
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Figure  6.3-2 ELISpot for ACPA secretion by day 10 in vitro differentiated PCs 
Peripheral blood B-cells from 1 control and 3 ACPA positive RA patients (Serum positive) 
were differentiated in vitro to antibody secreting cells by day 10 (Using protocol described 
in Figure  5.4-1)  and were incubated for eight hours in the plate at 370C. The labels at the 
top represent the primary coating of the well and the labels on the side represent the 
samples added. The labels at the bottom denote the detection reagents used. Only 
supernatant of RA2012 was positive by ELISA. 
The above protocol involves B-cell selection and change of culture conditions twice after the 
initial setup to generate plasma cells which takes 10 to 13 days in total. So, alternative 
methodologies which can use PBMCs that require less time and manipulation were sought. One 
such methodology described in the ELISpot kit protocol was used to generate antibody 
secreting cells. PBMCs from 1 control and 3 ACPA-positive RA patients were stimulated with 
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R848 and IL2 using the ELISpot kit protocol (Mabtech) (as described in methods section  5.4.5) 
and the generated antibody secreting cells on day 6 were incubated for eight hours in the plate 
at 370C.. The spots were developed as described in the methods section  5.9. The control and 
RA0513 showed some spots (not obvious in the picture below) but the corresponding uncoated 
wells also showed spots and therefore non-specific binding could not be ruled out. Biotinylated 
CFFCP2 was tried as a detection agent on captured IgG (columns 1 and 2) which did not detect 
ACPA either. In the bottom 4 rows instead of cells, plasma isolated on day 0 was used to detect 
IgG and ACPA similar to the ELISA technique. IgG was detectable from plasma with anti-IgG 
coat (columns 3,4) but ACPA was not detected by CFFCP coat (columns 5,6). This is 
suggestive of a lack of binding of CFFCP to the ELISpot plate. 
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Figure  6.3-3 ELISpot for ACPA-specific PCs with day 6 TLR stimulated PBMCs  
Peripheral blood mononuclear cells from a control and 3 ACPA+ RA patients stimulated 
with TLR agonist R848 and IL2 (as described in methods section  5.4.5) and tested on day 
6 when differentiation to antibody secreting cells has occurred. The cells were incubated 
for eight hours in the plate at 370C and spots were developed as described in the methods 
section  5.9. The labels at the top represent the primary coating of the well and the labels 
on the side represent the samples added. The labels at the bottom represent the sample 
added to the bottom 4 rows. In the first 2 columns of the bottom 4 rows biotinylated 
CFFCP2 was used for detection instead of anti-IgG biotin.   
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6.3.3 In vitro ACPA secretion by peripheral blood B-cells from RA patients  
B-cells from 3 ACPA positive RA patients and a control were cultured under standard protocol 
using BCR and CD40L stimulus as shown in Figure  5.4-1. When the undiluted supernatants 
were tested by ELISA (as described in methods section  5.8), there was detectable ACPA on 
day 6 and day 10 in one out of the three patients. In a separate experiment PBMCs from 3 
ACPA positive RA patients and a control were stimulated with IL2 and R848, a TLR7 agonist as 
described in methods section  5.4.5. On day 6 ACPA was detected from the supernatant in one 
out of the three patients. However ACPA secreting cells were not detectable with these samples 
when tested by ELISpot as seen in Figure  6.3-2 and Figure  6.3-3. The in vitro secretion of 
ACPA did not correlate with serum ACPA titre or disease activity within these samples.  
Table  6.3-1 Secretion of ACPA by peripheral blood B-cells in vitro and corresponding 
clinical details 
The top half of first table shows data from supernatant derived from B-cells differentiated 
using the B-cell receptor/CD40L stimulus (Figure  5.4-1). The bottom half shows data from 
supernatant derived from PBMCs cultured using toll-like receptor stimulus (R848 1 µg/ml) 
(Methods section  5.4.5). The second table shows the clinical details of the RA patients. 
The samples showing in vitro ACPA secretion are highlighted. MTx – Methotrexate, HCQ 
– Hydroxychloroquine, SSZ – Sulphasalazine, Depomed – Depomedrone, Pred – 
Prednisolone. 
 
  
0.68 0.69 0.02 0.02 0.02 0.02 0.05 0.05 0.23 0.18 D2626
1.92 1.90 0.00 0.01 0.00 0.01 0.03 0.03 3.30 3.35 RA0420
0.61 0.59 0.04 0.04 0.04 0.02 0.04 0.04 0.40 0.43 RA1317
2.11 2.16 0.02 0.03 0.87 0.84 1.00 0.95 3.38 3.28 RA2012
2.10 2.13 0.03 0.03 0.02 0.02 0.01 0.00 0.05 0.06 D2005
2.00 2.10 0.04 0.04 0.10 0.10 0.08 0.08 3.12 3.11 RA0513
2.14 2.07 0.01 0.02 0.31 0.31 0.00 0.01 3.12 3.11 RA0803
0.86 0.78 0.08 0.08 0.02 0.04 0.02 0.00 2.10 2.06 RA1318
PBMC/TLR
Day 6 1/100 Day 6 Neat Day 6 Neat Day 3 Neat Day 0 Plasma 1/100
Day 10 1/100 Day 10 Neat Day 10 Neat Day 6 Neat Day 0 Plasma 1/100
BCR/CD40L/B-cell
OD
IgG Buffer CFFCP2-ESP
Age Active Disease Medn CRP ESR WCC CCP RF
RA1317 62/F Yes MTx, HCQ, SSZ 31 50 9.88 15 23
RA0420 35/M Yes Depomed 5 7 5.02 >300 Neg
RA2012 57/F Yes MTx, Pred 5 8.68 340 213
RA0803 63/F No MTx, HCQ 5 19 8.59 340 166
RA1318 54/F No MTx, Pred 12 44 5.23 312 Ro, La Pos. dsDNA-70
RA0513 40/F Rx started 1/12 earlier MTx, Depomed 23 31 9.74 142
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6.4 Summary and discussion 
The sensitivity and specificity of the antigen peptide (CFFCP2) for detecting citrullinated protein-
specific cells was comparable to the diagnostic CCP2 assay when tested by ELISA. The 
citrullinated fibrinogen generated in house although specific, had lower sensitivity and therefore 
was not pursued further. It was not possible to detect antigen-specific cells by flow cytometry 
due to low sensitivity and non-specific binding. An improved approach utilizing tetrameric 
antigen, may however make this feasible in the future (82). ELISpot detected vaccine specific 
PCs, but ACPA-secreting cells were not detected, possibly due to lack of CFFCP binding to the 
ELISpot plate. Trying the peptide as a probe or attaching it indirectly to the plate could 
circumvent this lack of binding.  
The detection of ACPA from PBMC culture supernatant could be attributed to direct secretion of 
ACPA by peripheral blood plasmablasts. However, ACPA was detected in the supernatant when 
purified B-cells were differentiated to antibody secreting cells. The negative selection kit used 
for purifying B-cells depletes plasmablasts and therefore ACPA is likely to be derived from in 
vitro differentiated antibody secreting cells generated from peripheral blood B-cells. This 
confirms the presence of citrullinated protein-specific B-cells in the peripheral blood. It was 
interesting to note that ACPA secretion by ELISA was not demonstrable in 4 out of 6 RA 
peripheral blood samples tested, the reasons for which could be multi-factorial. Although the 
frequency of citrullinated protein-specific B-cells is not known, for vaccine antigens it is 
estimated to be 1 in 10000 (50) which is likely to be a significant limiting factor for their 
detection. The sensitivity of ELISA is possibly not adequate for ACPA detection from 
supernatants and it is not known whether co-secretion of RF or other proteins in the supernatant 
can affect ACPA detection. Recently published study demonstrated in vitro secretion of ACPA 
only after five-fold concentration of the supernatants which resulted in decreased specificity as 
evidenced by detection of ACPA from healthy donor culture supernatants (85). Citrullinated 
protein-specific B-cells could be recruited to secondary lymphoid structures and synovium which 
can reduce their frequency in peripheral blood. Therefore, the lack of ACPA detection from 
supernatants is likely to be due to technical limitations and other variables rather than absence 
of citrullinated protein-specific B-cells. 
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The detection of long-lived PCs by their antigen specificity is complicated by the vast array of 
potential antigen specificities that may need to be considered. The vaccine specific PCs when 
identified by ELISpot cannot be isolated for further phenotypic or gene expression analysis. A 
technique combining laser capture microdissection and a fluorophore for detection could make 
the isolation of ELISpot positive cells possible. However, if the long-lived PCs can be 
characterised phenotypically by other methods such as flow cytometry, ELISpot can then be 
used for detecting vaccine-specific PCs within the subset which would confirm their long life 
span.    
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7 Second Results Chapter: Phenotypic characterisation of cells 
associated with RA relapse post rituximab therapy 
B-cell depletion therapy in RA has re-invigorated research into the autoimmune mechanisms in 
RA particularly mediated by B-lineage cells. The initial aim of work in this chapter was to identify 
the broad B-cell subset (naïve, memory or plasmablast) that is most likely to contain the 
pathogenic population, which might then be further sub-classified with additional markers to 
improve specificity. An increased proportion of a certain subset selectively during relapse would 
be suggestive of its role in pathogenesis, and this clinical context was therefore the major focus 
of subsequent study. Since antigen specific B-cells were difficult to identify directly by flow 
cytometry from the whole B-cell population, it was reasoned that identification of a relapse 
associated and thus potentially pathogenic B-cell subset would facilitate the identification of 
antigen specific B-cells. Previous studies done in Leeds had shown strong correlation of 
baseline plasmablasts with clinical response and that persistence of plasmablasts 2 weeks post-
rituximab predicted poor clinical response (25, 86). Therefore, initial attempts were targeted 
towards identifying subsets amongst plasmablasts. 
Patients treated with rituximab had a higher proportion of naïve B-cells and reduced absolute 
numbers of all the 3 tested subsets – naïve, memory and plasmablasts (Figure  6.4-1). This was 
likely to be due to the direct effect of B-cell depletion by rituximab rather than secondary to the 
process. Therefore, it was hypothesized that the major subsets needed further subclassification 
to identify differential proportions in relapsing patients. Since the pathogenic B-cells can 
potentially be present in any of the three major B-cell subsets – naïve, memory or plasmablasts 
all the three were sub-classified into 4 further subsets based on expression of IgM and LAIR1 
(naïve and memory) or CD138 and LAIR1 (plasmablasts). This revealed heterogeneity within all 
the 3 tested B-cell subsets. However, only the heterogeneity within memory B-cells was 
significantly different in relapsing patients which cannot be explained by the direct B-cell 
depleting effect of rituximab (Figure  6.4-2). The significant differential heterogeneity was due to 
expansion of LAIR1 negative cells within the memory B-cells. However, if the LAIR1 negative 
cells were analysed as a proportion of total B-cells, this differential level within the relapsing 
patients was not evident Figure  6.4-3. Therefore, memory B-cells were pursued as the subset 
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with differential expansion of subpopulations during RA relapse post-rituximab containing 
potentially pathogenic cells.  
As noted above the major subsets were quite heterogeneous and therefore the plan was to sub-
classify memory B-cells into as many populations as possible by flow cytometry which can then 
be merged if necessary depending on subsequent clinical correlation. 34 markers which are 
expressed on the surface of B-lineage cells that are likely to indicate an active immune 
response such as activation markers, costimulatory and regulatory molecules, cytokine and 
chemokine receptors and markers associated with stages of B-cell life cycle were assessed. 
The markers which were expressed by between 90% and 10% of the memory B-cells were 
deemed to be heterogeneous (Figure  6.4-4). 19 out of the 34 surface markers were 
heterogeneously distributed and considered for further analysis. Due to technical limitations the 
number of markers that can be used was restricted to four. LAIR1 was already demonstrated to 
be of clinical relevance and three other markers - CD24, CD84 and CD95 which do not have a 
similar surface expression profile to any of the other selected markers were chosen.  
When the memory B-cells were analysed for the concomitant expression of these four surface 
markers, 16 subsets could be defined as shown in Figure  6.4-6. The subset distribution pattern 
in RA patients relapsing post-rituximab was distinct compared to other patient groups and 
controls. The dominant memory B-cell subset was CD24-CD84-CD95+LAIR1- in patients 
relapsing post-rituximab whereas it was the polar opposite CD24+CD84+CD95-LAIR1+ subset in 
the other patient groups as shown in Figure  6.4-7. The proportion of CD24-CD84-CD95+LAIR1- 
was significantly elevated in patients relapsing post-rituximab compared to controls, rituximab 
naïve patients with active disease and patients in remission with biologics. This increase in 
proportion was not seen during B-cell reconstitution in other conditions where B-cells are 
therapeutically depleted such as B-cell neoplasms and campath pre-renal transplant 
(Figure  6.4-8). The absolute number of cells is usually the preferred index since proportions can 
be skewed by increase in the subset of interest or decrease in the other subsets. However, in 
patients relapsing post-rituximab, the B-cell numbers are reduced due to the depletion of B-cells 
and therefore exhibit lower absolute count of all the subsets. Therefore, the absolute counts are 
not comparable with other patient groups who were not exposed to rituximab (Figure  6.4-10). 
The above dataset contained only 3 patients who were in remission post-rituximab. The clinical 
review of patients receiving rituximab therapy is setup in such a way that they are reviewed only 
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if they have clinical symptoms. Therefore, it was difficult to capture the cohort of patients who 
are in remission post-rituximab. Further efforts were made to collect samples from patients who 
were more than 6 months since the last dose of rituximab. This revealed that patients who were 
in remission did not exhibit skewing of the memory B-cell subset distribution but could be 
skewed by other intercurrent illnesses (Error! Reference source not found.).             
Further evaluation of this CD24-CD84-CD95+LAIR1- memory B-cell subset was performed to 
understand the functional relevance of these cells in the RA disease process. The initial 
assessment was that of their immunoglobulin isotype which revealed that this subset of memory 
B-cells were predominantly class-switched whereas the polar opposite usually dominant 
CD24+CD84+CD95-LAIR1+ subset was predominantly of the IgM/IgD isotype (Figure  6.4-11). 
The surface phenotype of this relapse associated memory B-cell subset was compared with 
plasmablasts, since persistence of plasmablasts were shown to be predictive of poor response 
to rituximab in previous work done in Leeds (25). The plasmablasts were similar in terms of 
CD24, CD84, CD95 and LAIR1 expression but lack CD20 and express very high levels of CD38 
compared to memory B-cells (Figure  6.4-12). From sequential monitoring of the surface 
expression, CD24, CD84 and LAIR1 expression is lost and CD95 is gained following activation 
of B-cells before they differentiate to plasmablasts (Figure  8.2-1 ). Therefore, it was 
hypothesized that these cells could be in the stage of transition to plasmablasts. However, by 
definition plasmablasts are antibody secreting cells and also express CD38 but lack CD20 and 
therefore different. Results from further functional evaluation of these cells are discussed in the 
next chapter.     
In summary, this chapter describes the classification of B-cells into broader subsets followed by 
further subclassification to identify cell populations that are elevated during clinical relapse and 
are likely to be related to RA pathogenesis. 
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7.1.1 Identifying candidate B-cell subsets 
BCDT provides an excellent opportunity to study autoreactive B-lineage cells since the 
population which preferentially expands during relapse after depletion is likely to contain 
pathogenic cells. 12 patients who were relapsing after rituximab therapy were chosen along with 
7 rituximab naïve RA patients with active disease and 21 disease controls. CD19, CD20, CD27 
and CD38 were used to classify the B-cells into 3 broad subsets – naïve, memory B-cells and 
plasmablasts. IgM and LAIR1 identified four further subsets each in naïve and memory B-cells 
and for plasmablasts CD138 was used instead of IgM. Transitional B-cells were not separated 
from naïve B-cells in this analysis. 
Patients treated with rituximab were found to have lower total number of B-cells and an 
associated reduction in the absolute numbers of all subsets as seen in Figure  6.4-1. This makes 
the comparison of the absolute numbers of different subsets between patient groups inaccurate. 
The relative change in proportion of a subset is more comparable and an increase of a 
particular subset in the context of clinical relapse would suggest a possible role in pathogenesis.  
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Figure  6.4-1 Proportion and absolute numbers of naïve, memory and plasmablasts in 
controls, active rituximab-naïve RA and patients relapsing post-rituximab 
The dots represent individual patients and the bars represent median with 25th and 75th 
centiles. Figure B) shows naïve, memory and plasmablast subsets as a proportion of total 
B-cells and figure A) shows the absolute cell numbers. Each plot shows data for 3 patient 
groups – controls (n=21), patients relapsing post-rituximab (n=12) and active rituximab-
naïve RA (n=7) from left to right.  
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The plasmablasts, which were the initial cells of interest based on previous work done in Leeds, 
had nearly identical subset distribution between the three groups. There was differential 
heterogeneity within the naïve B-cell subsets between the 3 groups mainly due to high 
proportion of IgM positive cells in relapsing patients. This is likely to be due to the presence of 
higher proportion of immature/transitional B-cells with high surface IgM (45) within the naïve B-
cell subset in relapsing patients secondary to B-cell depletion by rituximab.  
The IgM-LAIR1- memory B-cell subset was elevated in relapsing patients and the differential 
heterogeneity in distribution of memory B-cells among patient groups is likely to be more 
informative compared to naïve B-cells and plasmablasts. This heterogeneity seen in memory B-
cells was not evident amongst plasmablasts. The absence of heterogeneity amongst 
plasmablasts could be due to convergence in phenotype when the memory B-cells differentiate 
into plasmablasts or that the plasmablasts are primarily derived directly from germinal centre or 
naïve B-cells. However the data would suggest that identification of heterogeneity in 
plasmablasts that correlates with the clinical status would require a different set of surface 
markers.  
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Figure  6.4-2 Distribution of subpopulations of the naïve, memory and plasmablast 
subsets compared between controls, rituximab-naïve RA patients with active 
disease and patients relapsing post-rituximab  
 
 
 
 
 
 
 
Naive IgM+LAIR1- % (p=0.822)
%
of
Na
iv
e
B
-c
el
ls
0
5
10
Naive IgM+LAIR1+ % (p=0.0004)
%
of
Na
iv
e
B
-c
el
ls
20
40
60
80
100
Naive IgM-LAIR1- % (p=0.432)
%
of
Na
iv
e
B
-c
el
ls
0
20
40
60
Naive IgM-LAIR1+ % (p<0.0001)
%
of
Na
iv
e
B
-c
el
ls
0
20
40
60
a)
    109 
 
 
 
 
 
 
 
 
 
Memory IgM+LAIR1- % (p=0.029)
%
of
M
em
or
y
B
-c
el
ls
0
20
40
60
Memory IgM+LAIR1+ % (p=0.041)
%
of
M
em
or
y
B
-c
el
ls
0
20
40
60
80
Memory IgM-LAIR1- % (p=0.03)
%
of
M
em
or
y
B
-c
el
ls
0
20
40
60
80
Memory IgM-LAIR1+ % (p=0.0004)
%
of
M
em
or
y
B
-c
el
ls
0
20
40
60
b)
    110 
 
 
 
The dots represent individual patients and the bars represent median with 25th and 75th 
centiles. a) naïve B-cell subsets, b) memory B-cell subsets and c) plasmablast subsets. 
Each plot shows data for 3 patient groups – controls (n=21), patients relapsing post-
rituximab (n=12) and active rituximab-naïve RA (n=7) from left to right. Only the significant 
p values for difference between the three groups (1 way ANOVA) are given within 
brackets.  
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When the total B-cell surface expression is examined, there is no significant difference in LAIR 
expression. The figure below shows the importance of classifying B-cells into naïve, memory 
and plasmablasts for analysing surface expression of markers. Evaluation of LAIR1 on total B-
cells masks the significant difference in expression of LAIR1 on memory B-cells amongst 
relapsing patients. Although the lower sample numbers for rituximab naïve patients (n=7) can 
introduce sampling errors, the main aim for this section of the study is to identify the gross B-cell 
subset based on the presence of heterogeneity and identified memory B-cells as the key 
subset. This was confirmed subsequently with larger sample numbers and significant 
differences in memory B-cell subsets were demonstrated as shown in Figure  6.4-8.   
 
Figure  6.4-3 Proportion of LAIR1- cells within naïve, memory and plasmablast subsets 
and total B-cells 
The dots represent individual patients and the bars represent median with 25th and 75th 
centiles. Each plot shows data for 3 patient groups – controls (n=21), patients relapsing 
post-rituximab (n=12) and active rituximab-naïve RA (n=7) from left to right. Only the 
significant p value (1 way ANOVA) is given within brackets. 
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7.1.2 Markers tested for heterogeneity within B-cell subsets 
Autoreactive B-cells expanded during active disease are likely to be of an activated phenotype 
with downregulation of inhibitory receptors. In selected cases 34 further markers known to be 
expressed by B-cells with a potential role in pathogenesis were chosen initially. Markers chosen 
include: 
• Activation markers – CD69, CD25, CD95, HLA-DR 
• Co-stimulatory molecules – CD80, CD86 
• Regulatory molecules – LAIR1, CD84 
• Cytokine receptors – CD25, CD126 
• Chemokine receptors – CD184, CD185, CD196 
• Markers for stage of differentiation – CD5, CD10, CD138 
Having shown that the memory B-cells exhibited greater heterogeneity and differences related 
to clinical state, the markers shown in Figure  6.4-4 were analysed for the presence of 
heterogeneity within the memory B-cell subset in 3 controls. B-cells were defined by their scatter 
profile and co-expression of CD19 and CD20. Memory B-cells were then identified by their 
CD27 positivity. The surface markers which were expressed by more than 90% of the memory 
B-cells and less than 10% of the memory B-cells were not considered for further analysis since 
they are likely to be expressed by all or none of the memory B-cells respectively. The rest of the 
markers were heterogeneous in distribution amongst memory B-cells, and many of these 
markers did not co-segregate. In other words when memory B-cells are divided into two 
fractions based on one marker, another marker would divide each of those fractions into two 
further fractions yielding four fractions in total. If two markers co-segregated, it would yield only 
two fractions but if they don’t four fractions can be visualised. Since many of the markers did not 
co-segregate, this is suggestive of great heterogeneity within the memory B-cells. Among these, 
four markers (CD24, CD84, CD95 and LAIR1) which are non-redundant were chosen for further 
analysis. The number of markers that could be chosen was also restricted by the practical 
consideration that only 4 spare channels were available given the need for 4 channels 
dedicated to backbone markers. 
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Figure  6.4-4 List of markers tested for heterogeneity within memory B-cells.   
B-cells were identified based on their scatter profile and CD19 and CD20 dual positivity. 
Memory B-cells were then gated based on their CD27 positivity. Memory B-cell subsets 
defined by positivity for the marker on the left expressed as percentage of memory B-cells. 
Red arrows indicate markers that were heterogeneous and chosen for further analysis. 
Data shown from 3 healthy controls. 
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The presence of heterogeneity and redundancy in surface marker expression by memory B-
cells is shown in the figure below. 
 
Figure  6.4-5 Examples of heterogeneous distribution of markers and redundancy 
Representative flow cytometry plots of memory B-cells defined based on their scatter 
profile and positivity for CD19, CD20 and CD27.The first plot shows heterogeneity in 
expression of CD24 by memory B-cells bu they are homogeneous for CD23 expression. 
The second plot shows CD95 and CD185 have similar expression profile on memory B-
cells and therefore only one of the markers is required making the other one redundant. 
The third plot shows expression pattern of non-redundant markers CD24 and CD84. 
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7.1.3 16 different memory B-cell subsets identifiable based on 4 surface 
markers 
Memory B-cells are heterogeneous for expression of all these 4 markers and the expression 
patterns are non-overlapping. Therefore, each of the four subsets identified based on 2 markers 
could be subdivided into 4 further subsets as shown below. Thus it was possible to segregate 
the memory B-cells into 16 different fractions. For further analysis, each one of the CD24/CD84 
quadrants was combined with each of the four CD95/LAIR1 quadrants as part of the gating 
strategy to generate the 16 subsets. 
 
Figure  6.4-6 Non-overlapping pattern of heterogeneity of expression of CD24, CD84, 
CD95 and LAIR1 by memory B-cells 
Representative flow cytometry plots of memory B-cells defined based on their scatter 
profile and positivity for CD19, CD20 and CD27. Cells from each CD24/CD84 quadrant 
coded with a different colour in the first plot are distributed at least in 3 different 
CD95/LAIR1 quadrants in the second plot. This schematically shows that the 
heterogeneity for these markers is non-overlapping. 
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7.1.4 RA patients relapsing post rituximab depletion show a skewed 
distribution of memory B-cell subsets compared to controls and 
untreated patients 
22 rituximab naïve patients with active disease, 18 patients relapsing post-rituximab and 9 
patients in remission with or without rituximab were analysed. 10 controls were also included. 
The control group consisted of 6 females (Average age 48.5) and 4 males (Average age 50). 
The patient group consisted of 43 females (Average age 54) and 9 males (Average age 62). 
Most patients who have been treated with rituximab had undergone 1-3 cycles of therapy and 1 
patient with 4 cycles, 2 patients with 5 cycles and 1 patient with 9 cycles. The patients who were 
in remission were post-rituximab (n=3) or on anti-TNF (n=4) or anti-IL6 (n=2) therapy.  
 
 
 
Table  6.4-1 Clinical status of patients included for memory B-cell subset characterization 
The first table shows the clinical status of the patients and the number of cycles of therapy 
undergone by rituximab treated patients is given in the second table. 
  
Clinical Status No. of patients
Control 10
Active Disease Anti-CD20 Naïve 22
Relapse post Anti-CD20 18
Remission (With or without Anti-CD20) 9
No. of 
cycles
No. of 
patients
1 4
2 5
3 5
4 1
5 2
9 1
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The peripheral blood memory B-cells were analysed by flow cytometry. Memory B-cells were 
defined based on their scatter profile and co-expression of CD19, CD20 and CD27 as shown in 
Figure  5.2-5. The memory B-cells were further sub-classified as shown in Figure  5.2-6. The 
memory subset distribution profile of the different patient groups shows the predominance of 
CD24+CD84+CD95-LAIR1+ subset in steady state and among controls which is replaced by a 
predominance of the reciprocal CD24-CD84-CD95+LAIR1- subset during relapse.  
 
Figure  6.4-7 The distribution of the 16 memory B-cell subsets in different patient groups 
The central line represents the median, boxes represent the 25th and 75th quartile and 
whiskers indicate the minimum and maximum data points. The subset depicted in green 
(CD24+CD84+CD95-LAIR1+) is the dominant subset in controls (n=10), active RA patients 
who are rituximab naïve (n=22) and remission (n=9) and the reciprocal subset depicted in 
red (CD24-CD84-CD95+LAIR1-) is dominant in patients relapsing post-rituximab (n=18). 
Memory B-cells were gated based on their scatter profile and CD19+CD20+CD27+. The 
memory B-cells were then sub-divided based on the expression of CD24, CD84, CD95 
and LAIR1. 
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7.1.5 RA patients relapsing post-rituximab therapy have a significantly 
higher proportion of CD24-CD84-CD95+LAIR1- memory B-cells which 
is not solely due to direct B-cell depletion 
The dataset in Table  6.4-1 was analysed for the proportion of CD24-CD84-CD95+LAIR1- 
memory B-cell subset (defined as shown in Figure  5.2-6) for comparison between the different 
patient groups. The patients relapsing post-rituximab have significantly higher proportion of 
CD24-CD84-CD95+LAIR1- memory B-cells compared to controls (p=0.029), active disease with 
no previous rituximab (p<0.0001) and patients in remission (p=0.0013).  
One possible explanation for the skewed memory B-cell distribution seen in patients relapsing 
post-rituximab could be a direct effect of B-cell depletion irrespective of the underlying disease 
process. The skewed memory B-cell distribution noted in RA could be the normal reconstitution 
pattern if B-cells are depleted. To exclude this possibility, the memory B-cell subset distribution 
in 19 lymphoma patients 12–18 months since last dose of rituximab and 4 renal transplant 
recipients 3-6 months post campath therapy were analysed. The included patients had rituximab 
for B-cell neoplasms including follicular lymphoma, chronic lymphocytic leukaemia, diffuse large 
B-cell lymphoma or mantle cell lymphoma and all these patients were in remission at the time of 
sample collection. The key difference in rituximab usage is the much higher dose in lymphomas 
and continued immunosuppression with DMARDs like methotrexate for RA. The B-cell 
reconstitution in lymphoma patients treated with rituximab is delayed up to 12-18 months due to 
the higher dose and repeated cycles (87). Therefore the 12-18 month time point was chosen for 
the evaluation of these samples. Campath-1H is a therapeutic monoclonal antibody directed 
against CD52 which depletes B-cells and T-cells. The B-cell numbers recover earlier following 
campath-1H therapy compared to rituximab and return to baseline in 3 months although mainly 
with transitional B-cells (88). The proportion of CD24-CD84-CD95+LAIR1- memory B-cells was 
significantly elevated in RA patients relapsing post rituximab compared to the lymphoma 
patients treated with rituximab (p<0.0001) and post-Campath therapy (p=0.022). The other 
instances of B-cell reconstitution after B-cell depletion did not exhibit this skewing of memory B-
cell subsets which suggests that the skewing is specific to the RA disease process. 
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Therefore, the CD24-CD84-CD95+LAIR1- subset is referred to as relapse associated memory B-
cell subset (RAMB). The polar opposite CD24+CD84+CD95-LAIR1+ subset which is the 
dominant subset in controls is referred to as usual dominant memory B-cell subset (UDMB). 
 
 
Figure  6.4-8 Proportion of CD24-CD84-CD95+LAIR1- memory B-cells in different patient 
groups 
The spots represent individual patients, the central line represents the median and the 
extreme lines represent 25th and 75th quartiles. P value for comparison between multiple 
groups was calculated by 1way ANOVA and two-tailed t test was used to compare 
between two groups. Controls (n=10), Rituximab naïve active disease (n=22), Remission 
(n=9), Relapse post-rituximab (n=18), Rituximab for Lymphoma (n=19) and Campath-1H 
(n=4). Memory B-cells were gated based on their scatter profile and CD19+CD20+CD27+. 
The memory B-cells were then sub-divided based on the expression of CD24, CD84, 
CD95 and LAIR1. 
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The dataset was analysed for the difference between patient groups if the major B-cell subsets 
were compared. This significant difference between patient groups cannot be recapitulated by 
simpler subset evaluation of naïve, memory B-cells and plasmablasts (Gating strategy as 
described in Figure  5.2-5). There was no difference in the proportion of plasmablasts between 
the three groups shown (p=0.1244). There was a reduction in proportion of memory B-cells 
(p=0.009) and increase in proportion of transitional B-cells (p<0.0001) as expected due to the B-
cell depletion effect of rituximab. The proportion of naïve B-cells (p=0.029) were reduced in 
patients treated with rituximab due to the higher proportion of transitional B-cells. Therefore, 
analysis of the proportion of major B-cell subsets did not reveal preferential increase in any of 
them during relapse to suggest the presence of a pathogenic subset.  
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Figure  6.4-9 Proportion of Naïve, Memory, Transitional B-cells and Plasmablasts in 
different patient groups 
The central line represents the median and the extreme lines represent the 25th and 75th 
quartiles. P value for comparison between multiple groups was calculated by 1way 
ANOVA and two-tailed t test was used to compare between two groups. Controls (n=10), 
Rituximab naïve active disease (n=22), Remission with biologic therapy (n=9) and 
Relapse post-rituximab (n=18). The proportion of memory (p=0.009) and naïve B-cells 
(p=0.029) were significantly reduced whereas the transitional B-cells (p<0.0001) was 
significantly elevated in patients relapsing post-rituximab directly due to the B-cell 
depletion. There was no difference in proportion of plasmablasts between patient groups 
(p=0.124). B-cells were classified into the subsets shown as per gating strategy described 
in Figure  5.2-5.  
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7.1.6 Skewing of the memory B-cell subset distribution is not appreciable 
by examining the absolute numbers due to the overall reduction in B-
cell numbers due to rituximab therapy 
Absolute count is a better marker of expansion of cell populations than percentages since 
percentage can be skewed by changes in the other subsets. However, patients who have been 
treated with rituximab tend to exhibit lower numbers of B-lineage cells for two to three years due 
to the delay in reconstitution. Therefore, evaluating the absolute numbers of the different 
subsets will show a universal reduction of all subsets in rituximab treated patients as shown 
below. Therefore, the relative proportion of the various subsets is a better index to identify 
potential pathogenic subsets in the clinical situations following B-cell depletion. 
 
Figure  6.4-10 Absolute numbers of relapse associated memory B-cells and total B-cells 
The spots represent individual patients, the central line is the median and the extreme 
lines represent 25th and 75th quartiles. The p-value (1way ANOVA) for comparison 
between 3 groups is given at the top and the ‘t test’ value for comparison between 
individual groups at the bottom. The cell counts are shown on a logarithmic scale. Controls 
(n=10), Rituximab naïve active disease (n=22), Remission (n=9) and Relapse post-
rituximab (n=18).  
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7.1.7 Memory B-cell subsets during remission following rituximab do not 
exhibit the skewing of their subset distribution like relapsing patients 
The review of patients following rituximab therapy is set up such that they have an open clinic 
appointment and contact the clinic for review only when the disease flares. Therefore, it is 
difficult to obtain samples from patients who are in remission and the initial dataset contained 
only 3 patients in remission post rituximab. To assess in more detail whether the relapse-
associated memory B-cell subset is different in patients who are relapsing or in remission post 
rituximab, samples were collected if the patients had a clinic visit after 3 months of last dose. In 
patients who were not due for clinical review, forms were given for a blood sample to be taken 6 
months after the last dose. The rituximab patient registry was scanned and patients who had not 
had repeat therapy or presented to the clinic for more than 6 months were identified and request 
forms were posted to those patients for sample collection. Samples from a total of 44 RA 
patients were collected and analysed. 
Out of the 44 patients, 7 showed total or near-total absence of memory B-cells due to delay in 
reconstitution or earlier sampling and therefore were excluded. The samples were collected at 5 
months or later from all the 37 patients. Clinical notes from these patients were reviewed to 
subdivide the patients into 2 groups – relapse and remission. 24 patients had relapse of RA 
inflammatory symptoms around the time of the sample. The clinical data from the remaining 13 
patients is shown in the table below. 
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Table  6.4-2 Clinical details and memory B-cell subsets in patients with no definitive 
evidence of RA flare-up 
24-84-95+LR1- and 24+84+95-LR1+ memory B-cells (defined as shown in Figure  5.2-6) 
are expressed as a percentage of memory B-cells in 13 patients. The clinical details 
available for the patients at the time of sampling are provided in the last column. * denotes 
patients who were in remission with no intercurrent inflammatory or infective illness. 
Patient 
 
24+84+ 
95-LR1+ 
% 
24-84-
95+LR1- 
% 
Clinical Scenario 
H20269 22.5 4.9 L Knee effusion ?mechanical, skin rash - ?folliculitis 
*H20563 3.4 41.5 Severe flare-up within 2 months of sample 
H20978 8.8 15.6 
L knee injected with depomedrone for ruptured baker cyst 5 
months before sample 
*H21746 30.4 2.2 VAS 10, DAS28-1.67, Remission 
*H21953 30.2 5.0 Clinically mild flare when reviewed a month later. 
*H24369 24.3 14.7 EMS 0. Vas - 10. Remission 
H25421 0.0 28.6 Multiple COPD exacerbations 
*H26453 12.9 12.9 In remission 6 weeks prior to sample 
*H26541 16.7 11.1 
EMS-10mins, VAS-40, No tender/swollen joints. CRP-8. Prev 
2 doses - half dose. So, premptive next dose 
H26684 0.0 65.2 Known MGUS, Quantiferon positive TB treated 9 months ago 
H301 3.4 25.2 Trochanteric bursitis. Injected with steroids 
H552 9.4 21.9 3 months prior to sample - EMS 30mins, cervical pain. 
H2770 6.5 16.9 
Well 3 months prior to and severe flare up 6 months after 
sample. Unclear how long symptomatic. Prev Ca bowel. 
Ileorectal anastomosis. 2 A&E visits with chest infection 
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The above 13 patients could be considered in remission since there was no definitive signs or 
symptoms of RA flare up at the time of sampling. However on reviewing the clinical picture in 
more detail, the majority of the patients had some infective or inflammatory process such as 
chest infections or joint symptoms, which were not necessarily thought to be due to RA. 
Nevertheless, these symptoms required treatment with antibiotics or steroids respectively. 
When the patients with infective or inflammatory processes before sampling were excluded 
there were only 6 patients who were in remission at the time of sampling. Five out of the six 
patients had a lower proportion of 24-84-95+LR1- and a higher proportion of 24+84+95-LR1+ 
memory B-cells similar to controls or pre-rituximab state. The remaining patient who did show 
the skewed phenotype presented with severe clinical symptoms within 2 months of the 
sampling. Therefore, skewing in the proportion of memory B-cell subsets during reconstitution is 
likely to indicate ongoing or recent inflammatory activity. While in some cases this may not be 
due to RA, it could be argued that detection of this skewing should initiate close follow up to 
monitor for signs of relapse.              
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7.1.8 The relapse associated memory B-cell subset is predominantly class-
switched in RA patients and controls 
ACPA measured in the clinical setting and known to be specific for RA is of the IgG isotype. 
Therefore the immunoglobulin isotype of relapse-associated memory B-cell subset was 
analysed for evidence of class-switching. Surface staining with antibodies against IgM and IgD 
was performed and the16 memory B-cell subsets were analysed individually for class-switching. 
The majority of the relapse-associated memory B-cell subset was class-switched in both the RA 
patients and controls. In contrast, the usual dominant memory B-cell subset was predominantly 
constituted by IgM+ memory B-cells. However, there was a lower proportion of class-switched 
memory B-cells within the usual dominant memory B-cell subset in RA patients compared to 
controls (p<0.0001). There was a lower proportion of class-switched memory B-cells in the 
relapse-associated subset in RA patients compared to controls, but this did not achieve 
statistical significance (p=0.064). In case of controls none of them had less than 75% class-
switched memory B-cells within the relapse-associated subset.      
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Figure  6.4-11 Proportion of class-switched cells within memory B-cell subsets in RA and 
controls 
The proportion of class-switched memory B-cells within the two polar opposite memory B-
cell subsets is shown for RA patients and healthy controls. The central line is the median 
and extreme lines represent 25th to 75th centiles. P-values from unpaired t test shown.  
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7.1.9 The relapse-associated memory B-cell subset surface phenotype in 
patients relapsing post-rituximab is reminiscent of plasmablasts 
The surface expression profile for the surface markers used to classify memory B-cells were 
examined on plasmablasts since plasmablasts have been shown to be predictive of clinical 
response in RA. Plasmablasts generated in vitro from peripheral blood B-cells of a control (as 
described in Figure  5.4-1) and peripheral blood plasmablasts from a RA patient relapsing post-
rituximab were evaluated. Plasmablasts were defined based on their scatter profile and 
CD19+CD20-CD27HiCD38Hi. The surface expression pattern of CD24, CD84, CD95 and LAIR1 
by in vitro generated plasmablasts and peripheral blood plasmablasts is similar to the relapse-
associated memory B-cell subset.  The surface expression profile of the relapse-associated 
subset is different to plasmablasts in terms of CD20 and CD38.   
 
 
Figure  6.4-12 Comparison of relapse-associated memory B-cell subset with plasmablasts 
The top two rows show the surface expression of the markers specified by plasmablasts 
generated by in vitro differentiation of normal B-cells and peripheral blood RA 
plasmablasts. Plasmablasts were defined based on their scatter profile and CD19+CD20-
CD27HiCD38Hi. The bottom row shows peripheral blood CD24-CD84-CD95+LAIR1- 
memory B-cells from a RA patient relapsing post-rituximab. 
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7.2 Summary and discussion 
Memory B-cells defined as CD27 positive are a very heterogeneous population and can be sub-
divided into 16 different subsets based on four carefully selected surface markers. Whilst all 
these subsets are unlikely to be functionally distinct, certain subsets might be. Once a subset is 
identified to be functionally distinct, in this case autoreactive, it could be further analysed. It can 
be argued that whether subsets need to be merged or a subset needs further subclassification 
depends on its sensitivity and specificity. Alternatively providing a mechanistic understanding of 
the factors governing phenotypic states and their relationship to transient or stable cell states, 
would provide a rationale for subset linkage or fractionation.  
Further phenotypic subclassification would be possible by using additional markers which is 
mainly limited by available technology. Even though additional markers can be used by flow 
cytometry with extra lasers and additional channels available for the violet laser in particular 
(Brilliant Violet fluorochromes), the data analysis becomes complicated. Additional channels 
also add to the complexity due to compensation issues. The recent advance of mass cytometry 
(CyTOF) enables assessment in theory  of up to 100 markers on a single cell with minimal 
signal overlap (89). The downstream analysis depends on complex clustering algorithms to deal 
with the vast amounts of multidimensional data generated (90).  Furthermore the destructive 
nature of this technology means that reduction to a more restricted flow cytometry panel would 
ultimately be necessary to allow functional cellular analysis, gene expression profiling and 
sequencing the immunoglobulin gene to identify the antigen specificity. 
On analysing the distribution of memory B-cell subsets in different patient groups, the RA 
patients relapsing post-rituximab showed a skewed distribution. A population of memory B-cells 
was identified which is of higher proportion in patients relapsing post-rituximab compared to 
controls, patients in remission and patients with active disease whose B-cells have never been 
depleted. The shift in proportions of cells with relapse could be due to two possible reasons – an 
increase in number of pro-inflammatory cells or decrease in number of regulatory cells. 
However, the clinical response to B-cell depletion makes the latter possibility less likely. The 
increased proportion of this subset is not reflected in the absolute cell numbers due to the 
general reduction in B-cells including memory B-cells following B-cell depletion by rituximab. 
The polar opposite CD24+CD84+CD95+LAIR1- memory B-cell subset is the dominant subset in 
    130 
 
 
all other patient groups except during RA relapse post-rituximab when CD24-CD84-CD95+ 
LAIR1- subset is dominant. This skewing in the distribution of memory B-cells is unlikely to be a 
direct effect of depleting B-cells since it is not seen in other instances of therapeutic B-cell 
depletion for non-autoimmune conditions such as B-cell lymphomas treated with rituximab or 
campath therapy prior to renal transplantation. Therefore, this memory B-cell subset is likely to 
be linked to disease pathogenesis in RA and may contain the autoreactive B-cells.  
The levels of the relapse associated subset can be elevated in some patients who have not had 
any evidence for clinical relapse of RA. However, these RA patients had other intercurrent 
infective or inflammatory processes requiring treatment with steroids or antibiotics post-
rituximab and prior to sampling. This suggests that the increase in the memory B-cell subset is 
quite sensitive to inflammatory processes and may be not be a specific marker for RA disease 
process. There could also be a potential selection bias, since patients who are well during 
remission do not have the need to attend clinics and did not have any blood sampling. There 
was less than 50% response rate from patients invited by post to have samples taken at 6 
months. Overall patients are more likely to respond if they had to seek medical help for flare up 
of RA or other reasons. This could have led to the pre-selection of patients who are relapsing or 
had other intercurrent illnesses. The RA patients are more prone to infections due to various 
factors (91) and also continue on immunosuppression post-rituximab compared to lymphoma 
patients in remission. This helps explain the difference in subset distribution pattern seen during 
remission in lymphoma and RA.    
The lower proportion of class-switched memory B-cells noted in RA patients compared to 
controls could simply be the effect of B-cell depletion and the fact that reconstituted B-cells have 
not had sufficient antigen exposure to generate enough class-switched memory B-cells. 
However, it is interesting to note that the class-switched memory B-cells segregate to the 24-84-
95+LR1-subset and non-class-switched cells segregate to the polar opposite 24+84+95-LR1+ 
subset in both controls and patients. The lack of surface IgM and IgD seen in the relapse 
associated subset could also represent B-cells with reduced levels of surface immunoglobulins 
prior to plasmablast differentiation. Although it raises the suspicion of lymphoma, such surface 
immunoglobulin negative B-cells have also been identified in lymph nodes with chronic 
inflammatory processes (92).  
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Higher plasmablast number at baseline (86) and persistence of plasmablasts(25) in the early 
stages following B-cell depletion predicts poor response to rituximab. The surface expression of 
the four markers namely CD24, CD84, CD95 and LAIR1 by the relapse-associated memory B-
cell subset is similar to plasmablasts. Therefore, it is possible that this subset could be 
precursors of plasmablasts or on their way to plasmablast differentiation and have functional 
similarities to plasmablasts in terms of RA pathogenesis. Therefore, it is likely that this subset 
contains pathogenic cells.  
To understand the functional role of this subset, it is essential to identify its antigen specificity 
particularly for citrullinated proteins. If antigen-specific (autoreactive) cells can be identified by 
an independent technique other than surface phenotyping, then those cells could be 
phenotyped using these markers to validate the technique. If this population does not contain 
autoreactive B-cells then its other functional characteristics could be important to pathogenesis, 
and the relationship of this phenotype to gene expression and Immunoglobulin gene somatic 
mutation status needs to be established.  
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8 Third Results Chapter: Functional characterisation of RA relapse 
associated B-cells 
Altered B-cell subsets have been described in autoimmune disorders and attempts have been 
made to identify subsets that correlate with the clinical status. The results from previous chapter 
identified CD24-CD84-CD95+LAIR1- memory B-cells were increased in proportion prior to 
relapse following rituximab therapy. This relapse associated subset has not been described in 
the literature before. These cells are likely to be involved in RA pathogenesis but also could be 
an epiphenomenon. To understand the role of these cells, the functional attributes of these cells 
need to be defined. The memory B-cell subsets of interest were flow sorted for further functional 
analysis and plasmablasts were also isolated at the same time to detect presence of ACPA 
secreting plasmablasts in the peripheral circulation. ACPA secretion was not detectable by 
ELISpot (Figure  8.1-1) which is likely to be due to technical issues with ELISpot but lack of 
ACPA secreting plasmablasts could not be confirmed due to lack of a positive control for ACPA 
secretion. The naïve B-cells isolated during the same flow-sort were differentiated to antibody 
secreting cells in vitro and tested for ACPA secretion by ELISpot. The naïve B-cells have class-
switched during the in vitro differentiation as evidenced by the secretion of IgG but ACPA 
secretion was not detectable (Figure  8.1-2). One of the functional attributes of the B-cells is their 
antigen specificity. Since detection of citrullinated protein specific B-cells was quite challenging, 
other attributes were sought. 
The functional role of B-cells could be inferred from the knowledge of the stage of B-cell life 
cycle the cell belongs to. The expression pattern of the four markers used to classify the 
memory B-cells resembled plasmablasts as shown previously (Figure  6.4-12). Therefore, it was 
hypothesized that this particular surface expression pattern was acquired following B-cell 
stimulation prior to plasmablast differentiation. Due to the difficulties in tracking human cell 
populations in vivo to determine the stage at which this phenotype is acquired, in vitro methods 
were sought. One such recently described protocol (60)which is able to generate plasmablasts 
and plasma cells from B-cells was utilized. The memory B-cells are heterogeneous in peripheral 
blood with them being predominantly CD24, CD84 and LAIR1 positive and CD95 negative. On 
stimulation, CD24 surface expression was lost and CD95 was gained quite early within the first 
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3 days. CD84 and LAIR1 expression were lost later closer to plasmablast stage. The closest 
stage in vitro to the relapse associated CD24-CD84-CD95+LAIR1- memory B-cell subset was the 
activated B-cell stage (ABC) between days 3 to 4. Gene expression analysis at different stages 
of in vitro B-cell differentiation was performed by Cocco et al (60) and the previously published 
data was reanalysed. It was hypothesized that the relapse associated subset is directly involved 
in RA pathogenesis via generation of proinflammatory mediators. Therefore, the group of genes 
that increase in expression levels during the ABC stage were assessed for the enrichment of 
proinflammatory mediators by gene ontology analysis. The analysis revealed 60 genes that are 
involved in immune system processes were enriched during the ABC stage. This included 
mediators directly related to RA pathogenesis such as TNFα, lymphotoxin, AIF1 and MMP7 and 
multiple chemokines such as CXCL9, CXCL10, CCL2, CCL3, CCL17 and CCL22 (Figure  8.3-3 
and Figure  8.3-4). To evaluate for the presence of protein expression accompanying 
transcriptional activity, TNFα was chosen which is well known to have a direct role in RA 
pathogenesis. Spontaneous secretion of TNFα on day 3 of in vitro differentiation by normal B-
cells was demonstrable by ELISpot (Figure  8.3-6). The secretion of the other inflammatory 
mediators could be confirmed in future work by multiplex luminex assay of the supernatants or 
ELISpot. This supports the hypothesis that the relapse associated B-cells are involved in RA 
pathogenesis. However, TNF secretion by sorted CD24-CD84-CD95+LAIR1- memory B-cells 
was not demonstrable by ELISpot (Figure  8.3-7). There were technical issues with the ELISpot 
assay due to low cell numbers and poor viability of the cells following the flow sorting. These 
issues can potentially be overcome by pooling samples from multiple patients to overcome the 
lower cell numbers and dialysing the antibodies used for flow sorting to exclude azide which can 
reduce cell viability. The secretion of pro-inflammatory mediators by relapse associated memory 
B-cells can also be evaluated by multiplex luminex assay of the supernatants and single cell 
gene expression analysis. 
There remains the possibility that the relapse associated subset seen in relapsing RA patients is 
unrelated to the in vitro day 3 ABC. Irrespective of the ABC being similar to the relapse 
associated subset, it was an interesting observation that B-cells secrete proinflammatory 
mediators during the differentiation of B-cells to plasmablasts. Studies in the past have 
demonstrated cytokine secretion by B-cells with highly potent stimuli but the dataset generated 
by Cocco et al. (60) used an activation protocol mimicking a physiological stimulus capable of 
generating long-lived PCs. Cytokine secretion has mostly been demonstrated in the past from 
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culture supernatants and a phenotype for B-cells secreting the inflammatory mediators has not 
been described. If a surface marker can be identified specific for the in vitro ABC stage, this can 
be assessed on in vivo B-cells to be considered as a biomarker. The previously published gene 
expression data was re-analysed for surface molecules that are expressed only on activation 
and lost on PC differentiation corresponding to the ABC stage. Two such markers were chosen 
– CD30 and TIM3 (Figure  8.3-8). CD30 has been well studied in B-cell neoplasms and is known 
to be induced on B-cell activation. The role of TIM3 in B-lineage cells has not been studied 
before which were additional reasons for choosing these two markers. 
The protein expression of the surface markers identified by the gene expression data was 
verified during in vitro differentiation of B-cells by flow cytometry. Surface expression of TIM3 
was gained by ABC on day 3 of in vitro differentiation and lost on day 10 (Figure  8.3-9). TIM3 
surface expression can be induced by CD40L and TLR stimuli as shown in Figure  8.3-10. The 
surface expression of CD30 followed a similar time course with earlier loss of expression by day 
6 on differentiation to plasmablasts (Figure  8.3-11) in line with the gene expression data 
(Figure  8.3-8). To exclude non-specific binding as a cause for the detected staining by flow 
cytometry isotype controls were evaluated which confirmed the staining to be specific for the 
tested anti-TIM3 and anti-CD30 antibodies Figure  8.3-12. The expression of TIM3 could be 
further confirmed by real-time PCR for TIM3 and alternative techniques for protein detection 
such as western blot at different time points during in vitro B-cell differentiation. Alternatively, 
cell lines representing different stages of B-cell differentiation could also be used. To ensure 
that the detection of TIM3 is not an in vitro artefact, TIM3 expression should be demonstrable on 
in vivo B-lineage cells as well.  
TIM3 has been extensively studied in T-cells and monocytes and is only expressed by a very 
low proportion of T-cells in peripheral blood. TIM3 is expressed on activation of T-cells. 
Therefore, different clinical situations such as an active inflammatory process or B-cells from 
lymphoid organs and sites which are likely to contain actively differentiating B-cells were 
evaluated. TIM3 was not detectable on surface of B-cells from healthy controls, patients with 
inflammatory disorders or lymph nodes, bone marrow and synovium (Figure  8.3-13 and 
Figure  8.3-14). Low levels of TIM3 expression was observed on B-cells from a spleen sample 
which was significantly weaker than the levels expressed in vivo. Since various B-cell 
neoplasms represent different stages of B-cell life cycle and TIM3 expression was transient in 
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vitro during B-cell differentiation, expression of TIM3 by B-cell neoplasms was assessed. Bone 
marrow samples from patients with follicular lymphoma, chronic lymphocytic leukaemia, mantle 
cell lymphoma, marginal zone lymphoma and plasma cell neoplasia were assessed and TIM3 
expression was detectable only in patients with marginal zone lymphoma (Figure  8.3-15).  
Since TIM3 has not been studied in B-cells so far, the role of TIM3 in B-cell biology and whether 
the detected TIM3 is functional is not known. Studying the effect of the ligand for TIM3 on B-
cells would throw more light on its role and also prove the presence of functional TIM3. 
Therefore, the effect of TIM3 ligand galectin 9 was evaluated in vitro during B-cell differentiation. 
Galectin 9 adversely affected viability of the differentiating B-cells which was not blocked by 
anti-galectin 9 or anti-TIM3 antibodies. The TIM3 agonistic and blocking antibodies did not have 
any effect on B-cell differentiation or cell viability. Therefore, the role of TIM3 in B-cell biology 
remains unclear and the noted effect of Galectin 9 on cell viability is not likely to be mediated via 
TIM3. Interestingly, there is on-going debate in the literature whether galectin 9 is a ligand for 
TIM3 (93). Further functional evaluation of TIM3 would require obtaining galectin 9 from different 
sources for testing after further confirmation of TIM3 expression in vitro with western blot which 
will be the subject of a future project. 
It is not known whether the relapse associated CD24-CD84-CD95+LAIR1- memory B-cell subset 
is a static or dynamic population. Sequential evaluation the proportion of this subset during an 
immune response is likely to provide vital information on its functional role. Since the onset of 
immune response is not predictable an alternative instance where the immune response occurs 
in a controlled fashion was sought. The annual seasonal influenza vaccination offered to health 
care professionals provided one such opportunity. This revealed that in more than half of the 
volunteers the proportion of the CD24-CD84-CD95+LAIR1- subset increased in a day following 
the vaccination without an accompanying increase in their absolute count. In most of the donors 
that showed this pattern, the absolute count of the polar opposite CD24+CD84+CD95-LAIR1+ 
subset decreased. Although it could be hypothesized that the increase in proportion of CD24-
CD84-CD95+LAIR1- subset could be due to recruitment of the other subsets into the secondary 
lymphoid organs, there could be alternative explanations such as increased cell death and 
decay in the other subsets which could not be ruled out.    
In summary, in this chapter different strategies to identify the functional role of the relapse 
associated subset were employed including identification of autoreactivity, directly pathogenic 
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inflammatory mediator secretion, variations during a controlled immune response and the 
properties of in vitro equivalent cells.                         
8.1 Flow sorting of two extreme memory B-cell subsets and 
plasmablasts from RA patients 
The key memory B-cell subsets need to be separated for further functional characterisation to 
understand their role in disease pathogenesis. The key role in pathogenesis could be secondary 
to autoreactivity or inflammatory cytokine secretion. 3ml of peripheral blood from 5 RA patients 
was stained with the same antibodies used for memory B-cell subset classification (Version 1 
Error! Reference source not found.) after red blood cell lysis with ammonium chloride. The 
stained cells were flow sorted with a similar gating strategy used to classify the memory B-cell 
subsets as shown in Figure  5.6-2 using Influx cell sorter (BD Biosciences).Four patients were 
ACPA positive and the other patient was ACPA negative. Out of the four ACPA positive 
patients, two were rituximab naive and two were relapsing post-rituximab. All patients had 
clinically active disease at the time of sampling. Since density gradient centrifugation can 
remove plasmablasts, ammonium chloride lysis was used to exclude red cells. Cells were then 
stained with the same antibodies used for memory B-cell subset analysis. The number of cells 
for each subset obtained is shown below. Due to the low numbers of cells in each fraction post-
sort, the cells from the 2 rituximab naïve patients were combined into a single sample. The 2 
post-rituximab samples were combined as well.  
Table  8.1-1 B-cell subsets obtained from flow sorting of 5 RA patients 
All 5 patients had active clinical disease. The total number of cells obtained by the sorting 
process (Influx cell sorter, BD Biosciences) from 3ml peripheral blood using 8 surface 
markers as described in Figure  5.6-2 is shown. 
 
 
Naïve Plasmablasts 24-84-95+LR- 24+84+95-LR+
Ritux naïve active 1 1600 4 11 3
Ritux naïve active 2 24806 40 159 21
CCP Neg 11126 25 104 9
Post-Ritux relapse 1 28776 42 641 11
Post-Ritux relapse 2 35072 45 137 8
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8.1.1 ELISpot for ACPA secretion by RA peripheral blood plasmablasts 
Plasmablasts were incubated for 8 hours in the ELISpot plates coated with anti-IgG or CCP as 
capture peptides. Due to the lack of binding of CCP peptides to the ELISpot plates as shown in 
Figure  6.3-3, streptavidin coat was used to capture the biotinylated peptides onto the plate. The 
secreted IgG that was bound to the plates was detected with biotinylated anti-IgG followed by 
streptavidin HRP. For the wells where streptavidin-biotinylated CCP was used for capture, HRP 
directly conjugated to anti-IgG was used. The spots were developed using the standard kit 
protocol as described in methods section  5.9.  
 
Figure  8.1-1 ELISpot for IgG and ACPA secretion by flow-sorted peripheral blood RA 
plasmablasts 
Flow sorted plasmablasts (defined as CD19+CD20-CD27HiCD38Hi) using the antibodies 
and gating strategy described in methods section  5.6.2 from 2 groups of patients with 
active disease – rituximab naïve and post-rituximab relapse (2 patients in each group) 
were incubated for 8 hours in wells coated with reagents shown in the top row. The 
reagents used for detection of the secreted antibodies bound to the plate are shown in the 
bottom row. The spots were developed using the standard kit protocol as described in 
methods section  5.9.     
 
There was no detectable secretion of ACPA by the plasmablasts from the 2 different patient 
categories. There was no detectable secretion of IgG either and therefore the assay lacked a 
positive control. Out of the 8 different ELISpot experiments performed, IgG detection has been 
consistent and the same technique was applied to this experiment. Therefore, the lack of IgG 
secretion is likely to be due to the poor viability of the cells rather than a technical issue since 
IgG detection has never been a problem with ELISpot as shown in Figure  8.1-2.  
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8.1.2 ELISpot for ACPA secretion by plasmablasts generated in vitro from 
RA naïve B-cells 
The naïve B-cells obtained during the flow sort were differentiated using CD40L/BCR/IL2/IL21 
based protocol (Figure  5.4-1) up to day 6 to generate plasmablasts. The cells were incubated 
for 8 hours in ELISpot wells coated with anti-IgG, isotype antibody or streptavidin-tagged 
citrullinated and arginine versions of the peptide. The spots were developed as per standard kit 
protocol described in detail in the methods section  5.9. There was no detectable ACPA 
secretion by the in vitro generated plasmablasts derived from naïve B-cells. It was interesting to 
note that naïve B-cells from RA patients class-switched during the in vitro differentiation process 
and generated IgG secreting plasmablasts. In the bottom row, instead of cells, serum from 
ACPA positive and negative patients was used in alternative wells. The technique was not able 
to detect ACPA from the serum in an ELISA like fashion although it detected IgG as shown in 
the bottom row of Figure  8.1-2. Therefore, the presence of plate bound peptides at the time of 
detection could not be confirmed.  
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Figure  8.1-2 ELISpot for ACPA and IgG secretion by in vitro generated plasmablasts from 
flow-sorted naïve B-cells of RA patients 
In vitro generated day 6 plasmablasts using CD40L/BCR/IL2/IL21 based protocol 
described in Figure  5.4-1 from flow-sorted naïve B-cells (CD19+CD20+CD27- - detailed 
gating strategy shown in Figure  5.6-2) of RA patients were incubated for 8 hours in wells 
coated with reagents shown at the top. The reagents used for detection of the secreted 
antibodies bound to the plate are shown in the bottom. The bottom row of wells was 
incubated with ACPA positive serum alternating with ACPA negative serum instead of 
cells. The spots were developed using the standard manufacturer’s protocol described in 
detail in methods section  5.9. 
The cell yield from flow sorting was poor and also affected the cell function and viability. ACPA 
detection was also limited by this factor and negative results were difficult to interpret in the 
absence of well-defined positive controls in the form of ACPA secreting PCs. Therefore other 
modes of functional evaluation were pursued. 
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8.2 Further functional characterisation of relapse associated B-cells.  
To understand the functional and pathogenic role of relapse associated B-cells it is important to 
know what stage of the B-cell life cycle these cells represent. The 4 surface markers namely 
CD24, CD84, CD95 and LAIR1 used to classify memory B-cells and identify the relapse 
associated subset show a similar expression pattern in plasmablasts. It is not known at what 
stage during differentiation they acquire this surface marker profile. It is not feasible to follow the 
B-cells in vivo through their life cycle to ascertain the stage of differentiation of the relapse 
associated B-cell. Since this subset is present only as a minor proportion in peripheral blood, it 
is possible these cells are usually tissue resident or present at sites of activity like secondary 
lymphoid organs with some spill over into peripheral blood. Presence of only low numbers in 
peripheral blood makes it difficult to study these cells in more detail. Identifying a site which is 
rich in this subset or an in vitro correlate of this subset would enable better functional 
characterisation of this subset. The technical challenges with detection of ACPA-specific B-cells 
and flow sorted subsets make this even more vital.       
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8.2.1 Sequential changes in expression of CD24, CD84, CD95 and LAIR1 
during B-cell differentiation 
Using the in vitro differentiation system it is possible to study the change in the expression of 
these markers in a sequential fashion following B-cell stimulation as they mature to 
plasmablasts. It was reasoned that this might enable identification of a stage which is similar to 
the relapse associated subset. Negatively selected peripheral blood B-cells from a healthy 
control were stimulated with CD40L and BCR stimuli and IL2 till day 3. On day 3 the cells were 
removed from CD40L and cultured with IL2 and IL21 in a nutrient rich media (Figure  5.4-1). The 
cells at various stages of differentiation were stained with the same antibodies used for memory 
B-cell phenotyping (Antibody cocktail version 1 from Table  5.2-3). CD95 expression is acquired 
and CD24 expression is lost quite early following stimulation during the initial 3 days. Loss of 
CD84 and LAIR1 occurs later quite close to the time of maturation to plasmablasts. A minor 
proportion can continue to express LAIR1 even during the plasmablast stage, which can also be 
seen in peripheral blood plasmablasts. When plasmablasts mature into PCs LAIR1 expression 
is completely lost (94). Based on the expression of these 4 markers the relapse associated B-
cells could be placed between days 3 to 5 of the differentiation, just before they differentiate into 
plasmablasts. However, the B-cells also start acquiring CD38 by this stage in vitro which is 
different to the relapse associated B-cells. These cells may still be identical in functional terms 
with the dissimilarities noted between the in vivo B-cell subset and the in vitro counterpart 
merely due to the different in vitro culture conditions and thus potentially not of functional 
relevance. Alternatively a distinct set of differentiation conditions may be required to promote 
the acquisition of this phenotype. 
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Figure  8.2-1 Sequential changes in surface expression of CD24, CD84, CD95 and LAIR1 
during B-cell differentiation 
Peripheral blood B-cells from a healthy control were stimulated with BCR and CD40L 
stimulus in the presence of IL2 till and day 3. On day 3 CD40L stimulus was withdrawn 
and cells were transferred to nutrient rich media with IL2 and IL21. CD24 expression was 
lost and CD95 was acquired quite early during B-cell differentiation whereas the loss of 
CD84 and LAIR1 occurred later. Data representative of 6 controls from 4 different 
experiments. 
 
  
Day 0 Mem-B
Day 3 ABCs
Day 4
Day 5
Day 6 Plasmablasts
Day 7
CD24 CD84 CD95 LAIR1 CD20 CD38
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8.2.2 Identification of B-cells with closely-related phenotype to the relapse 
associated subset 
Since the relapse associated subset was mainly seen in RA patients in high proportions, 
synovial fluid from various diseased states were evaluated. Synovial fluid collected in heparin 
from 3 patients with gout, one with lupus and 4 with RA who all had joint effusions were 
analysed. The sample was treated with ammonium chloride to lyse remnant RBCs and stained 
with the same antibodies used for memory B-cell phenotyping (Antibody cocktail version 1 from 
Table  5.2-3). In case of gout patients, the synovial fluid was predominantly neutrophilic and 
there was paucity of lymphocytes. In case of SLE and RA patients, the samples were mostly 
devoid of any cells except in one patient shown below. It is not clear whether the finding is 
typical for synovial fluid B-cells or occurs only in a proportion of patients due to lack of 
replicates. The day 4 activated B-cells generated by stimulation with CD40L and BCR stimuli 
and IL2 (Figure  5.4-1) are the closest to the relapse associated B-cells from the different stages 
of in vitro differentiation system. The synovial fluid B-cells had a similar expression profile 
except for CD84. However, from Figure  8.2-1 it is clear that CD84 expression could be lost in a 
quick fashion. Therefore, it is possible that CD84 is lost on egress to peripheral blood. The other 
interesting feature of the synovial fluid B-cells is that they can be divided into 2 populations 
based on their CD27 expression. CD27Neg cells are possibly at an earlier stage of their life 
cycle maturing into CD27Pos B-cells. It is also possible that this is the stage at which the 
bifurcation between memory B-cells and plasmablasts occurs in vivo but does not happen in 
vitro due to the lack of optimal conditions for generating memory B-cells.  
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Figure  8.2-2 Comparison of the relapse associated B-cells with plasmablasts, synovial 
fluid B-cells and in vitro generated activated B-cells 
Peripheral blood plasmablasts (defined as CD19+CD20-CD27HiCD38Hi) show similar 
expression profile except for CD20 and CD38. CD27 positive and negative synovial fluid 
B-cells are identical in terms of other markers tested and closely resemble 24-84-
95+LAIR1- subset except for CD84. Day 4 in vitro ABCs generated by CD40L and BCR 
stimuli and IL2 (Detailed protocol shown in Figure  5.4-1) are also related except for CD84 
and CD38.  
  
CD24 CD84 CD95 LAIR1CD19 CD20 CD27 CD38
Peripheral Blood
Plasmablasts
27 Pos SF B-cells
27 Neg SF B-cells
Day 4 In vitro ABCs
CD24- CD84-CD95+LAIR1-
Memory
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8.3 Functional profiling of the in vitro counterpart of relapse 
associated memory B-cell subset 
 The study of sequential changes in the markers used to classify the memory B-cell subsets 
during the course of in vitro B-cell differentiation from mature B-cells to plasmablasts revealed 
that the surface marker expression pattern was attained by the cells between day 3 and 
day 6.The gene expression changes occurring during this phase has been previously published 
by Cocco et al. and this pre-published data (60) was re-analysed for factors that were 
expressed at higher levels compared to the mature resting B-cells (Day 0). This reveals that B-
cells during particular stages of their normal differentiation cycle can secrete inflammatory 
mediators. To identify this stage of B-cells in vivo additional surface markers that are present 
only during this stage of B-cell differentiation were sought which could then be evaluated in 
peripheral blood of RA patients to identify the pro-inflammatory B-cells. The mechanism by 
which the depletion of B-cells by rituximab leads to clinical remission remains unclear. The 
reduction in proinflammatory mediators secreted by the circulating B-cells or during their 
differentiation into plasmablasts might represent a mechanism contributing to drug 
effectiveness. 
8.3.1 B-cells exhibit increased expression levels of proinflammatory 
mediators and chemoattractants during normal B-cell differentiation 
Gene expression analysis was performed at various stages of B-cell differentiation to 
plasmablasts from negatively selected peripheral blood B-cells from 3 controls  by Cocco et al. 
and the data was published previously(60). The gene expression was assessed on Illumina 
HumanHT-12 v4 arrays. The previously published data was reanalysed for the purpose of this 
study. From the published data 50 different clusters of genes with similar expression pattern 
were defined.  
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Figure  8.3-1 50 clusters of genes with similar patterns of expression during in vitro B-cell 
differentiation 
Negatively-selected peripheral blood B-cells were differentiated to plasma cells in vitro and 
gene expression analysis at baseline, days 3, 6, 13, 20 and 41 were performed on Illumina 
HumanHT-12 v4 arrays by Cocco et al. 50 gene clusters with similar expression patterns 
were generated by k-means clustering. Z-score (-2 to +2) derived from median expression 
values of each cluster is shown as the expression values for the clusters in the heat map. 
The representative ontology term from GO enrichment analysis is provided on the right for 
each cluster. The sample time points are indicated at the top. One of the samples on day 
20 failed quality control and was excluded. The RNA samples for days 13, 20 and 41 were 
obtained from sorted CD138 positive PCs.  The categories were defined based on heat 
map distribution. B-cell (B), Activated B-cell (ABC), Plasmablast (PB), Plasma Cell (PC).    
Reproduced with permission from Cocco et al. 
The Journal of Immunology, 2012, vol. 189 no. 12 5773-5785
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Since, the RAMB cells closely resemble the day 3 cells in the in vitro system, the activated B-
cell stage (ABC) in the publication was chosen for further analysis. The ABC stage did not have 
a separate cluster and therefore ABC/PB stage was chosen which contained 7 clusters – 11, 
12, 16, 18, 21, 22 and 25. When these clusters were examined 12, 16 and 25 contained genes 
that were highly expressed in plasma cells as well. The clusters 11, 18, 21 and 22 were chosen 
for further analysis. There were a total of 338 probes covering 261 genes in these 4 clusters. 
Since the RAMB were hypothesized to be involved in the inflammatory process in RA and 
closely resemble day 3 in vitro differentiated B-cells, the presence of pro-inflammatory genes in 
these 4 clusters were sought to provide a mechanistic explanation for the potential role of 
RAMB in RA.  
Gene ontology enrichment analysis was performed to identify the genes which are involved in 
an immune response using g:profiler (Version: r1440_e81_eg28. Date analysed – 29/09/2015, 
Gene Ontology annotations: GO direct 22/07/2015, GO terms: releases – 05/09/2015). 209 GO 
terms were significantly enriched (p<0.05) when the list of 261 genes was assessed. The full list 
of enriched GO terms sorted on their significance levels is provided in the table below. The 
comprehensive list of genes associated with each of the significantly enriched GO terms is 
provided as a spreadsheet in the e-version of the thesis. 
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Table  8.3-1 Gene ontology terms enriched on assessment of genes expressed during 
activated B-cell stage of in vitro differentiation. 
261 genes from the 4 ABC/PB clusters 11, 18, 21 and 22 shown in Figure  8.3-1 were 
assessed for GO enrichment (g:profiler Version: r1435_e80_eg27. Date analysed – 
29/09/2015) and the GO terms that were enriched are presented in order of their 
significance. 
p-value Term ID Term Name 
1.79E-54 GO:0000278 mitotic cell cycle 
4.27E-51 GO:1903047 mitotic cell cycle process 
7.3E-49 GO:0022402 cell cycle process 
1.3E-46 GO:0007049 cell cycle 
3.53E-38 GO:0000280 nuclear division 
4.14E-38 GO:0007067 mitotic nuclear division 
1.72E-36 GO:0048285 organelle fission 
8.91E-34 GO:0007059 chromosome segregation 
1.36E-30 GO:0051301 cell division 
1.76E-27 GO:0051276 chromosome organization 
2.46E-25 GO:0098813 nuclear chromosome segregation 
1.93E-23 GO:0006996 organelle organization 
2E-21 GO:1902589 single-organism organelle organization 
2.71E-21 GO:0000819 sister chromatid segregation 
2.92E-19 GO:0044770 cell cycle phase transition 
4.57E-19 GO:0044772 mitotic cell cycle phase transition 
3.69E-18 GO:0000070 mitotic sister chromatid segregation 
1.24E-17 GO:0000226 microtubule cytoskeleton organization 
2.87E-17 GO:0071840 cellular component organization or biogenesis 
1.68E-16 GO:0006260 DNA replication 
2.13E-16 GO:0007017 microtubule-based process 
3.7E-16 GO:0016043 cellular component organization 
1.29E-15 GO:0006259 DNA metabolic process 
2.39E-15 GO:0006261 DNA-dependent DNA replication 
7.02E-15 GO:0010564 regulation of cell cycle process 
1.12E-14 GO:0044763 single-organism cellular process 
1.54E-14 GO:0007052 mitotic spindle organization 
2.26E-14 GO:0051726 regulation of cell cycle 
2.16E-13 GO:0044699 single-organism process 
1.99E-12 GO:0007051 spindle organization 
2.11E-12 GO:0071103 DNA conformation change 
2.32E-12 GO:0007346 regulation of mitotic cell cycle 
6.96E-11 GO:0006310 DNA recombination 
1.02E-10 GO:0051302 regulation of cell division 
1.71E-10 GO:0034508 centromere complex assembly 
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p-value Term ID Term Name 
2.97E-10 GO:0006323 DNA packaging 
3.03E-10 GO:0043933 macromolecular complex subunit organization 
4.74E-10 GO:0031055 chromatin remodeling at centromere 
5.55E-10 GO:0051983 regulation of chromosome segregation 
8.55E-10 GO:0000075 cell cycle checkpoint 
1.01E-09 GO:0000082 G1/S transition of mitotic cell cycle 
1.48E-09 GO:0006270 DNA replication initiation 
1.65E-09 GO:0007264 small GTPase mediated signal transduction 
1.68E-09 GO:0071822 protein complex subunit organization 
1.96E-09 GO:0044843 cell cycle G1/S phase transition 
2E-09 GO:0007088 regulation of mitotic nuclear division 
2.83E-09 GO:0051783 regulation of nuclear division 
2.96E-09 GO:1902850 microtubule cytoskeleton organization involved in mitosis 
8.7E-09 GO:0061641 CENP-A containing chromatin organization 
8.7E-09 GO:0034080 CENP-A containing nucleosome assembly 
1.04E-08 GO:0034724 DNA replication-independent nucleosome organization 
1.04E-08 GO:0006336 DNA replication-independent nucleosome assembly 
1.08E-08 GO:0070507 regulation of microtubule cytoskeleton organization 
1.36E-08 GO:0007010 cytoskeleton organization 
1.78E-08 GO:1901990 regulation of mitotic cell cycle phase transition 
2.5E-08 GO:0032886 regulation of microtubule-based process 
3.62E-08 GO:0006271 DNA strand elongation involved in DNA replication 
4.81E-08 GO:0008608 attachment of spindle microtubules to kinetochore 
6.62E-08 GO:1901987 regulation of cell cycle phase transition 
9.29E-08 GO:0022616 DNA strand elongation 
1.25E-07 GO:0033260 nuclear DNA replication 
1.4E-07 GO:0050000 chromosome localization 
1.4E-07 GO:0051303 establishment of chromosome localization 
2.18E-07 GO:0043486 histone exchange 
2.32E-07 GO:0009987 cellular process 
3.13E-07 GO:0006974 cellular response to DNA damage stimulus 
3.4E-07 GO:0090068 positive regulation of cell cycle process 
4.42E-07 GO:0007080 mitotic metaphase plate congression 
4.87E-07 GO:0033044 regulation of chromosome organization 
6.78E-07 GO:0033043 regulation of organelle organization 
9.74E-07 GO:0016568 chromatin modification 
1.16E-06 GO:0051297 centrosome organization 
1.23E-06 GO:0044786 cell cycle DNA replication 
1.27E-06 GO:0008283 cell proliferation 
1.59E-06 GO:0050896 response to stimulus 
1.65E-06 GO:0006281 DNA repair 
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p-value Term ID Term Name 
1.66E-06 GO:0031145 anaphase-promoting complex-dependent proteasomal 
    2.45E-06 GO:0045787 positive regulation of cell cycle 
3.61E-06 GO:0031023 microtubule organizing center organization 
4.73E-06 GO:0051321 meiotic cell cycle 
5.4E-06 GO:0051310 metaphase plate congression 
5.97E-06 GO:0007093 mitotic cell cycle checkpoint 
8.12E-06 GO:0045930 negative regulation of mitotic cell cycle 
8.6E-06 GO:0034453 microtubule anchoring 
9.88E-06 GO:0065004 protein-DNA complex assembly 
1.37E-05 GO:0006325 chromatin organization 
1.66E-05 GO:0051304 chromosome separation 
1.74E-05 GO:0090307 mitotic spindle assembly 
1.81E-05 GO:0043044 ATP-dependent chromatin remodeling 
2.94E-05 GO:0007098 centrosome cycle 
3.44E-05 GO:0051225 spindle assembly 
3.53E-05 GO:0051383 kinetochore organization 
0.000037 GO:0051782 negative regulation of cell division 
4.13E-05 GO:0006338 chromatin remodeling 
4.48E-05 GO:0051716 cellular response to stimulus 
4.49E-05 GO:0070271 protein complex biogenesis 
4.49E-05 GO:0006461 protein complex assembly 
4.66E-05 GO:0033554 cellular response to stress 
4.98E-05 GO:0006950 response to stress 
5.51E-05 GO:0031497 chromatin assembly 
6.32E-05 GO:0031577 spindle checkpoint 
7.94E-05 GO:0007126 meiotic nuclear division 
8.22E-05 GO:0071824 protein-DNA complex subunit organization 
8.54E-05 GO:0045786 negative regulation of cell cycle 
0.000105 GO:0030071 regulation of mitotic metaphase/anaphase transition 
0.000108 GO:0010948 negative regulation of cell cycle process 
0.000109 GO:0000086 G2/M transition of mitotic cell cycle 
0.00011 GO:0006334 nucleosome assembly 
0.000112 GO:0065003 macromolecular complex assembly 
0.000117 GO:1903046 meiotic cell cycle process 
0.000124 GO:1902099 regulation of metaphase/anaphase transition of cell cycle 
0.000125 GO:0044839 cell cycle G2/M phase transition 
0.000146 GO:0007091 metaphase/anaphase transition of mitotic cell cycle 
0.000171 GO:0044784 metaphase/anaphase transition of cell cycle 
0.000252 GO:0010639 negative regulation of organelle organization 
0.000268 GO:0010965 regulation of mitotic sister chromatid separation 
0.00031 GO:0033045 regulation of sister chromatid segregation 
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p-value Term ID Term Name 
0.00031 GO:0033047 regulation of mitotic sister chromatid segregation 
0.000336 GO:0030261 chromosome condensation 
0.000358 GO:0051306 mitotic sister chromatid separation 
0.00044 GO:0006333 chromatin assembly or disassembly 
0.000472 GO:0045132 meiotic chromosome segregation 
0.000553 GO:0008150 biological_process 
0.000713 GO:0044710 single-organism metabolic process 
0.000723 GO:0048247 lymphocyte chemotaxis 
0.000764 GO:0000910 cytokinesis 
0.000897 GO:0035556 intracellular signal transduction 
0.000906 GO:0051784 negative regulation of nuclear division 
0.00101 GO:0034502 protein localization to chromosome 
0.00105 GO:0034728 nucleosome organization 
0.00116 GO:0007076 mitotic chromosome condensation 
0.00117 GO:0045931 positive regulation of mitotic cell cycle 
0.00123 GO:0046605 regulation of centrosome cycle 
0.00147 GO:0072676 lymphocyte migration 
0.00155 GO:0002548 monocyte chemotaxis 
0.00178 GO:0000018 regulation of DNA recombination 
0.00179 GO:0061640 cytoskeleton-dependent cytokinesis 
0.0023 GO:0051640 organelle localization 
0.00231 GO:0031109 microtubule polymerization or depolymerization 
0.00235 GO:0006301 postreplication repair 
0.00237 GO:0000083 regulation of transcription involved in G1/S transition of mitotic 
  0.00265 GO:2001251 negative regulation of chromosome organization 
0.00269 GO:0045839 negative regulation of mitotic nuclear division 
0.00337 GO:0051781 positive regulation of cell division 
0.00359 GO:0007094 mitotic spindle assembly checkpoint 
0.00404 GO:0006302 double-strand break repair 
0.00422 GO:0071173 spindle assembly checkpoint 
0.00482 GO:1903363 negative regulation of cellular protein catabolic process 
0.00494 GO:0045841 negative regulation of mitotic metaphase/anaphase transition 
0.00494 GO:0071174 mitotic spindle checkpoint 
0.005 GO:0000022 mitotic spindle elongation 
0.005 GO:0007100 mitotic centrosome separation 
0.00511 GO:0051129 negative regulation of cellular component organization 
0.00551 GO:0070925 organelle assembly 
0.00576 GO:1902100 negative regulation of metaphase/anaphase transition of cell 
 0.00583 GO:0000281 mitotic cytokinesis 
0.0062 GO:0031399 regulation of protein modification process 
0.0062 GO:0071345 cellular response to cytokine stimulus 
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p-value Term ID Term Name 
0.00633 GO:0031570 DNA integrity checkpoint 
0.00647 GO:0048522 positive regulation of cellular process 
0.00661 GO:0044711 single-organism biosynthetic process 
0.00762 GO:1901991 negative regulation of mitotic cell cycle phase transition 
0.00775 GO:0033046 negative regulation of sister chromatid segregation 
0.00775 GO:0033048 negative regulation of mitotic sister chromatid segregation 
0.00775 GO:2000816 negative regulation of mitotic sister chromatid separation 
0.00782 GO:0002376 immune system process 
0.00861 GO:0034097 response to cytokine 
0.0089 GO:0051231 spindle elongation 
0.0089 GO:0051299 centrosome separation 
0.00904 GO:0032435 negative regulation of proteasomal ubiquitin-dependent protein 
  0.00937 GO:0019886 antigen processing and presentation of exogenous peptide 
     0.0103 GO:0051985 negative regulation of chromosome segregation 
0.0124 GO:0051128 regulation of cellular component organization 
0.0133 GO:0002495 antigen processing and presentation of peptide antigen via 
   0.0135 GO:0031110 regulation of microtubule polymerization or depolymerization 
0.0139 GO:1901799 negative regulation of proteasomal protein catabolic process 
0.014 GO:0009314 response to radiation 
0.0142 GO:0051656 establishment of organelle localization 
0.0145 GO:0032434 regulation of proteasomal ubiquitin-dependent protein 
  0.0146 GO:1901988 negative regulation of cell cycle phase transition 
0.0147 GO:0006268 DNA unwinding involved in DNA replication 
0.0151 GO:0031572 G2 DNA damage checkpoint 
0.0161 GO:0051052 regulation of DNA metabolic process 
0.0172 GO:0002504 antigen processing and presentation of peptide or 
      0.0173 GO:0000003 reproduction 
0.0179 GO:0007019 microtubule depolymerization 
0.0199 GO:0009628 response to abiotic stimulus 
0.0202 GO:0044085 cellular component biogenesis 
0.022 GO:0051439 regulation of ubiquitin-protein ligase activity involved in mitotic 
  0.0223 GO:0046602 regulation of mitotic centrosome separation 
0.0223 GO:1901992 positive regulation of mitotic cell cycle phase transition 
0.0223 GO:0043146 spindle stabilization 
0.0256 GO:1903308 regulation of chromatin modification 
0.027 GO:0044237 cellular metabolic process 
0.0276 GO:1903051 negative regulation of proteolysis involved in cellular protein 
  0.0276 GO:0070098 chemokine-mediated signaling pathway 
0.0317 GO:1901989 positive regulation of cell cycle phase transition 
0.0317 GO:0032508 DNA duplex unwinding 
0.0339 GO:0051382 kinetochore assembly 
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p-value Term ID Term Name 
0.0339 GO:0051988 regulation of attachment of spindle microtubules to kinetochore 
0.0339 GO:0071459 protein localization to chromosome, centromeric region 
0.036 GO:1901360 organic cyclic compound metabolic process 
0.0362 GO:0043241 protein complex disassembly 
0.0379 GO:1902275 regulation of chromatin organization 
0.0391 GO:0007062 sister chromatid cohesion 
0.0419 GO:0032201 telomere maintenance via semi-conservative replication 
0.0447 GO:0016310 phosphorylation 
0.0467 GO:0031401 positive regulation of protein modification process 
0.0484 GO:0016446 somatic hypermutation of immunoglobulin genes 
 
The GO term “Immune system processes” (GO:0002376) was significantly enriched (p=0.0078) 
which contained 60 genes from the list of 261 genes. The change in expression levels of these 
genes during B-cell differentiation is shown in the figure below (Gene-E version 3.0.204). The 
genes were ordered by hierarchical clustering using average linkage and one minus Spearman 
correlation as the row distance metric. The GO term “Lymphocyte chemotaxis” (GO:0048247) 
was also significantly enriched (p=0.0007) and the term included 8 genes - CCL22, CCL17, 
CCL2, CXCL9, CXCL10, CCL4L2, CCL3L1 and CCL3.       
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Figure  8.3-2 Expression levels of genes linked with immune system processes that are 
elevated during the activated B-cell stage of in vitro differentiation to PCs 
261 genes from the 4 ABC/PB clusters were assessed for GO enrichment (g:profiler 
Version: r1435_e80_eg27. Date analysed – 29/09/2015) and 60 genes were linked with 
the GO term “immune system processes” (GO:0002376) (p=0.0078). The relative 
expression values over the time course of the differentiation series is provided for the 60 
genes in the heat map. The genes were ordered by hierarchical clustering using average 
linkage and one minus Spearman correlation as the row distance metric. 
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To further illustrate the kinetics of gene expression, the expression values for 10 genes from the 
wider list of genes linked to “immune system process” and “lymphocyte chemotaxis” were 
illustrated as line graphs. This included 3 proinflammatory genes – Tumour Necrosis Factor 
(TNF-α), Allograft Inflammatory Factor 1 (AIF1), Lymphotoxin alpha (LTA) and the enzyme 
involved in extracellular matrix breakdown - Matrix Metalloproteinase-7 (MMP7) shown in 
Figure  8.3-3. It also included six chemokine ligands shown in Figure  8.3-4, which recruit other 
inflammatory cells including monocytes, T-cells and dendritic cells.  
 
Figure  8.3-3 Gene expression levels of inflammatory mediators during normal B-cell 
differentiation 
Gene expression was assessed at various stages of B-cell differentiation to plasmablasts 
from negatively selected peripheral blood B-cells from 3 controls using Illumina HumanHT-
12 v4 arrays by Cocco et al. and the data was published previously (60). This graph was 
derived from reanalysis of previously published data. The absolute levels of gene 
expression by Illumina bead array at the time points indicated on the X axis from 3 
controls. The dots represent the mean and the bars represent the standard deviation. 
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Figure  8.3-4 Gene expression levels of Chemoattractant proteins during normal B-cell 
differentiation 
Gene expression was assessed at various stages of B-cell differentiation to plasmablasts 
from negatively selected peripheral blood B-cells from 3 controls using Illumina HumanHT-
12 v4 arrays by Cocco et al. and the data was published previously (60). This graph was 
derived from reanalysis of previously published data. The absolute levels of gene 
expression by Illumina bead array at the time points indicated on the X axis from 3 
controls. The dots represent the mean and the bars represent the standard deviation. 
CXCL – Chemokine (C-X-C motif) Ligand, CCL – Chemokine (C-C motif) Ligand.  
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Since anti-TNF therapy and B-cell depletion are both effective in RA, particular attention was 
given to TNF-α. The list surprisingly showed a multitude of pro-inflammatory and chemo-
attractant proteins in addition to TNF. To ensure that this is not an isolated change in 
transcriptional activity without change in protein levels, the amount of TNF-α secreted by Day 3 
B-cells was evaluated by ELISA of the culture supernatants. The cells were incubated at 370C 
for 4 hours. Media without cells was used as negative control and cells stimulated with a 
combination of PMA, Ionomycin and LPS was used as positive control. ELISA was performed 
according to standard manufacturer’s protocol (Bethyl laboratories, USA) as described in 
methods section  5.8. The level of spontaneous secretion by day 3 B-cells is below the sensitivity 
of ELISA and therefore TNF-α secretion was detected only with stimulation (Figure  8.3-5). 
However secretion of TNF became apparent when using a technique with higher sensitivity, 
namely ELISpot (Figure  8.3-6). For ELISpot, wells with unstimulated B-cells without any primary 
coating were used as additional negative controls. The cells were incubated at 370C for 4 hours 
and developed using standard ELISpot kit protocol (Mabtech, Sweden) described in detail in 
methods section  5.9.  
 
Figure  8.3-5 TNF secretion during day 3 of in vitro differentiation by B-cells detected by 
ELISA 
The mean optical density of the triplicate samples are plotted as dots and the bars 
represent the range. Cells were incubated at 370C  for 4 hours and supernatants were 
analysed. Media subjected to same conditions without the cells and stimulation with 
mixture of PMA (10 ng/ml), Ionomycin (1 μM) and LPS (1 μg/ml) were used as negative 
and positive controls respectively. ELISA was performed according to standard 
manufacturer’s protocol as described in methods section  5.8. 
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Figure  8.3-6 ELISpot for TNF secretion by B-cells during day 3 of in vitro differentiation  
Day 3 B-cells at a density of 30000 cells per well were incubated in triplicates on wells 
coated with anti-TNF capture antibody. Uncoated wells with B-cells were used as negative 
controls. Media subjected to same conditions without the cells and cells stimulated with 
mixture of PMA (10 ng/ml), Ionomycin (1 μM) and LPS (1 μg/ml) were used as negative 
and positive controls respectively. The ELISpot plate was incubated at 370C for 4 hours. 
Biotinylated anti-TNF followed by streptavidin-HRP was used to detect the spots as 
described in methods section  5.9. 
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8.3.2 ELISpot for TNF secretion by memory B-cell subsets 
The stage of in vitro differentiation that is closest to the relapse-associated memory B-cell 
subset is the stage when proinflammatory mediators are secreted. Therefore, TNF secretion by 
relapse-associated subset was evaluated. The flow sorted memory B-cell subsets as shown in 
Table  8.1-1 were seeded on to ELISpot plates coated with anti-TNF or anti-IgG capture 
antibodies whilst the antibody of same isotype but unrelated specificity served as negative 
control. Due to the very low cell numbers, cells from 2 patients who were rituximab naïve were 
combined. The 2 patients relapsing post-rituximab were combined into a single sample as well. 
The cells were incubated for 8 hours in cell culture media to allow for secretion. Anti-IgG or anti-
TNF antibodies were used for detection. There was no detectable IgG or anti-TNF secretion 
from these cells, which could be due to the low cell numbers and viability as noted in case of 
plasmablasts in Figure  8.1-1. 
 
Figure  8.3-7 ELISpot for TNF secretion by sorted memory B-cell subsets 
The 24-84-95+LR1- memory B-cell subset (LR-) and the opposite 24+84+95-LR1+ (LR+) 
subset from peripheral blood of 2 groups of RA patients with active disease – rituximab 
naïve and post-rituximab relapse (2 patients in each group) were incubated for 8 hours in 
wells coated with reagents shown in the top row. The spots were developed with 
biotinylated anti-IgG or anti-TNF as described in methods section  5.9. 
No Cells
IsotypeAnti-IgG Anti-TNF
Anti-IgG Anti-TNF
Active LR-
Relapse LR-
Active LR+
Relapse LR+
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8.3.3 Changes in surface markers that follow the pattern of inflammatory 
mediators 
To identify the in vivo counterpart of the cells that secrete inflammatory mediators in vitro, the 
changes in expression of surface markers that coincide with the secretion of inflammatory 
mediators were sought. Surface markers detectable by flow cytometry are more reliable to be 
used as biomarkers rather than functional assays of protein secretion. The gene expression 
data generated by Cocco et al (60) was reanalysed for this purpose. TIM3 (T-cell 
Immunoglobulin domain and Mucin domain 3 official gene symbol HAVCR2 – Hepatitis A Virus 
Cellular Receptor 2) and CD30 (TNFRSF8 – TNF Receptor Super Family) were identified which 
follow the similar pattern with peak around day 3 from baseline day 0 levels and start 
decreasing by day 6. A criteria of increase in absolute expression values by more than 1 
between days 0 and 3 and decrease by more than 1 between days 3 and 6 was used to identify 
potential markers since the expression of proinflammatory genes follow this pattern.  
 
Figure  8.3-8 Gene expression levels of surface markers that are elevated during 
plasmablast differentiation. 
Gene expression was assessed at various stages of B-cell differentiation to plasmablasts 
from negatively selected peripheral blood B-cells from 3 controls using Illumina HumanHT-
12 v4 arrays by Cocco et al. and the data was published previously (60). This graph was 
derived from reanalysis of previously published data. Levels of absolute gene expression 
of TIM3 (HAVCR2) and CD30 (TNFRSF8) at the various time points during B-cell 
differentiation as indicated in 3 controls. The markers were chosen based on change in 
transcript levels that follow the inflammatory mediators.  
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8.3.4 Changes in surface expression of TIM3 during B-cell differentiation 
The changes in TIM3 protein levels were examined sequentially in two controls during B-cell 
differentiation by flow cytometry to confirm the changes seen in gene expression. The cells were 
stained with CD24 FITC, TIM3 PE, CD4 PerCP-Cy5.5, CD38 PECy7, CD19 BV421, LAIR1 
pacific orange, CD27 AF647 and CD20 APC-H7. Live cells were gated based on their scatter 
profile and CD4 was used as a negative marker. Peripheral blood B-cells did not express TIM3 
and started expressing within two days of stimulation. The levels were at the highest on day 3 
and gradually declined with only a tiny proportion positive on day 10 as shown in Figure  8.3-9. 
There is heterogeneity in TIM3 expression from day 3 to day 10 with at least a small proportion 
of cells negative throughout the course of differentiation. It is not clear whether it just reflects 
different subsets of B-cells such as naïve and memory B-cells changing the expression levels at 
varying rates or whether a certain subset does not upregulate TIM3 altogether. 
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Figure  8.3-9 Changes in surface expression of TIM3 during B-cell differentiation 
Negatively selected B-cells from two donors were differentiated using CD40L, BCR 
stimulus and IL2 based protocol (Figure  5.4-1) and their surface expression of TIM3 was 
examined every day during their course of differentiation. Histograms showing TIM3 
expression levels (MFI) showing representative pattern of 5 different controls from 4 
different experiments. 
Day 0
Day 1
Day 2
Day 3
Day 4
Day 5
Day 6
Day 7
Day 10
Donor 1 Donor 2
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B-cells can be differentiated to PCs in vitro by using either CD40L or TLR ligand as co-
stimulatory agents (detailed protocol given in methods section  5.4.4). It is not known whether 
upregulation of TIM3 during B-cell differentiation is dependent on CD40L co-stimulatory signals 
from T-cells. Therefore, B-cells stimulated with the TLR 7/8 agonist R848 (1 µg/ml) was 
monitored which showed that the surface expression of TIM3 was upregulated with both CD40L 
and R848 stimuli as shown in Figure  8.3-10. The cells were stained with CD24 FITC, TIM3 PE, 
CD4 PerCP-Cy5.5, CD38 PECy7, CD19 BV421, LAIR1 pacific orange, CD27 AF647 and CD20 
APC-H7. Live cells were gated based on their scatter profile and CD4 was used as a negative 
marker. 
 
Figure  8.3-10 Upregulation of TIM3 expression on day 6 after B-cells were stimulated with 
CD40L or TLR agonist R848. 
Histograms of TIM3 expression levels (MFI) on day 6 from 2 donors are shown whose B-
cells were stimulated with either CD40L or the TLR agonist R848 (1 µg/ml). The detailed 
differentiation protocol is described in methods section  5.4.4. Data shown is from a single 
experiment. 
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8.3.5 Changes in surface expression of CD30 during B-cell differentiation 
CD30 was the other surface marker that was upregulated based on gene expression analysis 
during the stage when proinflammatory mediators are secreted. The sequential change in levels 
of CD30 on cell surface was examined by flow cytometry to confirm the changes seen by gene 
expression. The cells were stained with CD24 FITC, CD30 PE, CD4 PerCP-Cy5.5, CD38 
PECy7, CD19 BV421, LAIR1 pacific orange, CD27 AF647 and CD20 APC-H7. Live cells were 
gated based on their scatter profile and CD4 was used as a negative marker. Figure  8.3-11 
shows representative changes in levels of CD30 from 6 different experiments. The expression 
reached peak levels between day 3 and day 4 and reduced to almost baseline levels by day 6. 
Staining with TIM3/CD30 antibodies showed consistently higher signal than the isotype 
antibody. Therefore, the changes in levels of TIM3 and CD30 are not due to non-specific 
binding of the antibodies during certain stages of B-cell differentiation. 
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Figure  8.3-11 Transient upregulation in surface expression of CD30 during B-cell 
differentiation 
Negatively selected B-cells from 2 donors were differentiated using CD40L, BCR stimulus 
and IL2 based protocol (Figure  5.4-1) and histograms of levels of CD30 surface 
expression (MFI) at baseline, day 4 and day 6 are shown. Live cells were gated based on 
their scatter profile and CD4 was used as a negative marker. This is representative of 6 
experiments which all showed similar pattern of changes in CD30 expression.  
CD30 CD30
Control 1 Control 2
Day 0
Day 4
Day 6
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Figure  8.3-12 Changes in TIM3/CD30 expression is not due to non-specific binding 
Cells from day 4 of B-cell differentiation (detailed differentiation protocol represented in 
Figure  5.4-1)  when the levels of expression of TIM3 and CD30 are close to peak levels 
are shown. Cells were stained with anti-CD30, anti-TIM3 or isotype antibody and only live 
cells based on scatter profile were analysed. Dot plots showing CD19 on the x-axis and 
CD30/TIM3/Isotype along the y-axis.  
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8.3.6 Surface expression of TIM3 by B-lineage cells in vivo 
TIM3 is not expressed by the peripheral blood B-cells as seen in Figure  8.3-9. The increase in 
TIM3 expression occurs following activation of B-cells in vitro and therefore peripheral blood 
from patients with ongoing inflammatory process was analysed. The peripheral blood B-cells 
from a diseased control showing a reactive picture and from an active RA/SLE overlap patient 
were analysed (Figure  8.3-13). A slightly modified antibody cocktail (version 1 from Table  5.2-3) 
used for memory B-cell phenotyping was used for staining the cells following RBC lysis with 
ammonium chloride. CD84 from the memory B-cell panel was replaced with TIM3. B-cells were 
defined based on their scatter profile and dual positivity for CD19 and CD20. This did not show 
TIM3 expression by any B-lineage cells. 
Since the peripheral blood B-cells are likely to be resting and the changes in surface expression 
levels were seen during active differentiation, cells from other sites likely to contain activated B-
cells were sought. B-cells from the synovial fluid from the knee joint with clinically active disease 
of a RA patient did not show any increased expression. Cells from secondary lymphoid organs 
like spleen, lymph node and bone marrow which are sites of B-cell differentiation were 
analysed. 4 lymph nodes which were affected by different pathologies including reactive, 
granulomatous inflammation, infiltration by follicular lymphoma and lung carcinoma did not show 
a distinct TIM3 positive B-cell population although sparse TIM3 positive cells could be observed. 
Representative lymph node TIM3 expression pattern is shown in Figure  8.3-13. B-cells from 
reactive bone marrow did not show any increased levels of TIM3 expression either. However in 
the spleen sample analysed, TIM3 expressing B-cells were identified all be it as a minor 
proportion of cells.   
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Figure  8.3-13 Lack of TIM3 surface expression on in vivo B-cells 
Peripheral blood B-cells showing their surface levels of TIM3. Lymphocytes were gated 
based on their scatter profile are shown in grey and B-cells were gated based on their co-
expression of CD19 and CD20. Expression pattern in a lymph node which is 
representative of the 4 lymph nodes analysed. 
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Figure  8.3-14 TIM3 expression by B-cells derived from various sites. 
Lymphocytes are gated based on their scatter profile and B-cells were defined based on 
their co-expression of CD19 and CD20. Lymphocytes are denoted by grey colour and B-
cells by black colour except row 2 where all lymphocytes are coloured black. Low levels of 
TIM3 expressing B-cells were detected in spleen but not in reactive bone marrow or RA 
synovial fluid. 
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The various B-cell neoplasms represent different stages in a B-cell life cycle. Therefore TIM3 
expression by B-cell neoplasms was sought to identify the closest B-cell stage that expresses 
TIM3. 12 bone marrow samples from different B-cell neoplasms including follicular lymphoma, 
chronic lymphocytic leukaemia, mantle cell lymphoma, marginal zone lymphoma and plasma 
cell neoplasia were analysed. Other pathologies affecting the bone marrow like myelofibrosis 
and myelodysplastic syndromes were used as disease controls. The cells were stained with 
CD24 FITC, TIM3 PE, CD4 PerCP-Cy5.5, CD38 PECy7, CD19 BV421, CD27 BV605, LAIR1 
AF647 and CD20 APC-H7 after RBC lysis with ammonium chloride. Live cells were gated based 
on their scatter profile and CD4 was used as a negative marker. Out of the B-cell neoplasms 
affecting the bone marrow only marginal zone lymphoma (MZL) showed positive TIM3 
expression. The level of MZL cells in bone marrow did not correlate with TIM3 positivity as 
shown in Figure  8.3-15. 
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Figure  8.3-15 TIM3 expression on bone marrow marginal zone lymphoma B-cells 
Bone marrow samples from 3 patients with varying levels of marginal zone lymphoma 
involvement of the bone marrow. Lymphocytes are gated based on their scatter profile and 
B-cells were defined based on their co-expression of CD19 and CD20. Lymphocytes are 
denoted by grey colour and B-cells by black colour 
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While these data suggested that TIM3 expression was not a common feature amongst reactive 
or neoplastic B-cells, this needs to be viewed in the context of the transient nature of the B-cell 
activation state at which TIM3 expression is maximally observed in vitro. CD30, the other 
marker co-expressed in activated B-cells, though readily detectable amongst a sub-population 
of large activated B-cells by immunohistochemistry is not readily identified in most reactive 
conditions tested by flow cytometry. Equally CD30 is only expressed by a subset of B-cell 
neoplasms in the context of diffuse large B-cell lymphomas and classical Hodgkin lymphoma. 
Thus a logical further extension of this work will be to examine a range of reactive lymph nodes 
and suitable neoplasms for TIM3 expression by immunohistochemistry. 
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8.3.7 Effect of TIM3 ligand galectin9 on B-cell differentiation 
The effect of TIM3 has been extensively studied in T-cells. Stimulation of TIM3 on T-cells with 
galectin9 leads to apoptosis and cell death. However the role played by TIM3 on B-cell 
differentiation is not known. Since TIM3 is transiently expressed during B-cell activation and 
certain malignancies, targeting TIM3 might prove to be a therapeutic option in B-cell mediated 
autoimmune conditions and malignancies. Therefore, the in vitro effect of galectin9 on B-cell 
differentiation was studied.  
Galectin-9 had a very narrow active to toxic window. Doses of 10-25 nM of recombinant human 
galectin-9 (R&D systems) had minimal to no effect on viability of cells whereas the 50 nM dose 
used to modulate T-cells killed the majority of cells. Cell counts were obtained by flow cytometry 
using countbright beads (Invitrogen) after excluding dead cells with propidium iodide stain. 
Blocking (Clone 2E2) or agonistic TIM3 antibody (Clone 5D12) on day 3 did not have any effect 
on viability at 24 hours. Galectin-9 at 50 nM dose was toxic to cells at 24 hours which was not 
blocked by Anti-Galectin9 or anti-TIM3 antibody. The effect of galectin-9 for 24 hours on viability 
of B-lineage cells was similar up to day 11 of B-cell differentiation. Most cells have differentiated 
to plasmablasts or plasma cells by day 10 which do not express TIM3. Therefore, the effect of 
galectin9 is likely to be non-specific toxicity and not mediated via TIM3. However it should be 
noted that there has been previous debate in the literature regarding the efficacy of the R&D 
Galectin-9 used (93), and an alternate source of Galectin-9 would need to be evaluated to 
address this question further. 
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Figure  8.3-16 Effect of TIM3 ligand galectin9 on B-cells during various stages of B-cell 
differentiation 
a) Effect of galectin-9 treatment for 24 hours on day 3 B-cells on viability at the 
concentrations indicated on the X-axis.  
b) Effect of galectin-9 treatment for 24 hours on day 3 B-cells on viability in combination 
with anti-TIM3 or anti-Gal9 antibody as well as the antibodies without Gal9.  
c-f) Effect of galectin-9 treatment for 24 hours on day 4, 5, 7 and 11 cells on viability. DTT 
– Dithiothreitol. Live cells were counted by flow cytometry using countbright beads 
(Invitrogen) and dead cells were excluded with propidium iodide staining. 
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8.4 Alterations in memory B-cell subsets during immune response to 
seasonal influenza vaccination 
The memory B-cells are heterogeneous in steady state, while during in vitro differentiation the 
entire B-cell population changes as a whole. However, during an immune response in vivo 
whether there is predominance of certain subsets is not known. The changes in subset 
distribution pattern during an immune response can provide vital information regarding the 
functional relevance of the different subsets. The in vivo monitoring of relapse-associated 
memory B-cell subset seen in RA patients during relapse is challenging. The immune response 
can predate clinical symptoms and can be difficult to predict. Immune responses generated due 
to intercurrent infections and other inflammatory processes can also alter memory B-cell 
subsets. Immune responses to infections are also difficult to study due to the heterogeneity 
caused by varying levels of severity and different types of infections. Vaccination can induce an 
immune response in a controlled fashion, which should generate a similar immune response in 
the vacinees. Seasonal influenza vaccination is offered routinely to NHS staff and university 
staff in autumn in the UK. This opportunity was used to monitor the B-cell subsets in 6 controls 
in 2 different experiments. 
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8.4.1 Plasmablast response following influenza vaccination 
The memory B-cell subsets were evaluated before and at serial time points following the 
vaccine. All the controls have had the flu vaccine the year before and therefore the immune 
response is likely to be a mixture of primary and secondary immune response. However the 
antigens in the flu vaccine are altered on a yearly basis and therefore likely to induce more of a 
primary immune response depending on the degree of change from the previous year. B-cells 
were analysed at baseline, days 1,  6 and 13. All of the vaccinated controls made an immune 
response to the vaccine as evidenced by the increase in absolute plasmablast count on day 6. 2 
controls had a weak response (<2-fold increase in plasmablast count between day 0 and day 6). 
The other 4 controls had more than 7-fold increase in plasmablast count. The plasmablast 
response resolved to pre-vaccination levels in a week from the peak levels on day 6 in all 
except one control.  If the absolute plasmablast count at day 6 is considered as the only criteria 
for response irrespective of the base line levels, the 6 controls segregate into 3 groups: Low 
(less than 4000 cells/mL), Moderate (4000-10000 cells/mL) and Good (>10000 cells/mL) 
responders.  
 
Figure  8.4-1 Plasmablast numbers peak on day 6 following influenza vaccination 
Plasmablasts (defined as CD19+CD20-CD27++CD38++) in the 6 controls on the days 
specified on the X-axis following influenza vaccination. The absolute counts were derived 
using dual-platform methodology using the mononuclear cell counts by Sysmex 
haematology analyser.  
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8.4.2 Correlates of poor plasmablast response following influenza 
vaccination 
The proportion of the 16 memory B-cell subsets as a percentage of memory B-cells and their 
absolute count was monitored sequentially following the vaccination of 6 healthy controls. 
Peripheral blood B-cells were stained with antibodies given in Table  5.2-3 (Version 2) after RBC 
lysis with ammonium chloride. Memory B-cells were defined as CD19, CD20 and CD27 positive 
and further sub-classified as per the gating strategy demonstrated in Figure  5.2-6. 4 out of 6 
controls showed an increase in proportion of 24-84-95+LR1- subset after vaccination prior to 
plasmablast response but their absolute count remained stable. 3 out of 4 controls who showed 
this pattern of response had a decrease in the absolute count of the usually dominant 
24+84+95-LR1+ subset. In control 2 the decrease in absolute count of 24-84-95+LR1- subset is 
accompanied by an increase in its relative proportion. This is likely to be due to the absolute 
counts of the other subsets decreasing much more than the 24-84-95+LR1- subset. This 
suggests that the increase noted in the proportion of relapse-associated memory B-cell subset 
post vaccination is due to the decrease in the numbers of usual dominant subset. This relative 
change in proportions was not universal since control 6 showed a mild decrease in proportion 
and absolute count of the 24-84-95+LR1- subset.  
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Figure  8.4-2 Sequential change in proportions and absolute numbers of the 2 key 
memory B-cell subsets during immune response to influenza vaccination 
The sequential change in absolute cell counts (logarithmic scale) and percentages of 24-
84-95+LR1- and 24+84+95-LR1+ memory B-cell subsets in 6 controls are shown. Memory 
B-cells were gated based on their lymphocyte scatter profile and CD19PosCD20PosCD27Pos. 
The subsets were then defined based on the above markers. Detailed gating strategy is 
provided in Figure  5.2-6. 
 
The sequential change in proportion of each of the 16 subsets was analysed and the results are 
shown in Table  8.4-1. To decide whether that particular subset is showing an increase or 
decrease prior to plasmablast response arbitrary criteria were used – half or more than half of 
the samples showing an increase or decrease of 2 fold or more. 
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Table  8.4-1 Changes in the proportion memory B-cell subsets during an immune 
response to seasonal influenza vaccination  
The 16 memory B-cell subsets are classified into 3 groups based on whether their relative 
proportions increase, decrease or static before the plasmablast response. An arbitrary 
criteria of the change in proportion of more than 2 fold between base line and before 
plasmablast response in 3 or more samples was used to determine whether there was 
increase or decrease of that particular subset.  
Increase in Percentage Decrease in Percentage No change in Percentage 
24+84-95-LR- 24+84-95+LR- 24+84-95-LR+ 
24-84-95+LR- 24+84-95+LR+ 24+84+95-LR- 
24-84-95+LR+ 24+84+95+LR- 24+84+95-LR+ 
24-84-95-LR- 24+84+95+LR+ 24-84+95+LR- 
24-84-95-LR+   
24-84+95+LR+   
24-84+95-LR-   
24-84+95-LR+   
 
Changes in the various subsets seen in the table suggest some of the subsets might have a 
similar propensity and can be consolidated into fewer subsets with similar changes in 
proportions post vaccination. All subsets with CD24 negative memory B-cells show an increase 
in proportion except one whereas the subsets with CD24 positive memory B-cells show a 
decrease or no change in proportion following vaccination before the plasmablast response. 
The proportion of CD24 and CD95 dual-positive memory B-cells decreases prior to plasmablast 
response.    
The fold increase in plasmablast count between day 0 and day 6 has a positive correlation with 
the proportion (Spearman’s correlation coefficient (r) =0.429, p=0.420) and absolute count 
(r=0.543, p=0.297) of relapse-associated memory B-cell subset at baseline which did not reach 
statistical significance. The baseline proportion (r=-0.771, p=0.103) and absolute count (r=-
0.371, p=0.497) of usual dominant subset showed negative correlation, which was not 
    180 
 
 
statistically significant. Lower relapse-associated memory B-cell count of less than 2000 
cells/mL and higher usual dominant memory B-cell percentage of more than 30% was 
associated with a weak plasmablast response. 
 
Figure  8.4-3 Correlation of baseline parameters with plasmablast response 
Absolute counts (cells/mL) and proportion of the 2 key memory B-cell subsets (relapse 
associated and usual dominant subset) are represented on the Y-axis and the fold 
increase in plasmablast response between day 0 and day 6 represented on the X-axis. 
Plasmablasts were gated based on their scatter profile and 
CD27HighCD38HighCD20NegCD19Pos. Fold increase in plasmablasts was calculated as ratio 
of absolute plasmablast count on day 6 / absolute plasmablast count on day 0. The 
Spearman’s correlation coefficient (r) and p-value are given. There was a positive 
correlation with the proportion (r =0.429, p=0.420) and absolute count (r=0.543, p=0.297) 
of relapse-associated 24-84-95+LAIR1- memory B-cell subset at baseline which did not 
reach statistical significance. The baseline proportion (r=-0.771, p=0.103) and absolute 
count (r=-0.371, p=0.497) of usual dominant 24+84+95-LAIR1+ subset showed negative 
correlation with plasmablast response which again did not reach statistical significance.   
The analysis of correlation of the levels of the various memory B-cell subsets as well as the key 
B-cell subsets with the fold increase in plasmablast numbers between day 0 and day 6 is 
tabulated as below.  
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Table  8.4-2 Correlation of various baseline B-cell parameters with plasmablast response 
to influenza vaccination  
Non-parametric spearman’s test of correlation between the fold increase in plasmablasts 
between baseline and day 6 and the baseline parameters indicated in the first column. 
 Spearman's Coefficient 'R' P Value (two-tailed) 
Transitional B-cell% 0.371 0.497 
Naïve B-cell% -0.429 0.419 
Memory B-cell% 0.257 0.658 
Plasmablasts % 0.029 > 0.999 
Transitional B-cell Count 0.600 0.242 
Naïve B-cell Count -0.257 0.658 
Memory B-cell Count 0.086 0.919 
Plasmablasts Count -0.200 0.714 
24+84-95+LR- % 0.029 > 0.999 
24+84-95+LR+ % 0.314 0.564 
24+84-95-LR- % 0.371 0.497 
24+84-95-LR+ % -0.200 0.714 
24+84+95+LR- % 0.200 0.714 
24+84+95+LR+ % 0.200 0.714 
24+84+95-LR- % 0.200 0.714 
24+84+95-LR+ % -0.771 0.103 
24-84-95+LR- % 0.429 0.419 
24-84-95+LR+ % 0.886 0.033 
24-84-95-LR- % 0.886 0.033 
24-84-95-LR+ % 0.714 0.136 
24-84+95+LR- % 0.543 0.297 
24-84+95+LR+ % 0.543 0.297 
24-84+95-LR- % 0.714 0.136 
24-84+95-LR+ % -0.200 0.714 
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8.5 Summary and discussion 
The purpose of this chapter was to investigate the function of the different memory B-cell 
subsets and plasmablasts in vitro and in vivo to better delineate potentially relevant autoreactive 
populations in RA. 
ACPA secretion by flow sorted peripheral blood plasmablast was not detectable by ELISpot, the 
cause for which could be multifactorial. The cell numbers were too low and beyond the 
sensitivity of ELISpot. The functional ability of the cells might be impaired due to the sorting 
process and need time to recover or their viability has been affected. The potential reasons 
could be the mechanical stress experienced by the cells during the sorting process, stimulatory 
or inhibitory effects of the antibodies used for sorting and the azide content in the antibodies.  
The problem with cell numbers could be overcome by pooling samples from multiple patients 
which is not ideal. Density centrifugation which removes granulocytes cannot be used when 
plasmablasts need to be preserved. The ammonium chloride lysed sample retains granulocytes 
which increase the cell count many fold and reduces the sort efficiency and prolongs the sort 
duration. The other option is to enrich the sample for B-cells by magnetic selection before flow 
sorting. However, this option is not suitable for plasmablasts due to weaker expression of CD19 
and presence of exclusion markers in the negative selection kits. The mechanical stress to cells 
during sorting could be reduced by using a larger bore nozzle but it affects purity. The cells 
could be allowed to recover for a set period of time in vitro following the sorting process and 
then subject to functional assays. If the antigen specificity of the cell is the only parameter to be 
assayed, then the sorted cells could be expanded in vitro before further analysis. However 
culture techniques need to be validated and optimised for such low numbers of cells and the 
effects of flow sorting need to be accounted for as well. 
ACPA secretion by plasmablasts generated in vitro from naïve B-cells of RA patients was not 
detectable by ELISpot. This could be due to the sensitivity of the assay or lower frequency of 
CCP-specific cells within the naïve B-cells. The lack of a positive control for ACPA secreting 
cells reduces the confidence in negative findings from this assay. The anti-IgG coated wells 
were able to detect IgG present in the serum in an ELISA like fashion but not able to detect 
ACPA which again raises the sensitivity issue for ACPA ELISpot. The IgG detection has a signal 
amplification step using biotinylated anti-IgG followed by strep-HRP. Since CCP is immobilised 
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to the plate with streptavidin, the ACPA detection uses directly HRP conjugated anti-IgG and 
therefore lacks the amplification. 
The detected IgG secretion from in vitro generated plasmablasts derived from naïve B-cells is 
due to class-switching occurring in the in vitro differentiation system but is not clear whether this 
is confined only to RA patients since the experiment did not have any non-RA controls. The 
other possibility is that there are IgG positive B-cells within the sorted CD27 negative B-cells 
since RA patients are known to have increased proportion of 27- IgD- B-cells (70). In that study, 
other isotypes apart from IgD were not checked and might also include surface immunoglobulin 
negative B-cells. This could be further evaluated by surface phenotyping of the RA B-cells with 
antibodies against all immunoglobulin isotypes and CD79b. 
B-cells have been shown to secrete proinflammatory and regulatory cytokines following 
stimulation (95). In the past non-physiologic mitogenic stimuli have been used which may not be 
a true reflection of the events in vivo. Cell lines have been used as well which again is not ideal. 
Further studies mimicking physiological stimuli with primary B-cells have shown secretion of 
TNF, LTA, IL6 and IL10 by activated B-cells (96). The cytokines were detected in the 
supernatant but the cells were not followed during their differentiation in those studies to assess 
at what stage the secretion starts and how long into their differentiation it continues. There were 
no definitive phenotypes identified for the B-cells that secreted these cytokines. Secretion of the 
chemokine receptor ligands by B-cells have not been studied in the past except for CCL2 (97), 
CCL3 (98). 
TNF plays a key role in RA pathogenesis as evidenced by the good clinical response to anti-
TNF therapy (99). The B-cell derived LTA and TNFA have been shown to be involved in 
development of B-cell follicles (100) and follicular dendritic cells (101). AIF1 has been shown to 
be elevated in RA synovial fluid compared to osteoarthritis and induces IL6 production by 
synovial fibroblasts and PBMCs (102). AIF1 gene polymorphisms have been shown to be 
associated with active form of RA (103). High levels of MMP7 expression has been shown in 
rheumatoid nodules and is associated with early onset disease (104). These published studies 
have shown evidence of secretion of inflammatory mediators such as AIF1 and MMP7 in the 
context of RA but interestingly findings from this chapter are consistent with these mediators 
generated during normal B-cell differentiation. Therefore, activation of B-cells in a specific or 
non-specific fashion could trigger a proinflammatory milieu. The secretion of proinflammatory 
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mediators is transient during the B-cell differentiation. Therefore treatment strategies targeting 
certain stages of differentiation rather than the whole B-cell compartment might be a better 
option for some patients particularly if the B-cells with regulatory properties could be preserved.  
Multiple chemokine genes show an increase in expression levels during the stage of B-cell 
differentiation that is closest to the phenotype of relapse associated memory B-cell subset. 
Although gene expression does not always translate to protein, the chemokine ligands could 
contribute to the establishment of an inflammatory cell milieu within the joints in RA. CCR2, the 
receptor for the CCL2 secreted by B-cells is known to be elevated and more responsive in RA 
neutrophils (105). CCL3, also known as MIP1α (Macrophage Inflammatory Protein) is known to 
be elevated in RA synovial fluid (106) and is associated with susceptibility to RA based on 
genome-wide haplotype association analysis (107). CCL17, which is a potent chemoattractant 
of T-cells is elevated in synovial fluid of RA patients (108). CCL22 has been shown to be 
increased in plasma and synovial fluid of RA patients compared to controls (109). CXCL9 and 
CXCL10 are sensitive markers of disease activity (110) and CXCL10 polymorphism has been 
shown to be associated with extra-articular manifestations in RA (111).     
The secretion of proinflammatory cytokines and chemokines is confined to certain stages during 
B-cell differentiation which has not been studied in detail before. Surface markers of this 
particular stage such as CD30 and TIM3 were identified by gene expression analysis and 
protein expression was detected by flow cytometry. However, the gene expression pattern for 
TIM3 obtained by the Illumina array needs to be confirmed further with real-time PCR. TIM3 
protein expression needs to be confirmed with a different clone of antibody although the F38-
2E2 clone used in this study has been used in published literature (112). The protein expression 
also needs to be confirmed by a different technique such as western blot. CD30, also known as 
TNFRSF8 is a member of the TNF-receptor superfamily and was originally described as a 
marker of Reed-Sternberg cells in Hodgkin’s lymphoma. It is expressed by virus-infected 
lymphocytes, lymphoid neoplasms and subsets of activated B and T-cells (113). Stimulation or 
overexpression of CD30 can drive downstream NFκB activation through recruitment of TRAF2 
and TRAF5 (114). If B-cells at the stage when they express CD30 play a key role in RA 
pathogenesis by secretion of proinflammatory mediators and chemoattractants, therapeutic 
strategies to target this stage is feasible with already available naked or conjugated monoclonal 
anti-CD30 antibodies which have been through clinical trials in Hodgkin’s lymphoma (115). 
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There are 3 members of the TIM (T-cell Immunoglobulin domain Mucin domain) gene family in 
humans, TIM-1, TIM-3 and TIM-4 which have been linked with regulation of immune responses 
and disease processes such as autoimmunity and asthma (116). TIM3 was identified as a 
negative regulator of T-cell response in terminally differentiated T-cells. In humans, only 1-2% of 
CD8 T-cells and none of the CD4 T-cells express TIM3 in peripheral blood but activated T-cells 
in lymph nodes express TIM-3 albeit at low percentages which increases to 25% on stimulation 
(117). TIM-3 is predominantly expressed by TH1 and TH17 cells, and mediates regulation of 
cytokines such as IL2, IL6, IL17 and IFNγ at the transcriptional level. TIM-3 is also expressed by 
a variety of cells involved in the innate immune response including NK cells, monocytes, 
macrophages, dendritic cells, mast cells and endothelial cells, and mostly functions as an 
inhibitory receptor (118). However, in certain circumstances it can lead to activation of cells 
such as macrophages during mycobacterial infections (119). 
Synovial tissue from RA patients express higher levels of TIM-3 mRNA compared to 
osteoarthritis, and lower levels of Gal-9 mRNA in the peripheral blood mononuclear cells 
compared to controls (120). The proportion of TIM-3 positive T-cells and NK cells correlates 
negatively with disease activity in RA (121). Therefore, TIM-3 has been proposed as a 
therapeutic target in RA. Most of the studies have concentrated on T-cells and TIM-3 expression 
B-cells has not been explored as it is not expressed by resting B-cells. However, TIM-3 can be 
detected following B-cell activation in vitro (Figure  8.3-9) and in other secondary lymphoid 
organs (Figure  8.3-14). Since, TIM-3 has both regulatory and stimulatory properties, its role in 
B-cells cannot be extrapolated from its role in T-cells without further evaluation.                          
TIM3 ligand galectin-9 has been shown to regulate murine T-cells by induction of apoptosis 
(122). Human CD4 T-cells are also susceptible to galectin-9 induced apoptosis at 50nM 
concentration and the susceptibility is reduced in RA (123). The galectin-9 induced apoptosis 
was not specific when tested as evidenced by the inability to block the effect with anti-TIM-3 or 
anti-Galectin-9 antibodies (Figure  8.3-16). The noted cell death is unlikely to be mediated 
through TIM-3 since the susceptibility continued even after loss of TIM-3 expression. The 
negative result is likely to be due to the differences in Galectin-9 sourced from R&D systems 
since another study performed with the same Galectin-9 found a similar lack of specificity in T-
cells (93).The other studies used in-house recombinant proteins or Galectin-9 sourced from 
GalPharma. However, the role of TIM-3 in apoptosis in human T-cells remains unclear, since 
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TIM-3 antagonistic antibodies did not alter the proliferation or survival of human T-cells (117). In 
the same study, blockade of TIM-3 ligand interaction with TIM-3-Ig fusion protein did not 
increase cytokine secretion in human T-cells. A recently published study has shown that 
CEACAM1 expressed on activated T-cells forms a heterodimer with TIM-3 and is required for T-
cell inhibition (124), which might explain the differential effects of galectin-9 and TIM-3 
antibodies. To understand the role of TIM-3 in B-cells further detailed evaluation is required with 
alternative galectin-9 and TIM-3 antibodies in conjunction with CEACAM1. 
Influenza vaccination provides an excellent opportunity to study the immune response in a 
controlled fashion. The immune response, particularly the response of the B-lineage cells can 
be compared with the immune response during RA relapse. All the six controls tested showed a 
plasmablast response to the seasonal influenza vaccine. However, there was heterogeneity in 
the degree of response between controls with 2 controls showing less than 2-fold increase and 
the rest had greater than 7-fold increase in their absolute count. This was not dependant on the 
baseline plasmablast levels. The alternative way to assess the immune response would be to 
compare the levels of specific antibodies against the vaccine strain of influenza at baseline and 
at 4 weeks post vaccination in the serum. The options would be to source the vaccine proteins 
(Sino Biological Inc.) or use the influenza vaccine itself as the antigen to coat the ELISA plates 
which needs evaluation and optimisation.  
This plasmablast response positively correlated with the baseline proportion and absolute count 
of the RA relapse associated CD24-CD84-CD95+LAIR1- memory B-cell subset. Although this 
did not reach statistical significance a larger sample size may be needed to observe significance 
with this correlation. The baseline proportion and absolute count of the usually dominant 
CD24+CD84+CD95-LAIR1+ memory B-cell subset showed a negative correlation, which again 
did not reach statistical significance. The lack of statistical significance could be due to the low 
sample numbers. CD24-84- memory B-cells showed a positive correlation with plasmablast 
response irrespective of the CD95 and LAIR1 expression. Some of the other subsets showed a 
better correlation than the relapse associated subset. This suggests that different subsets could 
be recruited during an immune response to influenza vaccination compared to relapse in RA 
and there might be heterogeneity within the RA patients as well.  
Memory B-cells as percentage of total B-cells or the absolute count at baseline were less 
predictive of the plasmablast response than the subsets. This suggests that the heterogeneity 
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noted within the memory B-cells based on the surface expression of CD24, CD84, CD95 and 
LAIR1 transfers to a functional level and different subsets have a distinct functional role as 
noted in the case of influenza vaccination.     
There was an increase in the proportion of the RA relapse associated CD24-CD84-
CD95+LAIR1- memory B-cell subset following influenza vaccination. However the increase in 
proportion is not accompanied by an increase in absolute counts, which raises the suspicion 
that the noted increase in proportion is due to decrease in absolute counts of the other subsets. 
Indeed, there was a decrease in the absolute count of the polar opposite CD24+CD84+CD95-
LAIR1+ memory B-cell subset in the same time frame. This could be due to the recruitment of 
the usually dominant CD24+CD84+CD95-LAIR1+ memory B-cell subset into sites of immune 
response such as the secondary lymphoid tissues with vaccination, or the synovium in RA. This 
pattern of change in memory B-cell subsets needs to be confirmed in more subjects since it was 
not consistent in all donors. However, there are alternative explanations for the decrease such 
as increased cell death and decay. The way to address this would be to sample the lymphoid 
organs such as lymph nodes and bone marrow at baseline and post vaccination to assess the 
changes in proportion of the memory B-cells at these sites. It is interesting in the context of such 
a model to note that it is the baseline levels of CD24-CD84-CD95+LAIR1- subset that correlates 
with evidence of an active plasmablast response to vaccination. 
The recruitment of autoreactive memory B-cell subsets into the secondary lymphoid structures 
accounting for the skewing of the subset distribution is supported by the presence of follicular 
structures resembling germinal centers in RA synovium. The ectopic lymphoid structures in the 
synovium are surrounded by ACPA secreting PCs (10). The skewing of memory B-cell subsets 
seen during RA relapse could be due to the recruitment of usual dominant subset into or egress 
of the relapse associated subset from the synovial lymphoid structures. The study of synovial 
fluid was unwieldy with most samples lacking B-cells. This could be addresses further by 
evaluation of B-cells from synovial biopsies rather than from the fluid.      
In RA, it is difficult to monitor the changes in memory B-cell subsets due the unpredictable 
nature and lack of control over the immune response, which could also be altered by the 
concomitant use of corticosteroids and other immunosuppressants. Although it could be 
speculated that the increase in proportion of the CD24-CD84-CD95+LAIR1- subset in RA during 
relapse is due to the recruitment of CD24+CD84+CD95-LAIR1+ subset into the sites of 
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inflammation and secondary lymphoid tissues, whether the response of memory B-cells would 
be similar in case of vaccination and RA is questionable. However, this suggests that change in 
the proportion of memory B-cells is indicative of an ongoing inflammatory response. Therefore, 
in RA even if the CD24-CD84-CD95+LAIR1- subset does not contain the autoreactive or 
pathogenic B-cells, it is still a useful marker of disease activity and relapse.    
Since, there are limitations in studying the immune response in vivo, optimisation of in vitro 
methods becomes crucial.   
In summary, the memory B-cell subsets that are skewed during relapse post-rituximab in RA 
could contain the autoreactive B-cells and might also play a role in pathogenesis by secretion of 
proinflammatory mediators but needs further work to confirm this.        
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9 Fourth Results Chapter: Novel mode of B-cell regulation 
The study of plasma cells in vivo requires bone marrow sampling which is of considerable 
morbidity to patients and controls. Therefore, in vitro methods of PC generation would allow 
their study in details and also allow their manipulation. One of the restrictions in studying the 
antigen-specific cells was their low frequency. This could potentially be overcome by expansion 
of the cells in vitro and the antigen specificity could be inferred from the antibodies secreted by 
the cells of interest on differentiation to PCs. Therefore, in vitro modalities of generating PCs are 
vital for this study.  
Multiple B-cell abnormalities have been described in RA and the initial aim was to test whether 
there is a significant difference in generation of PCs from B-cells in RA and controls. When 
negatively selected B-cells from RA patients were differentiated in vitro, there was an 
unexpected 15 to 80-fold expansion of non-B lineage cells at the stage of plasmablast to PC 
transition (Figure  9.1-1). There were adaptations made to the standard differentiation protocol in 
terms of cell densities and plate size to enable the assay to be performed with reduced cell 
numbers and thereby reducing the amount of blood required from the patients and also enables 
assessment of patients with reduced B-cell count. Since this was noted only very rarely when 
the other researchers were performing the assay with healthy controls, it was not clear whether 
this phenomenon was specific to RA B-cells or due to alterations to the standard protocol. 
Although this could be an in vitro artefact it was imperative to understand the cause for this 
expansion to devise strategies to avoid the expansion of non-B lineage cells at later time points 
in the culture.   
Albeit rare, as it was noted in healthy controls as well, initially the changes in the culture 
conditions were evaluated as a cause for the expansion. On day 3 of the differentiation process 
the cells are removed from CD40L (mouse fibroblasts transfected with CD40L) and transferred 
to wells with nutrients and cytokines. It was hypothesized that due to the low density of B-cells 
and smaller sized wells there is a possibility of increased carry over of the CD40L fibroblasts 
causing the expansion. There was greater expansion of the non-B lineage cells when a 48 well 
plate was used instead of 24 well plate and this expansion could not be recapitulated by spiking 
the culture with CD40L transfected fibroblasts on day 3 (Figure  9.1-2). This excluded carry-over 
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of CD40L as the cause for the non-B lineage cell expansion. Since the expansion occurs 
between days 6 and 13, the change in culture conditions on day 6 such as addition of IFNα, IL6, 
IL21 and exposure to mouse stromal cell line M210B4 were suspected as a cause for the noted 
expansion. However, when negatively selected B-cells containing non-B cells were subjected 
directly to day 6 conditions, there was no expansion of the non-B lineage cells (Figure  9.1-3). 
Further attempts were directed at identifying the phenotype of expanding cells and it was 
predominantly constituted by NK cells (Figure  9.2-2). Given the very high degree of expansion 
of the cells there remained a suspicion whether the NK cells could be derived from the cell 
population that was CD19 on day 6. B-cells can lose their CD19 expression on differentiation to 
PCs and therefore other surface markers are required to distinguish the CD19 low to negative 
plasmablasts and PCs from the NK cells. To address both these questions four cell fractions 
were sorted flow cytometrically based on CD19 and CD27 surface expression on day 6. This 
revealed that the expanding NK cells were predominantly derived from the CD19 and CD27 
double negative cells on day 6 and CD27 negativity is a better marker on day 6 to identify these 
cells. Therefore, flow sorting the cells on day 6 based on CD27 could be used as a method to 
avoid the NK cell expansion.  
Sorting of the day 6 cells for every experiment is practically not feasible due to restrictions in 
availability of the sorter facility only during weekdays and patient samples could not always be 
timed with the availability of the sorter. Therefore, if there was a component of the in vitro 
system that could be identified as the cause for NK cell expansion, this could be altered to 
circumvent this issue. The in vitro differentiation protocol (Figure  5.4-1) uses allogenic cells 
(mouse derived) at two stages – CD40L transfected mouse fibroblasts on day 0 and the mouse 
stromal cell line M2-10B4 on day 6. The use of TLR agonist instead of CD40L did not prevent 
NK expansion (Figure  9.3-2). The complete exclusion of M2-10B4 from the culture did not 
prevent it either. Therefore, the NK expansion was not due to the presence of allogeneic cells in 
the culture (Figure  9.3-3). This rules out the use of strategies such as using human recombinant 
CD40L and conditioned media from M2-10B4 cells to prevent the NK expansion. Double-
purified B-cells and NK cells mixed at a ratio of 9:1 on day 0 led to NK expansion on day 10 
which confirms that the expanding NK cells are derived from the contaminating day 0 NK cells 
Figure  9.3-3.  
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The NK cell expansion also had adverse effect on plasmablasts and PCs in the culture with 
marked reduction in their numbers (Figure  9.3-4). Although it could be speculated to be due to 
direct killing by NK cells it will need further detailed assessment with NK cell cytotoxicity assays 
to determine the reason. Due to the adverse effect on the PCs it is essential to devise strategies 
to prevent NK expansion. 
It was hypothesized that if the mode of interaction between the B-lineage cells and NK cells 
could be identified, a simple strategy based on using a monoclonal antibody to block the NK 
cells could be employed to prevent the expansion. The stage at which the key interaction occurs 
need to be identified as well to deploy the preventive strategies. Freshly purified NK cells from 
the same donor did not expand when added to day 6 plasmablasts (Figure  9.4-1). This reveals 
that NK cells need prior priming for the expansion to occur. To test whether the B-NK interaction 
is contact dependant, the NK cells were cultured in transwells with and without B-cell contact 
(Figure  9.4-3). NK cells which were not in contact did not expand and this suggests that the 
interaction is contact dependant.       
Blocking the contact dependent B-NK interaction is an attractive option to prevent the NK cell 
expansion if it can be achieved with monoclonal antibodies that are readily available. This would 
avoid the multiple purification steps required at baseline and flow sorting on day 6. If this B-NK 
interaction can be demonstrated to occur in vivo, it opens up the option of therapeutic targeting. 
Two pathways involved in B-NK interaction were evaluated. Peripheral blood NK cells can be 
expanded up to 1000-fold by stimulation with CD137L. However, blocking NK cells on days 3 
and 6 with anti-CD137 antibody did not prevent the expansion (Figure  9.5-1). B-cells are known 
to express CD58 during activation and NK cells express CD2 which is involved in stable 
interaction by nano-tube formation. Antibodies blocking CD2 and CD58 were not able to prevent 
the expansion either (Figure  9.5-3).       
NK cells are key players in immunity against viruses and therefore the possibility of viral 
contamination in the cultures which was accessible to the NK cells only after differentiation past 
the plasmablast stage was considered. EBV is known to be a latent virus inhabiting B-cells and 
enters lytic phase on plasma cell differentiation. Therefore, sample from a healthy control whose 
cells consistently showed this expansion was tested for EBV DNA by PCR and was positive 
(Figure  9.6-1 and Figure  9.6-2). It is interesting to speculate that EBV containing B-lineage cells 
are directly targeted and killed by NK cells particularly with IFNα support. However it would 
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require a large body of work to detect the various EBV proteins in multiple samples and 
demonstrate evidence of direct killing by NK cells. It can be proven to be primarily due to EBV 
by performing the experiments in parallel with EBV positive and negative donors. This was 
beyond the scope of this study and therefore was not pursued further and will be addressed in a 
future project. 
If the NK cell expansion is primarily due to presence of EBV, it will pose a significant problem 
whenever there are contaminating NK cells on day 0 since the prevalence of latent EBV in the 
general population is estimated to be about 90%. Alternative purification methods were sought 
due to the failure to detect a molecular pathway that is amenable to blockade to prevent the NK 
expansion. The purification strategies were re-visited to improve the efficiency by using the 
reagents in excess as shown in Figure  9.7-1. The required purity on day 0 was achievable by 
modifying the cell selection process and additional positive selection with CD20 beads was used 
if the purity was less than 95%. 
9.1 Strict purification required for In vitro differentiation of RA B-cells 
Using the recently reported novel assay for the generation of long-lived PCs in vitro (60), the 
plan was to assess the perturbation in function of B-lineage cells in RA beyond autoantibody 
production. This method could also be used to expand the antigen-specific cells which are at 
low frequency to generate PCs and then analyse antigen-specificity by ELISA of supernatants 
or ELISpot as complementary to the other methods of direct detection of antigen-specific B-
cells. Therefore, it is essential to be able to perform this assay on RA B-cells consistently. 
 
9.1.1 Differentiation of B-cells from RA patients led to expansion of non-B 
lineage cells between day 6 to day 10 of the differentiation process 
B-cells purified from 10 ml of peripheral blood from 3 RA patients were differentiated under 
standard protocol using CD40L, IL2, IL21 and BCR stimulus (Figure  5.4-1). The initial seeding 
concentration on day 0 was reduced to 250000 cells/well (one-fifth of standard concentration) to 
minimise the amount of blood sample required from patients. As an additional measure, 48 well 
plates were used instead of the standard 24 well plate. There was an unexpected proliferation of 
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non-B lineage cells (defined as annexin V, 7-AAD, CD19, CD20, CD38 and CD138 negative) 
between day 6 and day 13. The significant increase in percentage of non-B cells is unlikely to 
be an artefact due to decrease in the number of B-lineage cells as shown by the absolute count 
(obtained using countbright beads as described in methods section  5.2.2) in Figure  9.1-1. There 
was a 15-80 fold increase in the number of non-B cells between day 6 and day 13. 
 
Figure  9.1-1 Expansion of non-B lineage cells between day 6 and day 13 of in vitro B-cell 
differentiation 
The first graph shows the percentage of Non-B lineage cells (CD19 negative lymphocytes) 
within the cultures from 3 RA patients at different time points and the next graph shows 
their absolute numbers. The fold expansion was calculated as the number of non-B 
lineage cells at day 13 from a single well divided by the number of non-B lineage cells 
plated on to a single well on day 6. Live cells were identified based on negativity for 
annexin V and 7-AAD. The non-B lineage cells were identified as CD19 and CD20 dual 
negativity on day 0 and negative for CD19, CD20, CD38 and CD138 from day 6. 
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9.1.2 Expansion of non-B lineage cells is not due to carry over of CD40L 
cells from day 3 
The contaminating cells (CD19 negative lymphocytes) observed in the RA derived B-cell 
differentiations limit the application of the assay and therefore attempts were made to resolve 
the issue. Of note similar expansions were observed on a sporadic basis in differentiations 
derived from healthy donors, with some bias to particular donors. Such expansion had also 
been observed occasionally by other researchers using the differentiation system, but were not 
a common event overall affecting in the region of 1/20 of all differentiations performed across 
multiple researchers in the same lab.  Nonetheless given the observation in RA patients and the 
potential interest of the observation, this needed further investigation. 
It was confirmed that the expansion of non-B lineage cells could be reproduced using media 
prepared by an independent experienced operator, excluding this as an explanation. The 
magnitude of expansion was higher with a 48-well plate compared to a 24-well plate and can be 
reduced by swapping from a 48 to a 24-well plate on day 6 (Supplementary Data Figure  14.1-4). 
Worsening of expansion with smaller sized wells is suggestive of an effect which is dependent 
on close contact. This could potentially be mediated by increased carryover of CD40L cells 
(plated on day 0) from smaller sized wells when cells are transferred to CD40L-free culture 
conditions on day 3.  
Negatively selected peripheral blood B-cells from 2 controls were differentiated till day 3 
according to the standard protocol in 24 or 48 well plates (Figure  5.4-1). To exclude carry over 
as a cause of the noted expansion, on day 3 the cells were plated on to wells coated with 
CD40L cells (mouse fibroblasts transfected with CD40L). 1%, 10% and 100% of the day 0 
densities of CD40L cells were used. The starting proportion of non-B lineage cells (defined as 
annexin V, 7-AAD, CD19, CD20, CD38 and CD138 negative) on day 0 was 7.2% and 0.5% for 
D1503 and D2103 respectively. The absolute cell counts were assessed by flow cytometry 
using countbright beads (Figure  5.2-2). The expansion (measured as fold change from day 0 to 
day 10) seen with 48 well plate could not be recapitulated by using any of the 3 densities of 
CD40L cells between day 3 and day 6 in a 24 well plate. Therefore, the increased expansion of 
non-B lineage cells in a smaller sized well cannot be explained by interaction with CD40L cells 
between day 3 and day 6. The prolonged presence of CD40L also had a delaying effect on 
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differentiation of B-lineage cells like delay in upregulation of CD38 and persistence of CD30 
(Data not shown). 
 
Figure  9.1-2 Effect of prolonged CD40L exposure on expansion of non-B lineage cells 
Fold change in non-B lineage cells within the culture from 2 donors 1503 and 2103 shown 
which excludes prolonged CD40L exposure as a cause for non-B lineage cell expansion. 
24W Std and 48W Std represent samples cultured throughout in 24 and 48 well 
respectively. +CD40L refers to addition of day 0 concentration of CD40L cells to the 
culture on day 3, and +1% and +10%CD40L represent addition of 1% and 10% of the day 
0 concentrations. Fold change from day 0 to day 10 was calculated as (Number of cells on 
day 10 derived from a single day 0 well) / (Number of cells which started on day 0 in a 
single well). Live cells were identified based on negativity for annexin V and 7-AAD. The 
non-B lineage cells were identified as CD19 and CD20 dual negativity on day 0 and 
negative for CD19, CD20, CD38 and CD138 from day 6. The cell count was performed 
using countbright beads.   
1503 48W Std 34.48
1503 24W Std 7.15
1503+1%CD40L 7.14
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9.1.3 Non-B lineage cells do not expand when plated directly onto day 6 
culture conditions 
To assess whether the combination of cytokines, nutrients and the stromal cell layer used on 
day 6 can directly cause the expansion of non-B lineage cells, purified B-cells (with admixed 
non-B-cells) from 2 donors were plated directly on to day 6 culture conditions. The starting non-
B cell percentage was 7.2% and 0.5% for D1503 & D2103 respectively. There was no 
expansion of non-B lineage cells which suggests the day 6 conditions such as IL6, IFNα, IL21 or 
the mouse stromal cells do not cause the observed expansion without prior activation. 
 
 
 
Figure  9.1-3 Culture of cells directly under day 6 conditions 
Figures show the total cell counts and non-B lineage cell counts on day 0 and day 7 from 
a single well which were plated directly on to the day 6 conditions of the standard protocol 
(addition of IL6, IFNα, IL21 and the mouse stromal cells). 
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9.2 Identity of the contaminant population which expands between 
day 6 and day 10 
When RA B cells were placed in the B differentiation assay that is known to generate PCs and 
maintain them in culture long-term, it was noted that the assay behaved in a different way to that 
seen with normal B cells.  Specifically there was the emergence of predominant CD19 negative 
lymphocytes instead of B-lineage cells. 
9.2.1 The contaminating cells were predominantly NK cells 
Negatively selected peripheral blood B-cells from a healthy donor was differentiated using the 
standard protocol (Figure  5.4-1).The cultured cells were evaluated at baseline and at various 
stages of differentiation with a T-cell panel (CD45 APC-Cy7, CD16 PE, CD3 PE-Cy7, CD4 
PerCP-Cy5.5, CD8 APC) used for routine diagnostic purposes at HMDS with additional CD19 
Pacific Blue antibody to identify the expanding population as shown in Figure  9.2-1: 
 
Figure  9.2-1 Gating strategy for analysing B-lineage, NK and T-cells 
Mononuclear cells defined by their scatter profile were further sub-classified as below: 
• B-lineage: CD19 +/wk, CD3- CD16- CD4- CD8- 
• NK-cells: CD16+ CD3- CD19Neg CD4- CD8+/- 
• T-cells: CD3+ CD19Neg CD16-  
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The cells expanding between day 6 and day 10 were predominantly constituted by NK cells and 
it was more than 90% of the expanding population in the experiment shown below. 
 
Figure  9.2-2 Identity of the expanding population between day 6 and day 10 
Negatively selected B-cells from a healthy donor were differentiated using the standard 
protocol as shown in Figure  5.4-1. The proportion of various cell lineages identified using 
gating strategy described in Figure  9.2-1 at day 0, 6 and 10 of in vitro differentiation 
showing expansion of NK cells between day 6 and 10. The proportions provided for the 
different cell lineages are expressed as percentage of the live cells in the well. Green – B-
lineage cells, Red – T-cells, Blue – NK cells.  
 
Once the contaminating cells were identified to be predominantly NK cells, a specific antibody 
panel was developed which was used to identify the NK cells and other non-B lineage cell 
populations in future studies (Figure  5.2-7).   
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9.2.2 Sorting on CD27 expression at day 6 allows removal of contaminating 
non-B-cell populations. 
There was a 50-100 fold expansion of non-B lineage cells between day 6 and day 13. 
Therefore, it was not clear whether the expanding CD19 negative population between day 6 and 
day 10 is derived from the cells that are CD19 positive or negative on day 6. Samples from two 
donors were stained with CD19PE and CD27 AF647 antibodies and flow-sorted into 4 
populations based surface expression of CD19 and CD27 on day 6 on high speed Mo-Flo cell 
sorter as shown below.   
 
Figure  9.2-3 Flow-sort of in vitro differentiated day 6 cells based on CD19 and CD27 
Scatter properties were used to gate live, nucleated cells and staining with CD19PE and 
CD27AF647 antibodies was used to sort the cells into 4 different populations on a Mo-Flo 
high speed cell sorter.  
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The sorted cells were re-suspended in media containing nutritional supplements, IL21, IFNα, IL6 
and Stromal cell support as described in methods section  5.4.4. The antibody panel and 
detailed gating strategy for quantifying NK cells is shown in Table  5.2-4 and Figure  5.2-7 
respectively. The NK cells were defined as CD16/CD56Pos CD3Neg CD19Neg CD4Neg CD27Neg. 
The expanding NK cells on day 10 were predominantly derived from the cells that were CD19 
and CD27 double negative on day 6. CD27 negativity provided a better marker to exclude the 
contaminant cells at day 6 rather than CD19 negativity due to the absence of any NK cells from 
the CD27 positive populations irrespective of their CD19 status. This could be due to a lower 
level of non-specific binding or better signal-to-noise ratio with the CD27 antibody. By sorting for 
CD27 positive cells on day 6, expansion of contaminating cells during further time points in the 
culture can be avoided. However, the effects of CD27 ligation on differentiation, proliferation and 
cell viability would need to be taken into account in subsequent analyses. 
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Figure  9.2-4 Proportion of CD56 positive NK cells on day 10 from the cells sorted on 
day 6 
The 4 fractions obtained by flow sorting (Figure  9.2-3) on day 6 by differentiating B-cells in 
vitro were continued in culture as per standard protocol with IL21, IL6, IFNα and stromal 
cell support as described in methods section  5.4.4. The proportion of CD56 positive NK 
cells on day 10 from two donors D1404 (2% contamination on day 0) and D1503 (10% 
contamination on day 0) derived from day 6 sorted and unsorted cells. Standard – 
Unsorted cells. Mixed – Sorted cells with all the four fractions mixed together. The 
antibody panel and detailed gating strategy for quantifying NK cells is shown in 
Table  5.2-4 and Figure  5.2-7 respectively. The NK cells were defined as CD16/CD56Pos 
CD3Neg CD19Neg CD4Neg CD27Neg.    
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9.3 Expansion of NK cells is not secondary to the presence of 
allogeneic cells in the culture system 
Having observed that expansion of NK cells occurs in the in vitro system between days 6 to 10, 
there is a possibility the culture conditions that change on day 6  are influencing the expansion. 
One potential candidate is the mouse stromal cell layer M2-10B4, which could be sensed by 
human NK-cells as allogeneic and therefore needs excluding.  
9.3.1 NK cell expansion is independent of the presence of mouse stromal 
cell layer M2-10B4 between Day 6 & Day 10 and direct 
addition/spiking of NK cells to highly pure B-cells, recapitulates 
inadvertent NK-cell expansion 
B-cells purified by negative selection and positive selection (CD20 magnetic beads by Miltenyi) 
from selected donors were cultured in parallel using standard conditions (Figure  5.4-1). From 
day 6, the culture was continued in a transwell (no contact with M2-10B4) or in contact with M2-
10B4 cells. NK cell numbers were calculated by flow cytometry using count bright beads and 
were defined as CD16/CD56Pos CD3Neg CD19Neg CD4Neg CD27Neg. The antibody panel and 
detailed gating strategy for quantifying NK cells is given in Table  5.2-4 and Figure  5.2-7 
respectively. There was a similar level of expansion of NK cells under both conditions. 
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Figure  9.3-1 NK cell expansion with and without M2-10B4 contact 
B-cells isolated by negative selection (Neg sel) and CD20 positive selection (Pos sel) on 
day 0 were differentiated in vitro according to the standard protocol (Figure  5.4-1). From 
day 6 the cells were cultured with (24 Well) or without (Transwell 24 Well) M2-10B4 
contact. NK cell numbers were calculated by flow cytometry using count bright beads and 
were defined as CD16/CD56Pos CD3Neg CD19Neg CD4Neg CD27Neg. The counts are shown 
on a logarithmic scale from cells plated on to a single day 6 well on day 10 and day 13.  
D6 D10 D13
Neg Sel 24Well 1804 47905 38180
Pos Sel 24Well 862 89443 61944
Neg Sel Transwell 24Well 541 11223 6887
Pos Sel Transwell 24Well 259 16079 8664
1
10
100
1000
10000
100000
Count
NK cells with and without M210B4 contact
    204 
 
 
The other allogeneic cell present in the in vitro differentiation system is the CD40L transfected 
L-cells used on day 0 to stimulate the B-cells. Although the expansion occurs at least 4 to 5 
days after the L-cells are removed, the possibility of their involvement in NK expansion cannot 
be ruled out. However, similar NK cell expansion was seen between days 6 and 10 when B-
cells were stimulated with TLR 7/8 agonist R848 (1 µg/mL) on day 0 instead of CD40L. 
 
Figure  9.3-2 NK cell expansion with CD40L and TLR stimuli on day 0 
Peripheral blood B-cells from 2 controls were stimulated with CD40L transfected mouse 
fibroblasts (L-cells) or TLR7/8 agonist R848 on day 0 and the proportion of NK cells 
detected in the cultures on days 6 and 10 shown. NK cells were defined as CD16/CD56Pos 
CD3Neg CD19Neg CD4Neg CD27Neg. Data shown is representative of 3 different experiments. 
The simplest explanation for the results and the sporadic nature of the expansion was therefore 
that the degree of B-cell purity and the presence of contaminating NK cells at day 0 is the 
determinant. To address this, B-cells were double purified using sequential negative followed by 
positive selection with anti-CD20 beads, and cultured in parallel with and without addition of 
purified NK cells according to the standard protocol Figure  5.4-1. On day 6, cells from both 
conditions were plated with and without M2-10B4 to assess the effect of M2-10B4 on NK cell 
expansion. NK cell numbers were calculated by flow cytometry using count bright beads and 
were defined as CD16/CD56Pos CD3Neg CD19Neg CD4Neg CD27Neg. Although there was a slight 
reduction in the proliferation without M2-10B4, there was still a significant expansion of NK cells 
without any M2-10B4. Thus an allogeneic signal from M2-10B4 cells is not necessary to drive 
expansion. Importantly this experiment also showed that differential purity of input B-cells is a 
critical factor and that the direct addition of NK cells at day 0 to highly pure B-cells can drive 
subsequent expansion between days 6 and 10. 
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Figure  9.3-3 Effect of M2-10B4 on NK cell expansion 
Double purified B-cells were differentiated with and without addition of purified NK cells 
using standard protocol up to day 6 (Figure  5.4-1). At day 6 the culture was continued with 
and without the mouse stromal cell M2-10B4 support. Figure shows the number of NK-
cells on day 10 derived from a single day 6 well. NK cell numbers were calculated by flow 
cytometry using count bright beads and were defined as CD16/CD56Pos CD3Neg CD19Neg 
CD4Neg CD27Neg. 
Pure B= Double-purified B-cells on day 0 cultured without any M2-10B4 on day 6,  
Pure B + NK = Double-purified B-cells on day 0 mixed with 10%NK cells on day 0 cultured 
without any M2-10B4 on day 6,  
Pure B + M2-10B4 = Double-purified B-cells on day 0 cultured in contact with M2-10B4 on 
day 6,  
Pure B + NK + M2-10B4 = Double-purified B-cells on day 0 mixed with 10%NK cells on 
day 0 cultured in contact with M2-10B4 on day 6 
 
Transformation of CD19Pos cells to NK cells and differentiation of NK cells from precursor stem 
cells are ruled out by this data and data from Figure  9.2-4. 
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9.3.2 Effect of NK cell expansion on antibody secreting cells 
The effect of NK cell expansion between days 6 and 10 on plasmablasts when they differentiate 
into plasma cells was studied in the same experiment described in Figure  9.3-3. The number of 
plasma cells surviving on day 10 was markedly reduced due to NK expansion. This is unlikely to 
be due to a block in differentiation since there was higher number of plasma cells and slightly 
reduced number of plasmablasts on day 6 when NK cells were present in the culture suggestive 
of slightly accelerated differentiation. To account for the slightly decreased number of 
plasmablasts on day 6 when NK cells were present (242000 vs 175000), normalised counts are 
shown for plasmablasts in Figure  9.3-4. Plasmablasts and PCs showed equivalent survival with 
and without M2-10B4. Therefore, the plasmablast and plasma cell death is not due to killing of 
M2-10B4 by NK cells since the key role for M2-10B4 is to support long-term survival. The 
plasmablasts survival was also decreased by two- to three-fold which is suggestive of NK cell 
mediated cell death in plasmablasts and plasma cells. Although these data suggest that NK-
cells have the capacity to curtail plasmablast/plasma cell responses at least in vitro, there could 
be other potential reasons for cell death such as lack of nutrient supply. To demonstrate direct 
NK mediated killing of the B-lineage cells further NK cell cytotoxicity assays are required which 
was beyond the scope of this project and therefore not pursued.  
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Figure  9.3-4 Effect of NK cell expansion on antibody secreting cells 
Double purified B-cells were differentiated with and without addition of purified NK cells 
using standard protocol up to day 6 (Figure  5.4-1). At day 6 the culture was continued with 
and without the mouse stromal cell M2-10B4 support. The top figure shows the number of 
plasma cells defined as annexin V and 7-AAD negative, CD20-CD38HiCD138+ on days 6 
and 10 derived from a single day 0 well (250000 B-cells). The bottom figure shows 
number of persisting plasmablasts defined as annexin V and 7-AAD negative, CD20-
CD38HiCD138- on day 10 from a normalised count of 100000 plasmablasts on day 6. The 
cell count is shown on a logarithmic scale.  
Pure B = Double-purified B-cells on day 0 cultured without any M2-10B4 on day 6,  
Pure B + NK = Double-purified B-cells on day 0 mixed with 10%NK cells on day 0 cultured 
without any M2-10B4 on day 6,  
Pure B + M2-10B4 = Double-purified B-cells on day 0 cultured in contact with M2-10B4 on 
day 6,  
Pure B + NK + M2-10B4 = Double-purified B-cells on day 0 mixed with 10%NK cells on 
day 0 cultured in contact with M2-10B4 on day 6 
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9.4 Potential contact-dependant interaction between B-lineage cells 
and NK cells 
The expanding NK cells are derived from pre-existing NK cells in the culture. Having shown 
NK cell expansion is not dependant on sensitization by non-human cells and is not mediated 
solely by the combination of cytokines and nutrients on day 6, the next question was whether 
the interaction is contact dependant. This would allow simple strategies such as monoclonal 
antibodies to block this interaction in the culture. It is also critical to know at what stage during 
the B-cell differentiation this interaction occurs to understand the mechanism. 
 
9.4.1 Plasmablasts are not directly able to induce NK cell expansion 
without prior priming 
To identify the stage of B-cell differentiation which induced the NK cell expansion, plasmablasts 
were evaluated initially. Negatively selected B-cells were stimulated with IL2 CD40L and BCR 
stimuli as before (Figure  5.4-1) and differentiated to plasmablasts by day 6. NK cells from the 
same donor were freshly isolated on day 6 and co-cultured with the day 6 plasmablasts at 3 
different concentrations. NK cells were cultured in transwells on their own or with B-cells but no 
contact or in contact with B-cells. NK cell concentrations were chosen to recreate the levels 
seen on day 6 in previous experiments. NK cell numbers were calculated by flow cytometry 
using count bright beads and were defined as CD16/CD56Pos CD3Neg CD19Neg CD4Neg CD27Neg. 
The antibody panel and detailed gating strategy for quantifying NK cells is given in Table  5.2-4 
and Figure  5.2-7 respectively. There was no expansion of NK cells cultured alone or in trans 
with Plasmablasts. There was one and a half to five-fold expansion when NK cells were in 
contact which is much less than what was observed in previous experiments. 
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Figure  9.4-1 Freshly-isolated NK-cells on their own or co-cultured with Plasmablasts on 
day 6 do not expand without prior priming 
Negatively selected peripheral blood B-cells were stimulated with IL2, CD40L and BCR 
stimuli to generate plasmablasts on day 6 as before (Figure  5.4-1). Freshly isolated NK 
cells were added on to the plasmablasts at the concentrations shown above. The top 
figure shows the number of NK cells on day 10 and day 13 derived from cells plated on to 
a single well on day 6. The bottom figure shows the fold expansion from day 6 on days 10 
and 13 calculated as the number of cells on day 10 or day 13 divided by the number of 
cells plated on day 6 into a single well. Fold change of less than 1 represents a decrease 
in number. In conditions labelled NK+PB – cells were in contact and NK/PB – cells were 
not in contact. NK cell numbers were calculated by flow cytometry using count bright 
beads and were defined as CD16/CD56Pos CD3Neg CD19Neg CD4Neg CD27Neg. In the data 
table below the figures the top 3 rows show NK cells cultured on their own at different 
concentrations, the middle 3 rows show NK cells cultured with plasmablasts without 
contact in a transwell and bottom 3 rows show NK cells mixed with plasmablasts.  
Day 6 Day 10 Day 13
0.4%NK 1660 706 119
1%NK 4150 2540 259
10%NK 41500 33382 12565
0.4%NK/PB Transwell 1660 1386 719
1%NK/PB Transwell 4150 2761 4003
10%NK/PB Transwell 41500 29589 14002
0.4%NK+PB 1660 2814 8363
1%NK+PB 4150 4162 5895
10%NK+PB 41500 31461 21333
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Day 10 Day 13
0.4%NK 0.43 0.07
1%NK 0.61 0.06
10%NK 0.80 0.30
0.4%NK/PB Transwell 0.84 0.43
1%NK/PB Transwell 0.67 0.96
10%NK/PB Transwell 0.71 0.34
0.4%NK+PB 1.69 5.04
1%NK+PB 1.00 1.42
10%NK+PB 0.76 0.51
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9.4.2 The B-NK interaction is contact dependant 
To establish whether the B-NK cell interaction is contact dependant or mediated by soluble 
mediators, purified NK cells and B-cells were cultured as shown in Figure  9.4-2. 
 
Figure  9.4-2 Outline of transwell experiment to establish nature of NK-B interaction 
The figure shows the scheme of transwell experiments. Labels within the wells show what 
cells were seeded into the different compartments. 
 
 
Negatively selected B-cells and NK cells on their own or with B-cells were stimulated with IL2 
CD40L and BCR stimuli as before (Figure  5.4-1).  The NK cells were cultured with B-cells on the 
same side as well as the opposite side of the transwell to assess the contact dependant nature 
of the interaction. The mouse stromal cell M2-10B4 was not used in this experiment between 
days 6 and 10. NK cell numbers were calculated by flow cytometry using count bright beads and 
were defined as CD16/CD56Pos CD3Neg CD19Neg CD4Neg CD27Neg. The antibody panel and 
detailed gating strategy for quantifying NK cells is given in Table  5.2-4 and Figure  5.2-7 
respectively. The purity of B-cells and NK cells were 99.5% was 98% respectively. NK cells 
which were not in contact with B-cells did not expand irrespective of the presence of soluble 
mediators from B-cells. The contact dependant nature of the interaction was reproducible in 
another similar experiment (data not shown).  
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NK-cells
B-cells
NK-cells
B + NK-cellsDay 0
NK-cells
B/NK – NK
B/NK – B
B+NK/NK – NK
B+NK/NK – B
NK – TW
B-Std
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Figure  9.4-3 NK cell expansion when grown in transwells with and without B-cell contact  
The number of NK cells derived on day 6 and day 10 from a single day 0 well. The pure B-
cell fraction on day 0 contained a small proportion of NK cells (0.5%). Data shown is 
representative of 2 different experiments. 
 
The above experiment clearly shows the contact dependant nature of the NK-B interaction. NK 
cells within the transwell separated from a mixed culture of B-cells and NK-cells fail to expand, 
while the NK cells in the mixed culture on the outer side of the transwell in contact with B-cells 
expand dramatically. However, plasmablasts cannot directly induce NK cell expansion which 
needs prior priming or is dependent on interaction with B-lineage cells prior to the plasmablast 
stage, as shown in Figure  9.4-1. 
The conclusion can be reached that NK cells if present at day 0 can be driven to expand 
dramatically on transfer into conditions that also promote plasma cell differentiation if cultured in 
contact with activated B-cells. Thus the contamination issue originally encountered can be 
avoided by using sequential negative followed by positive selection of B-cells on day 0 or 
excluding CD27Neg cells on day 6 by flow sort. Furthermore the expansion of NK-cells can be 
actively promoted by using a forced co-culture approach independent of the M2-10B4 stromal 
layer.  
Day 0 Day 6 Day 10
NK cells other side of transwell
to B-cells 24489 4752 1125
NK cells other side of transwell
to B+NK cells 24489 3597 1062
Pure NK cells 24489 3589 242
B-cells other side of transwell to
NK cells 97 1265 7559
B-cells 97 944 6933
B-cells and NK cells same side
of transwell (in contact) 24576 88879 1447417
0
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9.5 Evaluation of receptors and ligands involved in NK-B cell 
interaction 
The cause for expansion of NK cells induced by the differentiating B-cells was shown to be 
contact dependent. The surface proteins involved in stimulation of NK cells by B-lineage cells is 
not known. The knowledge of the receptor-ligand interactions involved would aid in devising a 
strategy to prevent the expansion during in vitro culture. If this phenomenon of NK cell 
expansion occurs in vivo and is involved in disease pathogenesis, it opens up therapeutic 
options by blockade of this interaction.  
9.5.1 NK-B cell interaction is not dependent on CD137 
CD137/137L pathway is one of the co-stimulatory pathways involved in NK cell activation. 
Peripheral blood NK cells can be expanded 1000-fold in vitro in 3 weeks by combination of 
CD137L and IL15 (125). CD137L is known to be expressed by B-cells in lymphoid follicles and 
germinal centers (126) and therefore could be a potential mode of interaction in vitro which 
could be responsible for the noted NK cell expansion. This pathway and thereby the interaction 
should be amenable to inhibition by CD137 blocking antibody. B-cells and NK cells purified on 
day 0 were mixed at a ratio of 10:1 and differentiated following the standard B-cell differentiation 
protocol (Figure  5.4-1) and the proportion of NK cells was evaluated on day 10. NK cells were 
defined as CD16/CD56Pos CD3Neg CD19Neg CD4Neg CD27Neg and the antibody panel and detailed 
gating strategy used for quantifying NK cells is given in Table  5.2-4 and Figure  5.2-7 
respectively. The addition of 10 µg/ml of blocking anti-CD137 at various stages of differentiation 
did not block the expansion of NK cells as shown in Figure  9.5-1. 
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Figure  9.5-1 Effect of anti-CD137 on the percentage of NK cells on day 10 of culture 
Purified peripheral blood B-cells and NK cells were mixed at a ratio of 10:1 on day 0 and 
simulated using IL2, CD40L and BCR stimuli and differentiated as before (Figure  5.4-1). 
Blocking anti-CD137 antibody was added at a concentration of 10µg/ml at the time points 
specified. NK cells were defined as CD16/CD56Pos CD3Neg CD19Neg CD4Neg CD27Neg and 
expressed as percentage of live cells on day 10 of the culture.   
9.5.2 NK-B cell interaction is not mediated via CD2/CD58 pathway 
NK cell cytotoxicity requires stable interaction with target cells which is mediated by interaction 
of CD2 present on  NK cell surface with CD58 by promoting nanotube formation (127). Initially 
B-cells from controls and RA patients were evaluated for surface expression of CD58. 
Peripheral blood containing an equivalent of 1 million white cells from patients and controls was 
treated with ammonium chloride to lyse the RBCs and then stained with CD48 FITC, CD58 PE, 
CD24 PE-CF594, CD16 PerCP-Cy5.5, CD2 PE-Cy7, CD19 BV421, CD3 V500, CD56 APC, 
CD27 AF700 and CD45 APC-H7. B-cells were defined based on their scatter profile and as 
CD19+CD3-CD56-. The proportion of CD58 positive B-cells was not significantly different (p = 
0.48, One-way ANOVA) between healthy controls (n=3), disease controls (n=3), rituximab naïve 
active RA patients (n=5) and RA patients relapsing post-rituximab (n=6). However, a proportion 
of the RA patients relapsing post-rituximab had higher levels of CD58 expressing B-cells 
(Figure  9.5-2). Since the CD2/CD58 pathway could also be potentially linked to RA 
pathogenesis, it was explored further.  
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    Figure  9.5-2 Expression of CD58 by peripheral blood B-cells by different patient groups 
B-cells expressing CD58 on their surface expressed as a proportion of total B-cells in the 
different patient groups - healthy controls (n=3), disease controls (n=3), rituximab naïve 
active RA patients (n=5) and RA patients relapsing post-rituximab (n=6) shown. B-cells 
were defined based on their scatter profile and as CD19+CD3-CD56-. The central lines 
represent the mean and the extreme lines represent the standard deviation. All the RA 
patients in this dataset had active disease at the time of sampling. The difference between 
the groups was not significant (p=0.48, One way ANOVA). 
The gene expression data previously published by Cocco et al. (60) was reanalysed for the 
change in CD58 expression levels during the course of in vitro B-cell differentiation. CD58 was 
expressed on day 3 by differentiating B-cells and does not reach baseline levels till day 13 as 
seen in Figure  9.5-3 . The NK cell expansion occurs only after day 6 when the culture conditions 
change although CD58 is expressed from day 3. Therefore, the change in cytokine 
combinations or other culture conditions on day 6 is likely to be required as an additional trigger 
for the activation of the CD2/CD58 pathway. To evaluate this further the effect of CD2/CD58 
blockade on NK cell expansion was studied. B-cells and NK cells purified on day 0 were mixed 
at a ratio of 10:1 and differentiated following the standard B-cell differentiation protocol 
(Figure  5.4-1) and the proportion of NK cells was evaluated on day 10. NK cells were defined as 
CD16/CD56Pos CD3Neg CD19Neg CD4Neg CD27Neg and the antibody panel and detailed gating 
strategy used for quantifying NK cells is given in Table  5.2-4 and Figure  5.2-7 respectively. The 
differentiating cells were treated with 10 µg/ml of tissue-culture grade anti-CD2 or anti-CD58 at 
baseline, day 3 and day 6. The addition of anti-CD2 or anti-CD58 at various time points during 
B-cell differentiation did not alter the NK cell expansion noted by day 10, as shown in 
Figure  9.5-3. 
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Figure  9.5-3 CD58 expression during B-cell differentiation and effect of CD2/CD58 
blockade on NK expansion 
a) Levels of absolute gene expression of CD58 at the various time points during B-cell 
differentiation as indicated in 3 controls. The data presented is reanalysis of data 
previously published by Cocco et al. (60). The dots represent the mean and the bars 
represent standard deviation.  
b) Purified peripheral blood B-cells and NK cells were mixed at a ratio of 10:1 on day 0 
and differentiated as per standard protocol (Figure  5.4-1). Blocking anti-CD2/anti-
CD58 antibody was added at a concentration of 10µg/ml at the time points specified. 
NK cells were defined as CD16/CD56Pos CD3Neg CD19Neg CD4Neg CD27Neg and 
expressed as percentage of live cells on day 10 of the culture. NK cell expansion was 
resistant to CD2 and CD58 blockade. 
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9.6 Further evaluation of cause for NK-B cell interaction 
The mechanisms driving expansion of NK cells after day 6 remained unclear. During one of the 
experiments where cells from individual day 3 wells from the same donor were differentiated 
separately, it was noted that one of the wells did not show NK expansion on day 10 under same 
culture conditions. This could be due to the unequal distribution of the contaminating NK cells. 
However, this also raised the possibility of a subset of B-cells present in low frequency leading 
to expansion. EBV is present in B-cells in the latent phase. When B-cells undergo differentiation 
to plasmablasts, EBV enters lytic phase. This might be a key factor in triggering the NK cell 
expansion. Therefore evidence for the presence of EBV DNA was sought.   
 
9.6.1 EBV DNA detected in the sample that consistently showed NK 
expansion 
Plasmablasts generated in vitro on day 6 using standard IL2, CD40L and BCR stimuli based 
activation protocol (Figure  5.4-1) from a donor whose samples consistently led to NK cell 
expansion in the previous experiments, even with low level of NK-cell representation was 
analysed. The EBV DNA was detected using nested PCR which has been developed as a rapid 
method for diagnosing EBV infection in the context of non-Hodgkin’s lymphoma (81) and the 
detailed protocol is described in the methods section  5.10. The first round of PCR reaction 
generated an 800bp fragment, which was then subjected to another round of PCR with primers 
designed to amplify both EBV type 1 and 2. Cell lines Raji and HeLa were used as positive and 
negative controls respectively. Annealing temperature of 600C and MgCl2 concentration of 
1.5mM was used. The band corresponding to the size of the second round PCR product was 
also detected by using the primary DNA sample directly in the second round PCR.  
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Figure  9.6-1 Electrophoresis of PCR products for detecting EBV DNA 
Day 6 plasmablasts generated in vitro using standard IL2, CD40L and BCR stimuli based 
activation protocol (Figure  5.4-1)from a control (D1503) and 3 different cell lines – GM, 
HeLa and Raji were used. Annealing temperature of 600C and MgCl2 concentration of 
1.5mM was used. Products generated by the single PCR reaction are shown in the bottom 
row and the top row shows products of the two stage nested PCR. 
 
 
 
Using 1st round PCR Product
Using Primary DNA Sample
D1503 GM HeLa Raji
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The PCR product from the second reaction was size selected on agarose gel by electrophoresis 
and sequenced. The sequenced product showed 98% homology to human herpes virus 4 (EBV) 
genome. Although this confirms the presence of EBV DNA in the plasmablasts, it does not 
prove that EBV is the main cause for NK cell expansion. To prove EBV as the definitive cause 
for the NK cell expansion it will require substantial amount of work which is beyond the scope of 
this project but could be addressed in a future project.   
 
Figure  9.6-2 Sequencing of the EBV PCR product 
The nested PCR product from the control was sequenced by Sanger sequencing. The 
obtained sequence had 98% homology to EBV genome. 
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9.7 Exploration of additional cell-selection strategies to improve B-
cell purity 
Differentiation of B-cells required high level of purity on day 0 to prevent expansion of non B-
lineage cells post day 10. Therefore methods for improving the purity of the day 0 negative B-
cell selection process were sought. The contaminating cells are mostly NK cells and T-cells. 
Methods of blocking the B-NK interaction and thereby the NK expansion with monoclonal 
antibodies is a much more viable strategy than multiple purification steps or flow cytometry 
based sorting and therefore pursued. However, due to the lack of positive findings from the 
pathways tested and the possibility of EBV being involved in the interaction, the cell selection 
strategies were re-visited. Monocytes have very high levels of Fc receptor and therefore can 
capture the depleting antibodies from the negative B-cell selection kit in a non-specific fashion. 
This can lead to reduction in the antibodies available to deplete the non-B cells. Indeed a likely 
explanation for differences between differentiations was whether column capacity was 
overloaded, while in the context of samples form inflammatory states the performance of column 
based purification appeared less reproducible. Therefore, the cell selection strategy was 
specifically modified to counteract these factors by using mixture anti-CD3/CD14/56 tagged 
magnetic beads to deplete T-cells, monocytes and majority of NK cells respectively. 
9.7.1 B-cell negative selection purity improved with higher concentrations 
of reagents or additional purification steps 
PBMCs obtained by density centrifugation was incubated with CD14 microbeads and depleted 
by passing through the magnetic column (detailed cell-selection protocol provided in methods 
section  5.3). Depleting the monocytes alone before negative B-cell selection did not achieve the 
necessary purity. It required an additional round of purification with anti-CD3/CD56 magnetic 
beads to improve the purity as shown in Figure  9.7-1. Therefore, monocytes are unlikely to be a 
key cause for the purification issues. Two step sequential selection using anti-CD3/CD56 
magnetic beads either before or after the negative B-cell selection kit improved the purity to 
more than 99%. Using the reagents (biotinylated antibody cocktail and anti-biotin magnetic 
beads) in excess (10 times the manufacturer’s recommendation) also gave very high purity of 
99%. This is suggestive of the fact that the antibodies may be consumed in a non-specific 
fashion by other cell types.  
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Figure  9.7-1 Additional cell-selection strategies to improve B-cell purity 
B-cells were defined based on their scatter profile and CD19/CD20 dual-positivity. B-cells 
as a proportion of live cells is shown in the graph. PBMCs were isolated by density 
centrifugation and then subjected to the cell selection process as described in methods 
section  5.3. 
a) Double negative selection refers to strategy of using negative B-cell selection kit and 
mixture of anti-CD3/14/56 beads sequentially. The purity after the first round of 
selection is denoted by black bars and the second round of selection is denoted by 
grey bars. With high dose selection, 10 times the recommended volume of biotinylated 
antibody cocktail and anti-biotin magnetic beads were used. The black bar denotes 
purity using the standard concentration and the grey bar denotes the high 
concentration.  
b) Triple selection involves 3 rounds of successive negative selection with antiCD14 
beads, negative B-cell selection kit and anti-CD3/CD56 beads. The purity from the 3 
successive rounds of negative selection is depicted in the bar graph. 
0
20
40
60
80
100
B
-c
el
lP
er
ce
nt
ag
e
After
Baseline
Double Neg Selection
(Neg B First)
Double Neg Selection
(CD3/14/56 Depletion First)
High Dose Selection
a)
0
20
40
60
80
100
B
-c
el
lP
er
ce
nt
ag
e
Triple Selection
b)
    221 
 
 
Reviewing the lymphoprep protocol to isolate mononuclear cells, it was noted that one of the 
wash steps specifically targets platelets. The protocol was modified to change the wash step to 
use ice-cold PBS rather than PBS at room temperature. This is likely to reduce platelet 
aggregation which could be the cause for consumption of the depleting antibodies. With the 
modified protocol and using twice the recommended amount of the antibody cocktail, 
acceptable levels of purity of >95% was achieved. The purity was checked following negative B-
cell selection and the second stage of negative selection with anti-CD3/CD56 magnetic beads 
was used only if the purity was low.      
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9.8 Summary and discussion 
In vitro differentiation of RA B-cells was attempted which led to the finding of non-B-cell 
expansion post day 6 of culture. This was also seen sporadically in some control samples but 
was worse in case of RA patients. The identity of the expanding non-B cells was established to 
be NK cells. NK cell activation is based on the balance of stimulatory and inhibitory signals 
received by the surface receptors and can be activated by allogenic cells. Therefore the cells of 
mouse-origin in the culture system were suspected to be the cause for expansion namely, 
CD40L transfected fibroblasts (L-cells) between days 0 and 3, and the mouse bone marrow 
stromal cells (M2-10B4) that support plasma cell survival after day 6. This was excluded by 
using recombinant soluble CD40L and the expansion occurred in the absence of M2-10B4. NK 
cells differentiated using the same protocol used for B-cells did not show such expansion. The 
cytokine cocktail used in the culture on day 6 was not sufficient to stimulate NK cell proliferation 
without prior priming. It is not clear whether they need to be primed along with B-cells or just the 
culture conditions would suffice. 
The NK cell expansion was contact dependant since NK cells on the other side of a transwell 
did not proliferate. The molecules that can be involved in NK cell activation with corresponding 
ligands present in B-lineage cells were considered and two such pathways were assessed. The 
CD137 (41-BB, TNFRSF9) receptor/ligand system has been well studied in the context of T-cell 
co-stimulation (128). However, NK cells also express CD137 on activation (129) and B-cells 
express CD137L on activation (126). Majority of NK cells and T-cells express CD2 whose ligand 
is the adhesion molecule CD58 also known as LFA-3 (Lymphocyte Function Associated Antigen 
-3) (130). Although peripheral blood B-cells do not express CD58 (131), it can be induced on 
activation (Figure  9.5-3). The NK cell expansion was not inhibited by blocking antibodies anti-
CD137, anti-CD2 or anti-CD58 and therefore is unlikely to be mediated via CD137/CD137L or 
CD2/CD58 pathway.  
NK cells are lymphocytes of the innate immune system and are activated based on the balance 
of stimulatory and inhibitory signals provided by the target to the multitude of NK cell receptors. 
They play a key role in immunity against malignant cells and intracellular pathogens such as 
viruses (132). The B-cells during plasmablast transformation might be expressing unusual 
ligands in vitro, sensed by NK cells as something similar to a malignant cell which triggers their 
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expansion. The other possibility is the presence of viruses within the culture system. For the 
expansion to be mediated by a virus, it has to be present in the system from day 0 but invisible 
to NK cells until day 6. It is also possible that NK cells need additional IFNα added on day 6 for 
their proliferation. B-cells are known to harbour latent viruses such as EBV and EBV can survive 
long-term within resting memory B-cells without immune detection by shutting down expression 
of the viral proteins (133). However when the memory B-cells harbouring latent EBV undergo 
differentiation to plasmablasts, the virus enters a replicative phase irrespective of the mode of 
stimulation (134). During this replicative phase, the viral antigens and other cell danger 
molecules are expressed on the cell surface sensed by the NK cells. This along with IFNα 
induces an exuberant antiviral response with proliferation, cytokine secretion and cytotoxicity 
(135). Once the NK cells are activated, the immune response is not specific and targets both 
EBV positive and negative cells. This possibly leads to death of the B-lineage cells in the 
system as well as the mouse stromal cells. The other possible explanation for reduction in PC 
numbers with NK expansion is secondary to reduced cell survival due to lack of nutrients in the 
system and not direct killing. This will need further evaluation by NK cell functional assays. 
Presence of surface markers such as LAMP-1 would be suggestive of cytokine secretion and 
cytotoxicity. The specificity of killing by expanding NK cells can be established by isolating them 
from the culture and testing on cell lines and plasmablasts from a different donor.  
The sample which had most consistently shown NK cell expansion in fact had detectable EBV 
DNA on day 6.EBV as the main cause for NK cell expansion could be further confirmed by 
detection of EBV mRNA. The definitive way of proving this would be to differentiate B-cells from 
an EBV-negative control which is ethically not feasible due to the requirement of pre-screening 
the donors for EBV and there is a high prevalence of latent EBV of >95% in the adult 
population. The other option is to sort the EBV positive and negative cells based on LMP2A 
which is expressed by EBV harbouring B-cells and check for NK expansion. However, none of 
the available antibodies are validated for flow cytometry to perform this experiment.           
EBV also known as HHV-4 (Human Herpes Virus) has been linked with RA pathogenesis 
through multiple mechanisms (136). RA patients have higher frequency and levels of antibodies 
directed against EBV proteins and reduced cytotoxicity against EBV infected lymphocytes. 
Molecular mimicry due to similarity in sequences between EBV proteins and synovial tissue and 
human heat shock proteins has also been proposed (137). Higher proportion of RA patients 
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have EBV DNA/RNA detectable by PCR in the synovial tissue(138), and increased frequency of 
EBV specific T-cells have been demonstrated within the synovial fluid (139). Higher frequency 
of EBV-infected B-cells (140) and higher EBV viral load (141) were detected in peripheral blood 
of RA patients. Although these studies suggest a link between EBV and RA, no direct proof of 
pathogenesis has been established. 
Antibodies directed against citrullinated proteins are specific for RA. Antibodies directed against 
citrullinated-EBV derived peptides were detected in 45% of RA patients and levels correlate with 
ACPA (142). These antibodies were shown to cross-react with citrullinated proteins specific for 
RA such as fillagrin (143). EBV present in the synovial tissue and synovial fluid possibly elicits a 
low level antigen-specific response. When the B-cells with latent EBV are activated in an 
antigen-specific or polyclonal fashion the EBV enters a replicative phase. This generates an 
explosive immune response by NK cells and T-cells similar to that seen above which recruits 
other inflammatory mediators and cells that can perpetuate inflammation and incite tissue 
damage. NK cells were also noted in synovial tissue of early RA patients and correlated with 
inflammatory markers in serum (144). NK cells from synovial fluid of RA patients exhibit an 
activated phenotype (145) and were also involved in triggering osteoclastogenesis and bone 
destruction (146). B-cells from tonsils can stimulate NK cells when they are activated and are 
differentiating to plasmablasts (147). This pattern of interaction between activated B-cells and 
NK cells was shown to be contact-dependant (148). Although not specifically tested, presence 
of latent EBV in the B-cells used in these previously published studies could not be ruled out. 
Thus EBV harbouring B-cells through activation of NK cells could play a key role in loss of 
tolerance and tissue damage in RA.  
Large granular lymphocytic leukaemia (LGL) is a lymphoproliferative disorder characterised by 
clonal expansion of NK cells or more commonly, CD8 cytotoxic T-cells. 25% of LGL patients 
have a history of RA and LGL patients also have a higher frequency of HLADR4 haplotype 
(149). LGL is also associated with other autoimmune disorders such as Sjogren’s syndrome and 
the underlying pathogenic process is chronic antigenic stimulation causing polyclonal expansion 
followed by clonal proliferation (150).EBV DNA has been detected in a proportion of NK-LGL 
patients and has been linked to pathogenesis (151). In some of the experiments in this chapter 
when T-cells were present in the contaminating population, there was expansion of T-cells but 
not to the same degree as NK cells (Data not shown). Therefore, the contact dependant B-NK 
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interaction observed in his chapter could be contributory to the development of LGL in RA 
patients.    
Regulation of antibody production and thereby the immune response of B-cells is thought to be 
mainly mediated by competition for survival niches in the bone marrow. NK cells in addition to 
rapid immune response against infections and tumours also possess immunoregulatory 
properties. Regulation of T-cells by NK cells is mediated by multiple different mechanisms 
including perforin-mediated killing, cytokines such as IFNγ and IL10, and various NK receptor-
ligand interactions such as NKG2A/D, NKp46 resulting in cell death (152). NK cells play a key 
role in termination of antibody responses in the context of vaccination (153) and respiratory 
syncytial virus infection (154). Therefore, irrespective of the presence of EBV, the NK cell 
proliferation during plasma cell differentiation could be a novel key mode of NK cell mediated 
regulation of B-cells that has not been appreciated or studied in detail.  
    226 
 
 
10 Fifth Results Chapter: Phenotyping of long-lived plasma cells 
Persistence of anti-microbial and autoantibodies after therapeutic B-cell depletion for various 
autoimmune disorders including RA is a clear proof of the presence of long-lived PCs. Clinical 
improvement or reduction in autoantibodies following B-cell depletion would be consistent with 
pathogenesis being mediated by short-lived PCs. The lack of clinical response after B-cell 
depletion would suggest pathogenesis that is at least in part mediated by long-lived PCs. The 
antibodies secreted by long and short-lived plasma cells could be of different clinical relevance 
in different pathological conditions. To understand this difference it is imperative to identify the 
long-lived plasma cells phenotypically for which until recently there were no known markers 
(155). ELISpot can be used to confirm the antigen specificity of PCs thereby their longevity 
depending on time since exposure to the antigen. However potential phenotypic markers need 
to be identified for testing by ELISpot.  
Examination of the PCs from bone marrow of RA patients would be ideal to understand the 
behaviour of the short-lived and long-lived PCs in RA. However, it is difficult to recruit patients to 
have a bone marrow examination performed when it does not influence their clinical care 
directly due to the significant pain caused by the procedure. Although small, there is a definitive 
risk associated with the procedure including bleeding and infection and it also requires the 
expertise of the Haematologists. It will also require an additional hospital visit by the patients. 
The previous study attempting bone marrow examination failed to recruit more than 2 patients. 
Therefore, the surplus bone marrow samples from the diagnostic lab (HMDS) which were 
analysed and found not to have any disease involvement were used for analysis. This will allow 
deeper understanding of normal PC biology and specific questions in relation to RA such as 
antigen specificity if required can be addressed in future studies.  
CD19 was identified based on historical work at the HMDS in monitoring marrow reconstitution 
following bone-marrow ablation, where CD19Pos PCs return earlier compared to CD19Neg PCs. 
Myeloma is characterised by presence of CD19Neg PCs in majority of the cases and the cell of 
origin for myeloma is thought to be the long-lived PCs. Therefore CD19 negativity was pursued 
as a marker of long-lived PCs. The aim of the study was not related to myeloma PCs. However, 
since CD19 negativity was pursued as a marker of long-lived PCs and majority of the myeloma 
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cases are characterised by CD19Neg PCs, it is essential to understand the difference between 
the normal CD19Neg and myeloma PCs. Since myeloma PCs are considered to be derived from 
long-lived PCs, comparison of the features that are different between CD19Pos and CD19Neg 
normal PCs with myeloma PCs might reveal clues regarding mechanisms contributing to 
longevity.  
A significant proportion of CD19Neg PCs were present in bone marrow of controls which were 
polyclonal and therefore different to myeloma PCs (Figure  10.1-1). To test whether the CD19Pos 
and CD19Neg PCs are genuinely distinct populations, the differences in expression of other 
surface markers were evaluated and in particular enrichment for markers associated with PC 
longevity such as CD28 (156) was assessed. This revealed that there was further heterogeneity 
within PCs as noted for memory B-cells and 4 out of the 8 subsets identified based on 
expression of CD28/CD45/CD56 were differentially distributed between CD19Pos and CD19Neg 
PCs (Figure  10.1-2) and CD28 was predominantly expressed by CD19Neg PCs (Figure  10.1-3). 
Since myeloma PCs are understood to be derived from long-lived PCs, The expression levels of 
markers used to phenotype myeloma PCs were assessed to check whether the myeloma PCs 
are distinct from normal PCs which revealed that CD19Pos and CD19Neg PCs were different to 
myeloma PCs and similar to each other for majority of the markers tested. For those markers 
with differentially expressed markers, the profile of myeloma PCs followed an exaggerated 
pattern to that of normal CD19Neg PCs (Figure  10.1-4). Long-lived PCs are likely to express 
higher levels of anti-apoptotic molecules and lower levels of pro-apoptotic molecules and the 
expression of BCL2 and CD95 by CD19Neg PCs were consistent with this hypothesis 
(Figure  10.1-5).  
The expression of molecules associated with survival in itself does not prove the longevity of the 
CD19Neg PCs. Therefore, evidence for a prolonged life-span for CD19Neg PCs in vivo was 
sought. Bone marrow ablation therapy depletes entire PC compartment and therefore both short 
and long-lived PCs and B-cell depletion is likely to deplete the short lived PCs from the marrow 
due to their constant requirement for replenishment from the B-cells. To test this further, 
reconstitution of PCs during remission following bone marrow ablation for myeloma and 
therapeutic depletion of B-cells with anti-CD52 therapy for CLL were studied. When both 
CD19Pos and CD19Neg PCs were depleted the CD19Neg PCs did not recover to normal levels 
even after 5 years following their depletion (Figure  10.2-1). However, on B-cell depletion, the 
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CD19Pos PCs were almost completely depleted but recovered within 2 years (Figure  10.2-2) 
whereas the CD19Neg PCs remained stable. These results are suggestive of distinct kinetics in 
generation of CD19Pos and CD19Neg PCs.  
From data available so far and from the published literature, there still remains few unanswered 
questions. It is not known at what stage during the course of differentiation, the decision to 
become a CD19Neg PC is made and whether they are derived from CD19Pos PCs. Human and 
murine B-cell differentiation shows phenotypic divergence even for key antigens and murine 
models do not allow direct extrapolation of phenotypes linked to plasma cell longevity (157, 
158). Direct in vivo assessment of plasma cell longevity in humans is challenging both 
technically and ethically, and in vitro approaches have been hampered by the lack of model 
systems allowing long-term human plasma cell maintenance in vitro. However, the recently 
developed assay previously described allows the maintenance of long-lived human plasma cells 
in vitro (60) and therefore the generation of CD19Pos and CD19Neg PCs was studied in vitro. 
CD19Neg PCs can be generated by stimulation of B-cells with IL2, CD40L and BCR stimuli 
based protocol in vitro (Figure  5.4-1) and it was confirmed using 3 different CD19 antibody 
clones and fluorochromes (Figure  10.3-1).Long-lived PCs are likely to be under stricter control 
and therefore likely to be generated via a classical germinal centre reaction. It is not known 
whether CD40L stimulus is mandatory for generation of CD19Neg PCs. Therefore, stimulation 
with TLR agonist instead of CD40L was tested and CD19Neg PCs were generated with TLR 
stimulation. The CD19Neg PCs were generated quite early during in vitro differentiation of PCs 
with both CD40L and TLR stimuli. To test whether the CD19Neg PCs are generated early in vivo, 
the immune response to seasonal influenza vaccine was studied which is suggestive of early 
CD19Neg plasmablast generation (Figure  10.3-7) but requires further studies for confirmation.  
The in vivo studies described above provide an indirect evidence for longer life span of CD19Neg 
PCs. When tested in vitro by long-term cultures, the change in the relative proportions of 
CD19Neg PCs and CD19Pos PCs was suggestive of a longer life span for CD19Neg PCs 
(Figure  10.3-8). One possible explanation for the delayed reconstitution of CD19Neg PCs shown 
in Figure  10.2-1 is that CD19Neg PCs are derived from CD19Pos PCs with time. To address this in 
vitro generated CD19Pos PCs were flow sorted and monitored for the development of CD19Neg 
PCs in vitro which did not reveal any evidence to support the hypothesis (Figure  10.3-9).  The 
immunoglobulin repertoire of the bone marrow CD19Pos and CD19Neg PCs was analysed to 
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understand the similarities and differences between the two populations. A lower degree of 
overlap in the IGHV sequences between cell populations would be suggestive of their distinct 
nature and therefore the overlap between CD19Neg and CD19Pos PCs was assessed. Memory B-
cells are known to have shorter CDR3 length compared to transitional and naïve B-cells (159). 
Therefore, differences in CDR3 length might be suggestive of their cell of origin and when it was 
analysed; CD19Neg PCs were noted to have shorter CDR3 length.  
In summary, this chapter addresses various different properties of CD19Pos PCs and CD19Neg 
PCs in vivo and in vitro to identify the subset which is likely to contain the cells with potential for 
longevity.   
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10.1 Phenotyping and characterisation of bone marrow plasma cells 
To phenotype PCs, an approach similar to that used for classification of memory B-cells was 
employed. Since CD19 negativity was pursued as a marker of long-lived PCs and myeloma PCs 
are known to be CD19 negative, normal PCs were initially checked for light chain restriction. 
The expression levels of pro-survival and apoptotic proteins were compared between the PC 
subsets. The surface markers used for routine phenotyping of myeloma PCs were compared 
and contrasted.   
10.1.1 Polyclonal CD19Neg PCs can be detected in normal bone 
marrow and are a heterogeneous population 
PCs were analysed from 23 bone marrow samples investigated for possible haematological 
malignancy but lacking evidence of disease involvement of the marrow. The surplus bone 
marrow samples were subjected to RBC lysis with ammonium chloride and stained with the 
antibodies in Table  5.2-2 for surface staining or Table  5.2-5 for intracellular staining. PCs were 
defined as CD38HiCD138HiCD45int/wk and based on their scatter profile as per the gating strategy 
shown in Figure  5.2-4. In all cases the majority of PCs co-expressed CD19 and CD45 but a 
minor population of CD19Neg45int PCs were detected in all samples, representing a median 24% 
of total PCs (interquartile range 16-35%, range 1 – 52%). The malignant PCs seen in multiple 
myeloma and MGUS (Monoclonal gammapathy of uncertain significance) are mostly CD19 
negative but are typically monoclonal. Analysis of cytoplasmic immunoglobulin light chain of the 
initial 11/23 cases demonstrated that the CD19Neg PCs were polytypic in all cases, with a 
median cytoplasmic kappa:lambda ratio of 1.7:1 (range 1 – 3.8:1). The CD19Neg PCs had a 
predilection for kappa light chain with a slightly higher kappa:lambda ratio with p-value of 0.002 
(Wilcoxon matched-pairs signed rank test).  
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Figure  10.1-1 Proportion of CD19Neg PCs and analysis of light chain usage 
Surplus bone marrow samples from 23 controls were investigated for various 
haematological conditions and reported to have a normal bone marrow were subjected 
to RBC lysis with ammonium chloride and stained with the antibodies in Table  5.2-2 or 
Table  5.2-5. PCs were defined as CD38HiCD138HiCD45int/wk and based on their scatter 
profile as per the gating strategy shown in Figure  5.2-4.  
a) CD19 positive and negative PCs as a proportion of total PCs in disease free bone 
marrows from 23 controls are shown. The boxes represent the upper and lower 
quartiles and the whiskers represent the minimum and maximum values. 
b) Kappa/Lambda ratio of CD19Pos and CD19Neg PCs from the first 11 controls in a) 
shown. The ratio is significantly different between the two PC subsets (p = 0.002, 
Wilcoxon matched-pairs signed rank test). The horizontal bars represent median with 
interquartile range.    
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10.1.2 The PC subset distribution pattern varies between CD19 
positive and negative PCs 
PCs were analysed from 12 bone marrow samples investigated for possible haematological 
malignancy but lacking evidence of disease involvement of the marrow. The surplus bone 
marrow samples were subjected to RBC lysis with ammonium chloride and stained with the 
antibodies in Table  5.2-2. PCs were defined as CD38HiCD138HiCD45int/wk and based on their 
scatter profile as per the gating strategy shown in Figure  5.2-4. Using the common markers 
used for phenotyping neoplastic PCs such as CD19, CD45, CD56 and CD28, PCs can be sub-
divided into 16 different subsets as shown in Figure  10.1-2. This reveals a marked 
heterogeneity within the PC pool which is likely to be even greater with additional markers. The 
relative proportion of each subset within the CD19Pos and CD19Neg PCs was analysed. A higher 
proportion of CD19Neg PCs were CD56 positive, CD28 positive and CD45 weak compared to 
CD19Pos PCs (Figure  10.1-2). This pattern of cell surface expression is similar to myeloma PCs.  
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 Figure  10.1-2 Differences in subset distribution of CD19Pos and CD19Neg PCs 
Surplus bone marrow samples from 12 controls were investigated for various 
haematological conditions and reported to have a normal bone marrow were subjected to 
RBC lysis with ammonium chloride and stained with the antibodies in Table  5.2-2. PCs 
were defined as CD38HiCD138HiCD45int/wk and based on their scatter profile as per the 
gating strategy shown in Figure  5.2-4. PCs expressed as percentage of CD19Pos or 
CD19Neg PCs divided into 8 subsets each based on CD45/56/28 expression. The boxes 
represent the upper and lower quartiles and the whiskers represent the minimum and 
maximum values. Paired t-test (Wilcoxon signed-rank) ‘p-value’ shown with the significant 
values in bold. The boxes represent the upper and lower quartiles and the whiskers 
represent the minimum and maximum values. Dotted bars – Normal CD19Pos PCs, Clear 
bars – Normal CD19Neg PCs (n=12) 
 
However, only CD28 has been mechanistically linked to PC longevity through downstream 
NFKB signalling (156). CD28 has also been shown to be a key pro-survival and apoptotic 
resistance mediator in myeloma PCs through the PI3K/Akt/FoxO3a/Bim pathway (160). CD28 
expression is quite variable in normal human PCs and the common pattern is that the 
CD28PosPCs are mostly confined to the CD19Neg PC subset. Occasionally there was the 
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presence of CD28Pos PCs within the CD19Pos PC subset or complete absence of CD28Pos PCs 
(Figure  10.1-3). Further analysis of the CD28Pos PCs revealed that the majority were CD19 
negative and CD45 weak (p=0.001) (Figure  10.1-3). 
 
 
 
Figure  10.1-3 CD28 expression by normal CD19Pos and CD19Neg PCs 
Surplus bone marrow samples from 12 controls were investigated for various 
haematological conditions and reported to have a normal bone marrow were subjected to 
RBC lysis with ammonium chloride and stained with the antibodies in Table  5.2-2. PCs 
were defined as CD38HiCD138HiCD45int/wk and based on their scatter profile as per the 
gating strategy shown in Figure  5.2-4. 
a) Different expression patterns of CD19 and CD28 by PCs. CD19Pos PCs are coded as 
blue and CD19Neg PCs are purple. 
b) CD28 positive PCs divided into subsets based on expression of CD19 & CD45 
represented as percentage of total plasma cells. The boxes represent the upper and lower 
quartiles and the whiskers represent the minimum and maximum values. Paired t-test 
(Wilcoxon signed-rank) ‘p-value’ shown. (n=12) 
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10.1.3 Neoplastic myeloma PCs more closely resemble normal 
CD19Neg than CD19Pos PCs 
In addition to the fraction of cell populations expressing antigen, the level of expression was 
assessed in the samples from the previous section along with 11 myeloma patients, and the 
analysis was extended to a wider range of antigens in the following groups: control CD19Pos, 
control CD19Neg and myeloma PCs (all CD19 negative in this series). CD19Pos PCs from control 
bone marrow samples showed very few differences in protein expression to paired CD19Neg 
PCs except for CD45. CD56 expression identified a subset of normal CD19Neg PCs in the 
majority of control samples. As reported in several previous studies, CD56 is strongly expressed 
in approximately three quarters of myeloma cases and the level of expression by neoplastic 
PCs is typically more than ten-fold the level detected on normal CD56PosCD19Neg PCs. In 
addition to CD56, there were significant differences in levels of expression of CD27, CD81 and 
CD117 between neoplastic and normal CD19Neg PCs but there were no differences for these 
markers between normal CD19Pos and CD19Neg PCs (Figure  10.1-4).  
Thus for the majority of markers, normal CD19Pos and CD19Neg PCs are phenotypically similar 
but for those markers with differential expression, namely CD45 and CD56, the profile on 
neoplastic PCs follows an exaggerated pattern of that seen on normal CD19Neg PCs. 
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Figure  10.1-4 Comparison of antigen expression levels on normal CD19Pos, normal 
CD19Neg and myeloma plasma cells 
Surplus bone marrow samples from 12 controls and 11 myeloma patients were subjected 
to RBC lysis with ammonium chloride and stained with the antibodies in Table  5.2-2. PCs 
were defined as CD38HiCD138HiCD45int/wk and based on their scatter profile as per the 
gating strategy shown in Figure  5.2-4. Surface expression levels (Median channel 
fluorescence) of the various antigens on normal plasma cells and myeloma plasma cells 
shown. Only samples with more than 20 events in each subset were included in the 
analysis. ‘P values’ (Kruskal-Wallis test with Dunn’s multiple comparisons) for comparison 
of the MFIs between the different populations for the tested antigens is given in the table 
below. The boxes represent the upper and lower quartiles and the whiskers represent the 
minimum and maximum values. Dotted bars – Normal CD19Pos PCs, Clear bars – Normal 
CD19Neg PCs, Striped bars – Myeloma PCs. Plasma cells were gated based on their 
scatter profile and expression of CD138 and CD38. The level of CD19 expression on B-
cells was used to guide the gating of the CD19 negative plasma cells. The CD19 levels on 
CD19Negplasma cells were lower than the lowest CD19 expressing B-cells. 
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10.1.4 Differential expression of pro- and anti-apoptotic markers in 
CD19Pos and CD19Neg PCs. 
PC longevity is linked to resistance from apoptosis due to the differential expression of anti-
apoptotic proteins of the BCL2 family such as Mcl-1, Bfl-1/A1 and the TNF receptor superfamily 
member BCMA (161-163), while the pro-apoptotic FAS receptor is upregulated during B-cell 
activation. Expression of FAS receptor CD95 and intracellular BCL2 were therefore evaluated in 
11 control samples with only polyclonal PCs. Bone marrow samples from patients investigated 
for various haematological conditions but lacking evidence of disease involvement of the 
marrow were used. The surplus bone marrow samples were subjected to RBC lysis with 
ammonium chloride and intracellular staining was performed with the antibodies in Table  5.2-5. 
PCs were defined as CD38HiCD138HiCD45int/wk and based on their scatter profile as per the 
gating strategy shown in Figure  5.2-8. The expression of BCL2 was 28% higher in CD19Neg PCs 
(4-113%) compared to CD19Pos PCs from the same aspirate sample (P<0.0001). The 
expression of CD95 was 163% lower (79-284%) in CD19Neg PCs compared to paired CD19Pos 
PCs (P<0.0001) (Figure  10.1-5). The greater expression of BCL2 and lower expression of CD95 
would be in keeping with pro-survival phenotype in CD19Neg PCs. 
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Figure  10.1-5 Expression levels of BCL2 and CD95 by normal polyclonal 19Positive and 
19Negative PCs 
Surplus bone marrow samples from 11 controls were subjected to RBC lysis with 
ammonium chloride and stained with the antibodies in Table  5.2-5. PCs were defined as 
CD38HiCD138HiCD45int/wk and based on their scatter profile as per the gating strategy 
shown in Figure  5.2-8. Intracellular and surface protein expression levels as measured by 
the median channel fluorescence intensity of BCL2 and CD95, by polyclonal CD19Pos and 
CD19Neg plasma cells. (n==11). Representative flow cytometry plot of expression levels of 
BCL2 & CD95 by CD19Pos (Blue) and CD19Neg (Purple) PCs shown. 
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10.2 Differential life span of human plasma cell subsets in vivo 
It is challenging to track the life span of human PCs in vivo. Therefore, clinical situations where 
PCs or B-cells that generate the PCs are depleted were used to assess the life span of PCs in 
vivo.  
10.2.1 Normal CD19NegPCs display markedly delayed recovery after 
myeloablative treatment relative to CD19PosPCs.  
The depletion of normal bone marrow following high dose chemotherapy provides an 
opportunity to track the kinetics of bone marrow PC repopulation in humans. To ascertain 
whether the kinetics of CD19Pos and CD19Neg PC population recovery was similar or distinct, the 
data from thirty-one patients from the MRC Myeloma IX trial who had sequential bone marrow 
aspirate samples during remission after high-dose melphalan with autologous stem cell rescue 
was reviewed. Twenty-five patients were included, who fulfilled the criteria of having two or 
more samples in the seven years following therapy and remaining in remission. Normal CD19Neg 
PCs were defined based on weak CD45 and absence of aberrant CD56, CD27 or CD38 
expression, according to established criteria (164). The primary diagnostic flow data was 
reanalysed for the presence of normal CD19Pos and CD19Neg PCs in the 80 total samples. 
Overall the complete absence of PCs was the exception (6/80). CD19Pos PCs recover rapidly 
after successful treatment in 74/80 samples, and represented more than 90% of PCs in the 
majority of remission samples. Whilst CD19NegPCs also recovered in most patients, the kinetics 
of recovery was distinct. In the 80 samples analysed, CD19Neg PCs were undetectable in 19 
samples and remained at less than 1% of total PCs in 30/80 samples. Specifically, in samples 
taken within the first 3 years following myeloablation 26/48 had CD19Neg PCs represented at 
less than 1% of total PCs, while such low representation of CD19Neg PCs was significantly 
reduced in samples taken between year 4 and 7 (4/32 samples). Overall these results indicated 
a gradual increase in CD19Neg PCs with time (Figure  10.2-1). Bone marrow samples between 4 
to 6 years showed significantly higher proportions of CD19Neg PCs compared to samples 
between 1 to 3 years (p=0.0013). The results demonstrate a major difference in the kinetics of 
CD19Pos and CD19Neg PCs recovery when both populations are depleted simultaneously. Linear 
regression analysis of this data predicts that if such rates of reconstitution were maintained it 
would  take up to 50 years to reach normal levels of CD19Neg PCs (p=0.006, R2 = 9.33%). 
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Figure  10.2-1 CD19Pos plasma cells recover rapidly after myeloablative treatment with 
stem cell rescue while CD19Neg plasma cells may take several years to regenerate 
Scatterplot showing the 80 patient samples in the years following myeloablative therapy 
with autologous stem cell rescue for myeloma. The horizontal bars represent median and 
interquartile range. PCs were defined as CD38HiCD138HiCD45int/wk and based on their 
scatter profile as per the gating strategy shown in Figure  5.2-4. CD19Neg PCs are 
expressed as a percentage of total plasma cells. Figure shows progressive increase in the 
percentage of plasma cells that are CD19Neg. The values below 1% have been rounded off 
to 1% for the purposes of the logarithmic scale in this figure. 
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10.2.2 B-cell depletion therapy results in loss of CD19Pos PCs within 3 
months but CD19Neg PCs persist.  
In order to determine whether there was any difference in the longevity of CD19Pos and CD19Neg 
PCs we reviewed bone marrow samples from CLL patients undergoing alemtuzumab therapy 
reported previously (74). Alemtuzumab targets CD52 and effectively depleted normal B-cells 
and GPI-expressing T-cells in the peripheral blood of all patients in the study, although there 
was differential depletion of CLL cells. Normal plasmablasts and PCs express at most low levels 
of CD52, similar to other populations that are resistant to alemtuzumab treatment. Depletion of 
normal B-cells may therefore be expected to result in reduced levels of short-lived PCs whilst 
having little or no effect on long-lived PCs. PCs from Campath trial were analysed 
retrospectively using markers from the panel designed for detection of residual CLL, comprising 
CD19 PE-Cy5 (FMC63, prepared in-house), CD5 APC (UCHT2, prepared in-house), CD20 
FITC (B9E9, Coulter) and CD38 PE (HIT2, BD Biosciences). PCs were gated using CD38/CD20 
and light scatter characteristics and the CD19 threshold was set using CD20-CD5+ lymphocytes 
as a negative control. The CLL patients in this study were extensively pre-treated and the PC 
proportion was low because of extensive marrow infiltration, but the relative proportions of 
CD19Pos and CD19Neg PCs changed significantly after exposure to alemtuzumab with almost 
complete depletion of the CD19Pos fraction. During treatment, the proportion of CD19Neg PCs 
remained low but stable. There was some recovery of CD19Pos PCs 1-3 months after cessation 
of alemtuzumab treatment, although pre-treatment equilibrium was not reached until 6-24 
months after exposure to alemtuzumab (Figure  10.2-2). The results indicate that CD19Pos and 
CD19Neg PCs show distinct kinetics following therapeutic targeting of the immune system. 
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Figure  10.2-2 Recovery of PCs in CLL patients treated with Alemtuzumab 
In CLL patients treated with alemtuzumab, total B-cell depletion results in a reduction in 
CD19Pos plasma cells but CD19Neg plasma cells persist. The CD19Pos PCs start recovering 
1-3 months after treatment and reach normal levels by 2 years. The boxes represent the 
upper and lower quartiles and the whiskers represent the minimum and maximum values. 
Dotted bars – Normal CD19Pos PCs, Clear bars – Normal CD19Neg PCs. The different 
patient groups tested were - Before Rx (n=15), During Rx (n=38), 1-3 months post Rx 
(n=15), 6-24 months post Rx (n=18). Unpaired t test values given in figure A and paired t 
test value in figure B. PCs were gated using CD38Hi CD20- and light scatter characteristics 
and the CD19 threshold was set using CD20-CD5+ lymphocytes as a negative control. 
 
The CD52 expression of normal PCs is 10-fold lower then alemtuzumab responsive cells and 5-
fold lower than alemtuzumab resistant cells(165). However, some heterogeneity in the levels of 
CD52 expressed by PCs was also noted (165). Therefore CD52 expression was analysed 
specifically in CD19 positive and negative PC subsets. 5 surplus control bone marrow samples 
were subjected to RBC lysis with ammonium chloride and stained with CD52 FITC, CD28 PE, 
CD4 PerCP-Cy5.5, CD19 PE-Cy7, CD138 APC, CD38 AF700, CD45 APC-H7, CD56 BV421 
and CD27 BV605. PCs were defined as CD38HiCD138HiCD45int/wk and based on their scatter 
profile as per the gating strategy shown in Figure  5.2-8. Although the levels of CD52 was slightly 
lower in CD19Neg PCs, the CD19Pos PC levels were significantly lower than B-progenitors 
(p=0.04) which are not depleted by alemtuzumab (Figure  10.2-3). Although the level of CD52 
expression on both PC populations is significantly lower than alemtuzumab sensitive B-cells, the 
possibility of PCs being more sensitive cannot be ruled out. Therefore it cannot be excluded that 
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differential direct targeting of CD19Neg and CD19Pos PCs accounts for the preferential depletion 
of CD19Pos PCs. However, irrespective of the mode of depletion, the data demonstrate that in 
human bone marrow CD19Neg PCs are maintained independently of the CD19Pos PC population, 
and that CD19Pos PCs are reconstituted within 2 years which is much quicker than the 
reconstitution of CD19Neg PCs following myeloablation shown in Figure  10.2-1. 
 
 
 
Figure  10.2-3 Levels of CD52 surface expression by B-lineage cell subsets 
The median fluorescence intensity for CD52 surface expression by CD19 positive and 
negative PCs, B-progenitors and B-cells are shown (n=5). The CD19 positive PCs had 
significantly lower CD52 expression compared to B-progenitors which are not depleted by 
Alemtuzumab (p=0.04, paired t-test). PCs were defined as CD38HiCD138HiCD45int/wk and 
based on their scatter profile as per the gating strategy shown in Figure  5.2-4. B-cells 
were defined as CD19+CD45+CD4- and B-progenitors as CD19+CD45wkCD38+CD4-. 
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10.3 Generation and life span of in vitro derived CD19Neg plasma cells 
Multiple models for in vitro generation of plasma cells exist (54-59, 166, 167). However these 
systems failed to generate long-lived PCs and it was not known whether CD19Neg plasma cells 
could be generated in vitro. Therefore, presence of CD19Neg PCs was analysed in the recently 
described in vitro differentiation system which was developed in-house and can generate long-
lived PCs(60). 
 
10.3.1 CD19Neg PCs can be generated in vitro 
The origin and fate of human CD19Neg PCs is difficult to study due to requirement for sequential 
bone marrow sampling and lack of safe markers to track specific cell populations in vivo. Mouse 
models are not ideal due to the difference in surface phenotype of PCs compared to humans. 
Therefore, if CD19Neg PCs can be generated in vitro, they can provide an ideal model to study 
this subset.  
In vitro generated PCs were heterogeneous for expression of CD19. There was variability in the 
pattern of CD19 heterogeneity displayed by PCs namely - distinct peaks or a continuum of 
expression levels from positive to negative as shown in Figure  10.3-1. To establish the cause 
for this variability, different clones and fluorochrome conjugates of the CD19 antibody were 
tested on PCs generated in vitro using the standard differentiation protocol (Figure  5.4-1). The 
PerCP-Cy5.5 and PE-Cy7 conjugated antibodies were of the same clone whereas the PE 
conjugated antibody was a different clone. Out of the three different fluorochromes tested, 
PerCP-Cy5.5 has the weakest signal. CD19 PE and CD19 PE-Cy7 had similar signal intensities 
but CD19 PE-Cy7 provided the best distinction between CD19Pos and CD19Neg PCs. However, 
since PE-Cy7 is a tandem conjugate which is prone to dissociation and compensation issues, 
CD19 PE was chosen. There is also an intrinsic variability between samples in the pattern of 
CD19 heterogeneity even when the same antibody was used.  
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Figure  10.3-1 Different patterns of CD19 heterogeneity by in vitro generated PCs 
CD19 expression by PCs defined as annexin/7AAD negative (Live), CD20 negative, CD38 
& CD138 positive in the top row and CD38, CD27 & CD138 positive in the bottom row. 
Each column represents matched samples stained with different antibodies as indicated. 
The first two columns show day 10 PCs and the third column shows day 20 PCs 
generated in vitro using the standard protocol shown in Figure  5.4-1.   
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PCs from day 13 of the differentiation system were analysed for heterogeneity in surface 
expression of CD19. The CD19 expression levels (MFI) by flow cytometry was significantly 
different (p<0.0001) between the two subsets as shown in Figure  10.3-2. Some of the samples 
showed two peaks for the expression levels of CD19 and enabled easier segregation of 
subsets. In other samples there was no clear demarcation and in such cases the levels of 
baseline fluorescence seen with the isotype control was used as a guide to determine CD19 
negativity as shown in Figure  10.3-2.  
 
Figure  10.3-2 Evaluation of heterogeneity in surface expression of CD19 by PCs 
generated in vitro 
Median Fluorescence Intensity (MFI) of CD19 on day 13 plasma cells generated using the 
standard protocol (Figure  5.4-1) defined as annexin/7AAD negative (Live), CD20 negative, 
CD38 & CD138 positive. This shows the presence of two distinct populations. 
Representative histograms of the types of samples which do not exhibit a clear 
demarcation between CD19Pos and CD19Neg cells shown. In such cases, CD19 negativity 
was determined based on the level of background fluorescence of the isotype control.  
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10.3.2 CD19 negativity is established early during PC differentiation 
Negatively selected B-cells from controls were stimulated with IL2, CD40L and BCR stimuli and 
differentiated to PCs using the standard protocol (Figure  5.4-1). CD19 expression was 
sequentially analysed to determine at what stage during PC differentiation in vitro the CD19 
negativity is established. The proportion of CD19Neg PCs increased with time during the course 
of plasma cell maturation. CD19Neg PCs were a very minor proportion or undetectable in most 
samples on day 6. There was a significant increase in the proportion of CD19Neg PCs for all the 
samples between day 6 and day 10 (p<0.0001). The increase in proportion continued till day 20 
in most samples and it was significantly higher than day 10 (p=0.004). There was variability in 
the proportion of CD19Neg PCs generated by different samples. CD19Neg PCs are possibly 
generated from a distinct B-cell subset, the proportion of which is subject to biological variability 
within the same individual and/or between controls. Although the results are suggestive of 
CD19Neg PCs generated at the time of PC transition, it cannot be ruled out whether the CD19Neg 
PCs were CD19Pos before their transition in the short time frame between days 6 to 10. The in 
vivo data (Figure  10.2-1) would not support such quick evolution of CD19Neg PCs from CD19Pos 
PCs but cannot be ruled out in vitro. This can be addressed by sorting the CD19Pos PBs and 
PCs at multiple time points during the early stages of differentiation for generation of CD19Neg 
PCs. Alternatively if the cell of origin for CD19Neg PCs is identified, their PB to PC transition 
stage could be closely monitored in vitro.  
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Figure  10.3-3Sequential change in proportion of CD19Neg PCs during PC differentiation 
Negatively selected B-cells were differentiated to PCs in vitro using the standard 
differentiation protocol Figure  5.4-1). Change in the proportion of CD19Neg PCs (expressed 
as a percentage of total PCs) over short- and long-term in 8 and 16 controls respectively, 
acquired over 18 separate experiments. 
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10.3.3 CD19Neg PCs can also be generated using TLR7/8 agonist R848 
instead of CD40L for co-stimulation 
The standard B-cell differentiation protocol (Figure  5.4-1) uses CD40L stimulus in the form of 
mouse fibroblasts transfected with human CD40L (L-cells). Whether the generation of CD19Neg 
PCs is specifically linked to CD40L stimulation or other signals derived from L-cells is not 
known. Therefore, the TLR7/8 agonist - R848 was used to differentiate B-cells instead of L-cells. 
Viable PCs with phenotype similar to those generated with CD40L stimulus were generated and 
maintained the phenotype up to day 40 and possibly beyond as shown in Figure  10.3-4. The 
CD19 expression was also heterogeneous in PCs generated with both stimuli. 
 
Figure  10.3-4 PCs generated with CD40 L or TRL7/8 agonist R848 exhibit similar 
phenotype 
Negatively selected B-cells were differentiated to PCs in vitro using the standard protocol 
(Figure  5.4-1). Dot plots showing the presence of live (Annexin/7AAD negative) plasma 
cells (CD38 and CD138 positive) generated by CD40 ligand and TLR agonist R848 
stimulation on day 42 of in vitro differentiation. Histograms for CD19 expression by PCs 
generated with CD40L stimulus (top row) and TLR stimulus (bottom row) 
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The sequential change in proportion of CD19Neg PCs generated with different stimuli was 
compared in 3 controls. There was a trend towards higher proportions of CD19Neg PCs 
generated with TLR stimulus when the sequential changes in proportion of CD19Neg PCs during 
the early stages of PC maturation were plotted. However there was some variability during later 
stages (day 20) and when all the available time points were compared, the difference did not 
achieve statistical significance (p=0.084).  
 
 
 
Figure  10.3-5 Comparison of proportion of CD19Neg PCs generated with CD40L and TLR 
stimuli 
Negatively selected B-cells were differentiated to PCs in vitro using the standard 
protocol (Figure  5.4-1). 
a) CD19Neg PCs expressed as a percentage of total PCs (defined as Annexin/7AAD 
negative, CD38 and CD138 positive) generated by 3 controls in 3 different 
experiments at the specified time points.  
b) Comparison of the proportion of CD19Neg PCs generated with CD40L or TLR stimulus 
at identical time points in 3 controls shown. The time points are from 3 different 
experiments and vary between day 6 and day 42. ‘P value’ for the significance of the 
difference between the 9 pairs by paired t-test shown.  
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10.3.4 CD19Neg plasmablasts were generated early during immune 
response to seasonal influenza vaccination 
CD19Neg PCs develop quite early during in vitro differentiation. It is not clear whether CD19Neg 
PCs can be detected early in vivo during an immune response. Peripheral blood B-lineage cells 
from 6 healthy controls were sequentially sampled to monitor the immune response to seasonal 
influenza vaccination. The transcription factor interferon regulatory factor 4 (IRF4) induces the 
transition from a germinal center gene expression program to that of a PC via BLIMP1 induction 
(168, 169). The presence of CD19Neg plasmablasts was confirmed with intracellular IRF4 
staining after surface staining with the other 10 markers used in the memory B-cell panel which 
identified the relapse associated memory B-cell subset. IRF4 was tested in 3 controls at 2 
different points. Plasmablasts had the highest level of IRF4 expression of all the cells in the 
sample. The plasmablasts are CD20-CD38++CD27++CD24-CD84-CD95+IgD-IgM-LAIR1+/-. This 
expression profile of plasmablasts is known from the memory B-cell panels and also was 
confirmed with IRF4 staining. The CD19Neg plasmablasts had identical expression of all these 
above markers as well as similar scatter profile as CD19Pos plasmablasts as shown in 
Figure  10.3-6.   
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Figure  10.3-6 IRF4 and surface marker expression profile of CD19 positive and negative 
plasmablasts 
The scatter profile and surface expression of 9 different surface markers and intracellular 
IRF4 (transcription factor that heralds PC differentiation) by peripheral blood CD19Pos and 
CD19Neg plasmablasts 6 days post seasonal influenza vaccination. Representative of 3 
donors tested at 2 different time points (Pre vaccination and day 6). CD19Pos plasmablasts 
are denoted by purple colour and CD19Neg plasmablasts are shown in black.   
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The peak plasmablast response (increase in number of plasmablasts) is around day 6 which 
starts to resolve by day 14 in all the healthy controls and reaches normal levels by day 20. 
Controls 1 and 4 exhibited a weaker plasmablast response compared to the other controls. The 
disappearance of circulating CD19Neg plasmablasts was slightly delayed in some controls 
compared to CD19Pos plasmablasts.  CD19Neg plasmablasts were detected at baseline although 
at very low numbers. There was a significant increase in CD19Neg plasmablast numbers on day 
6 compared to baseline (p=0.04). There was a trend towards a decrease in proportion of 
CD19Neg plasmablasts on day 6 which was not statistically significant (p=0.12). Control 6 
showed no change in the CD19Neg plasmablast proportion and control 1 showed an increase on 
day 6. Based on this data it could be hypothesized that CD19Neg plasmablasts could be 
generated as a part of immune response to influenza vaccination but needs further confirmation 
by establishing their antigen specificity by ELISpot or expressing their immunoglobulin 
sequence in vitro.  
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Figure  10.3-7 Plasmablast response following seasonal influenza vaccination 
Absolute counts (Dual-platform methodology) and percentage of CD19Neg and CD19Pos 
plasmablasts (expressed as % of total plasmablasts) in the peripheral blood on the 
specified days since seasonal influenza vaccination. Plasmablasts were gated as 
CD27HighCD38HighCD20Neg within the lymphocyte scatter profile. The cell counts are shown 
on a logarithmic scale and percentages on a linear scale. Data shown from 2 different 
experiments with 3 controls each. The number of CD19Neg plasmablasts increased 
between baseline and day 6 in 5 out of 6 controls but their relative proportion did not 
increase in 5 out of 6 controls. P-values from paired t-test given.  
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10.3.5 CD19Neg PCs increase in proportion with time and can be 
maintained in culture for more than 100 days 
It was not clear whether the CD19Neg PCs generated in vitro are a transient population or 
capable of longevity like the in vivo CD19Neg PCs. To address this, long-term feeding 
experiments were undertaken in transwells on PCs generated in vitro from negatively selected 
peripheral blood B-cells as described in detail in methods section  5.4.4. It was possible to 
maintain live CD19Neg PCs and were detectable after 100days of culture and can survive 
possibly longer (Figure  10.3-8). 
The cell of origin for CD19Neg PCs is not known. CD19Neg PCs could possibly be generated by a 
distinct B-cell subset or CD19 negativity is determined stochastically during the process of B-cell 
differentiation. There was heterogeneity in expression of CD27 on day 6 plasmablasts. The 
plasmablasts that were lagging in CD27 expression gained CD27 to similar levels by day 20. To 
examine whether CD27 expression at the plasmablast stage was associated with the loss of 
CD19 in PCs, the plasmablasts were sorted into CD27 positive and negative fractions on day 6 
and continued in culture. The proportion of CD19Neg PCs generated was similar between the two 
sorted fractions as was the unsorted control.  
There is wide fluctuation in the cell numbers particularly that of the CD19Pos PCs during the 
initial plasmablast to PC transition. When cells numbers were normalised on day 30 there was 
similar rate of decline in CD19Pos and CD19Neg PCs with the rate slightly slower in case of 
19Neg PCs. There was a significant drop in CD19 MFI for the CD19Pos PCs which stabilised by 
day 30 whereas the CD19Neg PCs remained stable throughout. Although the levels of CD19 
expression dropped for CD19Pos PCs, they never reached the levels of CD19Neg PCs. For the 
experiment where CD27 positive fraction was sorted, data from the unsorted cells was used till 
day 20 since the CD27 expression equilibrated between the two fractions by day 20 and cells 
were CD27 positive by then. The noted increase in CD19 MFI in the sorted cells could be due to 
the residual staining from the antibodies used for the flow sorting.  
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Figure  10.3-8 Changes in PC characteristics during long-term culture 
a) Histogram of CD19 expression by in vitro generated PCs (defined as Annexin/7AAD 
negative, CD38 and CD138 positive) generated using standard protocol (Figure  5.4-1) 
at specified time points. Data shown representative of 3 samples over 2 different 
experiments.  
b) Data shown from 2 experiments. In one of the experiments CD19Pos plasmablasts on 
day 6 were sorted into CD27Pos and CD27Neg fractions. Proportion of CD19Neg PCs 
generated from 3 samples shown which demonstrates relative increase or slower 
decay of CD19Neg PCs. Data from the unsorted cells is shown up to day 20 for 
CD27Pos and CD27Neg fractions. 
c) The changes in absolute counts of CD19Neg and CD19Pos PCs normalized to the cell 
numbers on day 30 in 3 samples shown.  
d) Sequential change in CD19 MFI of CD19Neg and CD19Pos PCs shown for 3 samples. 
Data from the unsorted cells is shown up to day 20 for CD27Pos and CD27Neg 
fractions  
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10.3.6 CD19 expression changes in sorted CD19Neg and CD19Pos PCs 
It is not known whether the CD19Neg PCs are generated from the CD19Pos PCs or determined at 
the time of plasmablast to PC transition. To address this issue, PCs were sorted based on their 
CD19 expression after day 10 when the CD19Neg PC proportion reached 20-30%. Until this point 
the standard differentiation protocol was followed as described in detail in methods 
section  5.4.4. Live (7-AAD negative) CD138 positive were sorted into CD19 positive and 
negative fractions on BD Influx cell sorter. One of the samples was sorted on day 10 and the 
other two on day 16. The sorted cells were maintained in transwells with stromal cell support 
and re-fed twice per week with fresh nutrients and cytokines. The sorted PCs were monitored 
for 10-20 days for changes in phenotype.  
The CD19 negative fraction of the sort was of very good purity close to 100% but the CD19 
positive fraction was of much lower purity – 60 to 75%. The proportion of 25 – 40% of 
CD19Neg PCs present in the CD19 positive fraction was maintained at the same level in all 
samples. Interestingly, CD19Pos PCs were generated from CD19Neg PCs in all the samples 
suggesting a degree of plasticity in PCs, at least in vitro. The CD19 MFI of the CD19Pos PCs 
generated from CD19Neg PCs never attained the same levels as that of the native CD19Pos PCs. 
This suggests that CD19 expression could be dynamically regulated in PCs and interconversion 
between CD19Pos and CD19Neg PCs can occur. It is not known whether PCs in vivo maintain 
equilibrium between CD19Pos and CD19Neg subsets similar to seen in vitro due to survival or 
functional constraints. The other possibility is CD19 protein could be circulated between the 
surface and intracellular compartments without any changes in gene expression. The data from 
monitoring bone marrow PCs treated with myeloablative therapy and alemtuzumab is not 
suggestive of such recirculation of the CD19 protein in vivo. However such a process happening 
in vitro cannot be ruled out. Therefore, this will need further investigations for confirmation such 
as continuous monitoring of the CD19 protein in the live in vitro generated PCs by using time-
lapse confocal microscopy and testing of cytoplasmic and membrane fractions of sorted 
CD19Neg PCs for CD19 protein by western blot. 
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Figure  10.3-9 Phenotypic changes of flow sorted in vitro generated CD19Pos and CD19Neg 
PCs  
a) Histograms of sequential changes in CD19 expression by sorted PCs representative of 
3 controls from 2 different experiments. The live 7-AAD negative CD138 positive PCs 
were sorted into CD19 positive and negative fractions on BD Influx cell sorter between 
days 10 to 16 of B-cell differentiation when more than 20% CD19Neg PCs were present. 
The sorted cells were maintained in vitro for 10 to 24 days in transwells with re-
feeding.  
b) CD19Neg PCs expressed as percentage of total PCs defined as Annexin/7AAD 
negative, CD20 negative, CD38 and CD138 positive. This showed that CD19Pos PCs 
can be generated from the sorted CD19Neg fraction. 
c) CD19 MFI of the CD19Pos PCs generated from the sorted CD19Pos and CD19Neg 
fractions showed that the CD19Pos PCs generated from the CD19Neg fraction did not 
attain the levels of CD19 expression as the CD19Pos fraction. 
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10.4 Analysis of the immunoglobulin repertoire of bone marrow 
plasma cells 
It is not known whether the development of CD19 negativity is dependent on the antigen 
specificity of the plasma cell and thereby the immunoglobulin sequence. It is also not clear 
whether one of the subsets is generated from the other subset in vivo or is determined at the 
time of plasma cell differentiation. Analysis of the immunoglobulin sequence is likely to reveal 
the relationships between the two subsets and might provide clues to their B-cell of origin.  
10.4.1 Normal CD19Pos and CD19Neg PCs have a largely discrete 
immunoglobulin repertoire.  
The data from bone marrow PCs indicate that CD19Pos and CD19Neg PCs show extended 
phenotypic differences and have different kinetics of in vivo response following therapeutic bone 
marrow perturbation. These features suggest distinct origin and behaviour, but this conclusion 
would be contradicted if extensive overlap in IGHV repertoire usage could be observed. To 
address this RNA from FACS sorted CD19Neg and CD19Pos plasma cells from bone marrow of 4 
controls pre-enriched with CD138 magnetic beads was extracted by alcohol-chloroform method. 
RNA was reverse transcribed and IGHV region was sequenced from cDNA by next generation 
sequencing on Roche 454 GS Junior platform. Clinical details of the samples and number of 
cells in each fraction obtained from flow sort are given in Table  10.4-1. 
Table  10.4-1 Details of samples used for IGHV sequencing 
 
IGHV@ was amplified and sequenced with between 2535 and 8048 sequences corresponding 
to functional IGHV rearrangements identified in each case. More than 97% of the sequences 
were mutated (cut-off >2% difference from germ line) and the proportion of mutated sequences 
were similar between CD19Pos and CD19Neg PCs. There was little overlap between the 
immunoglobulin heavy chain repertoire with only 2.1 to 3.7% of unique IGHV rearrangements 
shared between the CD19Pos and CD19Neg fractions (Figure  10.4-1). Only a very low proportion 
Sample Clinical History No. of CD19 Pos PCs  No. of CD19 Neg PCs
H3627 Reactive Marrow 35000 25000
H3739 Leucopenia 10600 9612
BM12 Hip replacement 4774 4937
BM15 Hip replacement 1171 1282
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of sequences were present twice or more in both subsets (<2%) and <1% of sequences were 
present more than 5 times in both subsets (Denoted as frequent sequences in Figure  10.4-1).  
 
Figure  10.4-1 Low degree of IGHV sequence overlap between CD19Pos & CD19Neg PCs 
Venn diagram overlap depicts the percentage of identical amino acid sequences between 
the CD19Neg and CD19Pos plasma cell compartments. Sequences occurring 5 times or 
more are labeled as frequent. 
 
 
  
BM12 BM15
H3739H3627
Unique Sequences
CD19+
CD19-
55.8% 40.5%3.7% 52.6% 44.4%3.0%
42.0% 55.9%2.1% 50.9% 50.9%2.2%
Unique Sequences BM12 BM15 H3627 H3739
CD19Pos Sequences 1494 702 1840 1106
CD19Neg Sequences 1109 598 2422 1023
Overlapping Sequences 93 37 88 46
Overlap % 3.71 2.93 2.11 2.21
More than once in both fractions% 1.88 1.64 1.09 1.43
Frequent in both fractions % 0.50 0.78 0.19 0.66
More than once in 19+ as % of 19+ 60.04 68.66 48.64 64.83
Frequent in 19+ as % of 19+ 22.09 46.72 11.03 38.16
More than once in 19- as % of 19- 48.96 66.39 56.65 66.08
Frequent in 19- as % of 19- 10.73 40.80 21.10 30.69
More than once in either fraction % 55.94 68.01 53.57 65.53
Frequent in either fraction % 18.05 45.13 17.37 34.81
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The amino acid length was slightly skewed towards shorter CDR3 in the CD19Neg fraction 
compared to the CD19Pos fraction but was not consistent in all samples (p<0.0001 in 3 out of 4 
samples). The mutation load was significantly higher in CD19Pos PCs compared to CD19Neg 
PCs (p<0.0001).  
 
Figure  10.4-2 CDR3 length and mutation load in CD19Pos and CD19Neg PCs 
The amino acid length of the CDR3 region from 4 controls shown. The X-axis represents 
the relative proportion of each CDR3 length (bin size of 3) with in the CD19Pos PCs or 
CD19Neg PCs. The mutation load is calculated as percentage deviation from the germline 
sequence. The X-axis represents the relative proportion of each mutation load (bin size of 
3) with in the CD19Pos PCs or CD19Neg PCs. The CD19Pos PCs are represented by black 
bars and CD19Neg Pcs by clear bars. 
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The IGHV family usage showed no difference in preference between CD19Pos and CD19Neg PCs 
(Figure  10.4-3).   
 
Figure  10.4-3 : IGHV gene family usage by 19Pos and 19Neg PCs 
The relative proportion of sequences from each IGHV family (labelled along the X-axis) 
expressed as percentage of CD19Pos or CD19Neg PCs. Black cones – CD19Pos PCs, Light 
grey cones – CD19Neg PCs 
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10.5 Summary and discussion 
A definitive fraction of CD19Neg PCs exists in the normal bone marrow. Although this 
heterogeneity of the normal PC pool has been known for a long time, detailed studies of 
CD19Neg PCs have just begun to emerge (155). There remains uncertainty regarding the 
similarities between CD19Neg and CD19Pos PCs in terms of function, life span, mode of 
generation, in vivo kinetics and response to various immunomodulatory therapies. The analysis 
presented here confirms that division into CD19Pos and CD19Neg PCs is linked to extended 
differences in terms of phenotype and function between these populations. This extends recent 
data presented by Mei et al (155). While the similarity between the normal PC populations is 
greater than the similarity between either of these and neoplastic PCs, a number of antigens in 
particular CD45 and CD56 follow a similar trend in CD19Neg PCs to that observed in a more 
exaggerated version in neoplastic PCs of myeloma. Therefore, if a normal counterpart of 
neoplastic PCs exists, it is likely to reside within the CD19Neg PC fraction. Whether the additional 
differences in expression of CD56, CD45 and CD28 observed in this population represent 
distinct subpopulations, response to niche factors, or exaggerated stochastic variation remains 
uncertain. 
Tracking in vivo cellular populations in human is challenging. Therapeutically perturbed bone 
marrow samples have been taken advantage of to determine differences in response 
characteristics of CD19Neg and CD19Pos PCs populations. During the initial few years following 
bone marrow ablation therapy, the proportion of CD19Neg PCs was significantly lower compared 
to controls; this is consistent with a more restricted control over CD19Neg PC generation as 
might be expected for long-lived PCs. Although it cannot be excluded that a preferential loss of 
a specific niche essential of CD19Neg PC maintenance accounts for this difference, this seems a 
less likely explanation given the reconstitution of otherwise functional bone marrow in such 
patients. Long-lived antibody responses are generated from germinal center B-cells and 
potentially also from post-GC memory B-cells (170). Therefore depletion of memory B-cells due 
to prior therapy and the gradual re-encounter of antigens eliciting appropriate GC responses 
could in part explain the kinetics of recovery. Memory B-cells are known to have a shorter CDR3 
length compared to naïve B-cells (159). Thus the shorter CDR3 length noted in CD19Neg PCs 
would be consistent with origin either directly from a memory B-cell or from a common precursor 
of both memory B-cells and long-lived PCs such as a germinal center B-cell. Overlap of 1.1% in 
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amino acid sequences of CDR3 region has been noted in peripheral blood samples from the 
same individual for an estimated total B-cell repertoire size of 1.5 million which is constituted by 
tens of thousands of activated B-cells and millions of naïve B-cells (171). Although no definitive 
data for PC repertoire size exists, due to selective pressures during selection into the PC pool, it 
is likely to be much smaller than the total B-cell repertoire size. A smaller repertoire size would 
be expected to show a higher degree of overlap, thus a high degree of overlap in IGHV 
sequences between CD19Neg & CD19Pos PCs would have supported the conclusion that the two 
subsets represent a phenotypic continuum of a single population. In contrast the low degree of 
overlap observed supports predominantly independent derivation of the two populations. The 
alternate explanation is that CD19Neg PCs derived from CD19Pos PCs with gradual loss of 
expression of CD19 over time, while the IGHV@ repertoire differences could be explained by 
origin from distinct temporal waves of immune response this is not supported by the significant 
difference in CDR3 length and mutational load. 
While differential effects of alemtuzumab on PC populations or their niche components cannot 
be entirely excluded, the reciprocal persistence of CD19Neg PCs following B-cell depletion is 
again empiric data supportive of greater life span in this PCs population relative to CD19Pos 
PCs. This is supported by another recent study by Mei et al., where similar findings were noted 
following B-cell depletion with rituximab (155). Furthermore the data indicate that over the time 
course examined the CD19Neg population can be maintained in a fashion independent of 
variation in the CD19Pos PCs.  
Longevity of plasma cells is supported by extrinsic factors supplied by microenvironmental 
survival niches (51). However the stability of antigen specific immune responses in human 
supports an element of lifespan programming, determined by the nature of inciting immune 
response. A unifying theory would be that factors intrinsic to PCs, which are established during 
initial PC differentiation, determine subsequent affinity for survival niches, which in turn promote 
PCs survival. The presence of higher levels of anti-apoptotic factor BCL2 and lower levels of the 
death receptor CD95 in CD19Neg PCs could reflect an intrinsic survival advantage to this PC 
population. Indeed in mouse expression of BCL2 family member MCL1 is essential for the 
generation of long-lived PCs (161). Of the surface markers identified as differentially expressed 
between CD19Pos and CD19Neg PCs, only CD28 has been mechanistically linked to PC longevity 
(156). CD28 has also been shown to be a pro-survival and apoptotic resistance mediator in 
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myeloma PCs through the PI3K/AKT/FOXO3a/BIM pathway (160), but CD28 is expressed in 
only one-third of myeloma patients (172). CD28 has been identified as a potential factor 
contributing to the longevity of murine PCs (173). However contradictory evidence has also 
been provided in other mouse models, in which deficiency of CD28 was found to lead to both 
increased plasma cell numbers and increased antibody production (174). Although detected 
only at low level in this analysis, normal CD28+ PCs were predominantly CD19Neg, potentially 
supporting an association between CD28 expression and longevity. However, CD28 was 
heterogeneous both in relation to CD19 and within the CD19Neg PC population. Furthermore in 
some bone marrow aspirate samples, in which PCs in general were well represented, CD28 
expressing PCs were undetectable. Thus the detailed analysis of PC phenotypes suggests a 
highly selective role for CD28 in human bone marrow PC, but would not lend support to the 
argument that CD28 provides a general determinant of normal bone marrow PC survival or 
function in human. Further studies are necessary to determine the factors contributing to the 
heterogeneity of CD28 expression on normal human PC populations.  
In the context of in vitro model systems of human PC differentiation, CD19NegCD138Pos PCs are 
predominantly generated early during initial maturation from the CD19PosCD38Pos PB state, and 
are not generated substantially as a sequential process through loss of CD19 from 
CD19PosCD138Pos PCs. CD19NegCD138Pos PCs generated early can persist in this state and can 
be maintained independently of the bulk CD19Pos PC population for substantial periods of time. 
The identification of CD19Neg PBs in the peripheral blood at steady state and during active in 
vivo immune responses supports such an early divergence of CD19Pos and CD19Neg cell states 
as a feature of antibody secreting cells generated during in vivo immune responses. This 
complements the previous work which showed the presence of CD19Neg PBs in the bone 
marrow and peripheral blood (175), and the identification of CD19Neg PCs amongst inflammatory 
infiltrates (155). 
Several lines of evidence point to the possibility that CD19Neg PCs include the long-lived bone 
marrow PC populations in human. Consistent with such a proposal CD19Neg PCs increase with 
time amongst in vitro long-lived PCs and can be maintained independently of the CD19Pos PC 
pool, consistent with a greater potential for longevity. However CD19Neg PCs are generated 
within 3-4 days of the PB state in vitro, and CD19Neg PBs exist as an identifiable population in 
the peripheral blood at steady state and post vaccination in vivo although it needs further 
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confirmation with determining antigen specificity of the CD19Neg PBs. Thus absence of CD19 
alone in a PC population should not be taken as prima facie evidence of PC “age” but instead 
may reflect a greater potential for extended life-span. 
The data presented here, and that of Mei et al. (155), indicate that bone marrow PCs are not a 
uniform population but include subsets with differential protein expression and generation 
kinetics, different longevity after B-cell depletion, and with a non-overlapping immunoglobulin 
repertoire. Although neoplastic PCs are readily distinguishable from normal PC subsets, they 
share more features in common with normal CD19Neg PCs than with normal CD19Pos PCs. 
CD19Neg PCs can be generated early in vitro and also identified during immune response to 
vaccination. Identifying the developmental pathway of normal CD19Neg PCs is therefore likely to 
improve our understanding both of autoimmune B-cell disorders and the oncogenic process in 
myeloma and other neoplastic processes, as well as greatly enhancing understanding of the 
development of long-lived humoral immunity. 
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11 Discussion 
The role of B-cells in RA pathogenesis is a fundamental question in RA biology. The purpose of 
this work was to address aspects of this question, concentrating on the relationship between 
phenotypic memory B-cell sub-populations, autoantigen specificity and prediction of response to 
and relapse following BCDT. This has been facilitated in Leeds by the availability of a 
combination of clinical samples from one of the largest RA cohorts in Europe, a novel in vitro B-
cell differentiation assay to explore B-cell function and flow cytometry expertise. There are two 
major strands to the line of investigations. First, given that ACPA antibodies are strongly 
associated with RA, a major aim is to determine whether ACPA specific populations in memory 
B cells, plasmablasts and plasma cells may be associated with disease expression and relapse. 
Second, phenotypic markers for long-lived PCs were sought since short and long-lived PCs are 
differentially involved in RA and other autoimmune disease pathogenesis, and with the eventual 
future aim of testing whether ACPA secretion would be correlated with a distinct phenotypic 
subset 
11.1.1 Markers used for flow cytometric phenotyping of memory B-cell 
subsets 
Flow cytometric phenotyping for surface molecule expression and utilising expression profiles to 
identify novel B-cell subsets are techniques that have been successfully used in the past in 
autoimmunity to identify markers of disease response. In this study I found CD24, CD95, CD84 
and LAIR1 to be of particular value in fractionating peripheral blood memory B-cells into 
phenotypic subsets. To my knowledge the co-ordinated regulation of these surface proteins has 
not been previously studied, but their common association with signal transduction pathways 
would be in keeping with a potential for differential response within linked B-cell sub 
populations. 
CD24, a glycophasphatidylinositol (GPI)-anchored membrane sialoglycoprotein is considered to 
be a redundant costimulatory molecule in lymphoid tissues. It is overexpressed by multiple solid 
organ tumours and is a marker for diagnosis and poor prognosis (176). CD24 has been 
    268 
 
 
considered as a genetic checkpoint in T-cell homeostasis and a SNP has been shown to be of 
increased frequency in RA patients (177).  
CD95 (Fas) is a death receptor expressed by B-cells on activation and plays an important role in 
elimination of non-specific and autoreactive cells in the GC (178). CD95 mediated death signal 
can be overcome by antigen-dependant (BCR) and antigen-independent (IL4) survival signals 
and defective function of CD95 has been described in RA (179).  
CD84 is a member of the CD2 subset of Ig superfamily and interacts in a homotypic fashion. 
The cytoplasmic tail contains tyrosine motifs which when phosphorylated interact with SHP2 
and SH2D1A, and are known to enhance IFN secretion in T-cells (180). It has also been shown 
to downregulate FcRε1 mediated signalling in mast cells independent of SH2D1A and SAP 
binding and therefore speculated to play a role in allergy and autoimmunity (181).  
LAIR1 is another Ig superfamily member expressed by most cells of the immune system with 
two ITIMs (Immunoreceptor tyrosine-based inhibitory motif) in its cytoplasmic tails. LAIR1 cross-
linking leads to downregulation of BCR mediated calcium flux and Ig and cytokine secretion 
(182). Reduced expression of LAIR1 described on lupus B-cells is suggestive of a role in 
autoimmune process (68). 
Memory B-cells are understood to be a markedly heterogeneous population (183). Previous 
studies have in particular identified FCRL4 (Fc Receptor-like 4) expressing subset of memory B-
cells (184). However these studies used in-house generated antibodies and it was not 
detectable when tested (data not shown) with the commercially available antibody (Biolegend), 
thus the relationship to this population could not be defined. However the FCRL4 subset is 
predominantly CD27 negative and therefore unlikely to be related to the CD27 positive memory 
B-cell populations that were observed in this study. 
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11.1.2 Skewing of memory B-cell subsets regulatory or inflammatory 
With detailed phenotyping of B-cells post-rituximab therapy, patients were found to show a 
skewed distribution of memory B-cell subsets prior to relapse. In controls and RA patients who 
have not been exposed to rituximab the dominant memory B-cell subset is CD24+84+95-LAIR1+ 
whereas in patients relapsing post-rituximab mediated B-cell depletion the inverse subset CD24-
84-95+LAIR1- was dominant. This skewing was unlikely to be a direct effect of depleting B-cells 
or specific to rituximab as it was not seen in patients treated with campath prior to renal 
transplant or rituximab for B-cell neoplasms. Therefore, a direct link with the underlying 
autoimmune process is most likely.  
Given that rituximab is likely to be acting via direct depletion of B-cells, and the skewing of the 
subset distributions was linked to RA relapse, a direct pathogenetic role for these B-cell subsets 
is a possibility. This would suggest that, either the usual dominant memory B-cell subset that is 
reduced during relapse is regulatory or the relapse-associated memory B-cell subset which is 
raised contains pathogenic cells. It would be unusual for BCDT to have such a good clinical 
response, if reduced regulatory B-cells played a key role in RA pathogenesis. Although a key 
role for regulatory B-cells has been proven in various models of autoimmunity in mice, the same 
has not been possible in humans (185). The lack of increased autoimmunity in patients with a 
primary antibody deficiency due to total absence of B-cells, X-linked agammaglobulinaemia 
(XLA) and the presence of autoimmune complications in more than one-third of patients with the 
other variant of primary antibody deficiency where B-cells are present – common variable 
immunodeficiency (CVID) (186) further questions the central role of regulatory functions 
dependent on B-cells in human autoimmunity. Indeed the closest stage of in vitro differentiation 
that matches the RA relapse associated subset is the day 4-5 activated B-cells. During this 
stage the B-cells are capable of secreting multiple proinflammatory mediators, which would 
favour a more direct pathogenic role. 
Sequential monitoring of the memory B-cell subsets following influenza vaccine revealed an 
increase in proportion of the relapse associated memory B-cell subset similar to that seen 
during relapse following rituximab in RA. However, the absolute count of the relapse associated 
subset did not increase but the count of the polar opposite, usual dominant subset decreased. 
This would suggest that the rise in the proportion of the RA relapse associated subset reflects a 
decrease in numbers of the other memory B-cell subsets, and the most likely explanation for 
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this given the short timeframes in the post vaccination follow up would be differential recruitment 
to the secondary lymphoid organs. Whether this applies to RA relapse is not clear, but 
differential homing and tissue localisation could certainly provide a plausible explanation for 
differences in peripheral blood representation. 
Functional analysis of the memory B-cell subsets was rendered technically challenging due to 
their very low absolute numbers in the peripheral blood of relapsing RA patients. The process of 
flow sorting was also limiting due to the poor yield and poor viability and function of the cells 
post sorting, the cause for which could be physical stress from the sort or the multiple antibodies 
used. While in the timeframe of this study it was not possible to extend to a functional analysis 
of the different B-cell subsets, this would certainly be the logical extension to further delineate 
the functional significance of these subsets. A combination of gene expression analysis, IGHV@ 
sequence analysis and functional studies with ELISpot could be envisaged to further address 
this issue. 
11.1.3 BCDT – Therapeutic experiment for enriching pathogenic B-
cells 
From vaccine studies, the frequency of antigen-specific memory B-cells has been estimated to 
be 1 in 10000 B-cells, which has been shown to be protective (50). This proves that memory B-
cells are effective even at low absolute numbers in the peripheral blood, although these cells 
may be present in antigen rich tissues and secondary lymphoid organs which cannot be 
quantified. The lack of expansion in proportion of the relapse-associated memory B-cell subset 
in rituximab naïve RA patients could be due to the masking effect of various memory B-cell 
specificities accrued through decades of immune responses populating the memory B-cell 
compartment. During relapse post-BCDT, the expanding memory B-cells are most likely derived 
from an ongoing/recent immune response which in the case of relapsing patients are likely to be 
related to RA and thus more likely to be pathogenic given the ongoing exposure to inciting 
autoantigens.      
11.1.4 Relapse associated memory B-cells – destiny  
The work reported here in defined a novel memory B-cell subset which was explored further in 
patients and the in vitro model system. Similar surface expression profiles for the four markers – 
CD24, CD84, CD95 and LAIR1- characterising the relapse associated memory B-cell subset 
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has been seen during in vitro differentiation of B-cells to plasmablasts and also on in vivo 
derived plasmablasts. Hence the relapse associated memory B-cell could also be considered as 
plasmablast-like but the plasmablasts express high levels of CD38 and lose CD20 expression 
whereas relapse associated memory B-cells do not. At present it is unclear whether this 
phenotype represents a dynamic intermediate state, or alternatively is a stably maintained 
phenotype linked to specific functional properties.  
Interestingly, if these cells are pre-plasmablasts, this profile was not captured during in vitro 
differentiation suggesting that if these are genuine pre-plasmablasts they derive from a set of in 
vivo conditions not mimicked in the in vitro system. Alternatively this subset may represent early 
post-GC B-cells destined to be memory B-cells and not seen in vitro due to lack of memory B-
cell differentiation in the in vitro system.  
The link between the surface expression profile and the autoimmune process can be speculated 
based on the fact that CD95, which is expressed by the relapse-associated memory B-cell 
subset, is an activation marker and CD84 and LAIR1 which are down-regulated are known to 
have regulatory properties. This would be consistent with a predicted phenotype for autoreactive 
cells during relapse, with increased expression of activation markers and down regulation of 
regulatory receptors. This subset could be similar to CD38Neg antibody secreting cells described 
in human tonsils as precursors of CD38Pos PCs (187) or short-lived CD38Neg PCs generated 
using a CD40L based in vitro differentiation system (188). If this subset is a precursor of short-
lived PCs which are pathogenic, this could be the key population targeted by BCDT and would 
explain the effectiveness of BCDT. The identification of antigen specificity of this population 
would support this hypothesis. Nonetheless the inability to functionally isolate these cells, and to 
perform precursor-product relationship studies to assess transitions into alternate phenotypic 
states, currently precludes firm conclusions. Again these questions could be addressed in 
downstream investigations. 
Whilst it is thought that the earliest events in RA may take place in the lymphoid organs, there is 
little doubt that the synovial environment in RA can sustain or exacerbate autoimmunity as 
shown by the presence of secondary lymphoid structures and ACPA secreting cells in the 
synovium (10). Therefore, the definition of the memory B-cells that are recruited and generated 
from these secondary lymphoid structures in the synovium is likely to provide further insights 
into role of B-lineage cells in pathogenesis and thereby identify potential biomarkers. The 
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phenotypic definition of the long lived PCs on the other hand would allow the analysis of the 
nature of ACPA secreting PCs generated from the synovial lymphoid structures and resident in 
the bone marrow which might have different roles in RA pathogenesis.    
11.1.5 Detection of citrullinated protein-specific B-lineage cells has 
been challenging 
The principle antigen specificity that would have allowed a firm conclusion relating to a 
pathogenic role for distinct B-cell subsets would have to be demonstration of specificity to 
citrullinated proteins. This was the target of significant but ultimately unsuccessful 
experimentation. Although ELISA of culture supernatants of purified peripheral blood B-cells 
from RA patients positive for ACPA proves the presence of ACPA-specific B-cells in the 
periphery. However ELISpot failed to detect the ACPA secreting cells due to a technical issue in 
that the CCP did not bind to the ELISpot plate as shown in Figure  6.3-3. To resolve this issue 
the options were to pre-coat with Streptavidin and attach biotinylated-CCP to the plate or use 
the biotinylated-CCP as a probe. Streptavidin binding will also increase the affinity due to 
tetramerisation of the peptide. However the ELISpot assays were further hampered by the lack 
of positive controls in the form of ACPA secreting cells. 
Lack of detection of citrullinated protein-specific cells by flow cytometry is likely to be due to the 
low frequency of these cells (50), low-affinity to the monomeric peptide (189) and non-specific 
binding hampering the detection. Pre-enrichment for B-cells has been used to improve the 
sensitivity and dual fluorochrome tagging of a non-specific peptide and excluding cells positive 
for both fluorochromes has been shown to be an elegant and effective solution to exclude non-
specific binding (82). Tetramerisation of the peptide has the additional benefit of improving the 
affinity of the BCR for the peptide. 
The technical difficulties in identifying citrullinated protein-specific B-cells are reflected by the 
paucity of published literature. The only published method for detecting citrullinated protein-
specific B-cells in peripheral blood uses in vitro culture of RA B-cells and analysing the 
supernatants (85). However, this study required two rounds of strong stimuli, two-week culture 
and five-fold concentration of the supernatant for ACPA to be detected and as a consequence a 
high proportion of control samples were positive for ACPA secretion. In relation to this, the data 
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obtained in this study suggests an enhanced ability to detect ACPA secretion in vitro since a 
shorter stimulation and no supernatant concentration was required for detection. 
11.1.6 Role of B-NK cell interaction in RA pathogenesis 
The contact dependent B-cell driven NK cell expansion demonstrated in this study could be 
secondary to latent EBV entering lytic phase during plasmablast differentiation or a mode of B-
cell regulation by NK cells. EBV, which is known to be present at higher levels in RA peripheral 
blood and synovium could thus play a key role in breakdown of tolerance to citrullinated proteins 
and also perpetuate joint inflammation. LGL has been known to be triggered by chronic 
stimulation of NK cells and CD8 T-cells which could possibly be mediated by EBV containing B-
cells. Thus the NK cell stimulation and expansion driven by EBV containing B-cells in the 
synovium could play a key role in joint damage and might also have a role in the pathogenesis 
of LGL.         
11.1.7 Phenotype of Long-lived PCs and their role in RA pathogenesis 
Since, ACPA levels do not generally deplete with rituximab, the assumption is that ACPA is 
predominantly secreted by long-lived PCs. Substantial interest has focused on defining 
phenotypic characteristics that may allow identification of long-lived PCs. The analysis 
presented here demonstrates that normal bone marrow PCs are not a uniform population but 
comprise at least two subsets with differential protein expression and generation kinetics, 
different longevity after B-cell depletion, and with a non-overlapping immunoglobulin repertoire. 
This is also mirrored in recent work published by Mei et al. which reached similar conclusions.  
CD19 negativity identifies a subset of plasma cells that have a propensity for longer life span but 
does not necessarily represent aged PCs. CD19NegPCs are observed quite early in the in vitro 
differentiation system. Therefore, it is possible that CD19 negativity is determined quite early 
during the differentiation process, which could be linked to the strength of BCR signalling or the 
B-cell subset from which the PC was derived. The observed lower rate of decay in cell numbers 
of CD19Neg PCs compared to CD19Pos PCs in the in vitro long term culture is suggestive that the 
half-life of CD19Neg PCs is longer. Sequential monitoring of the sorted in vitro generated 
CD19Pos PCs does not support the hypothesis that CD19Pos PCs mature into CD19Neg PCs with 
time albeit in the limited time frame studied. However it does not exclude the possibility that 
CD19Pos PCs could mature into CD19Neg PCs with time in vivo. The controversy regarding 
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determinant of longevity of PCs is not resolved conclusively although in this in vitro system 
where all cells are provided equivalent support, the longevity is not determined by competition 
for niches.  
While ACPA secretion may derive predominantly from long-lived, and presumably CD19Neg PCs, 
change in ACPA levels does not correlate with clinical response. This argues against a direct 
role in pathogenesis. In contrast, the level of rheumatoid factor decreases with B-cell depletion 
and rises during relapse (39). A unifying model would be that ACPA secreted by long-lived PCs 
are weakly pathogenic on their own and is markedly enhanced with cross-linking by rheumatoid 
factor secreted by short-lived PCs.  
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12 Conclusions and Future directions 
The initial aim of identifying the citrullinated protein-specific B-cells was achievable by ELISA 
from culture supernatants but other strategies such as ELISpot and direct identification by flow 
cytometry which has potential to be used as a biomarker turned out to be far more challenging. 
This can be further pursued by  
• Using citrullinated protein or peptide tetramers (82) for detection and their confirmation 
by single cell sorting and sequencing the immunoglobulin gene to be expressed in a 
hybridoma. 
• Investigating for the presence of citrullinated protein specific B-cells in the synovium and 
lymphoid organs such as bone marrow which is likely to overcome the issue of their low 
frequency in the peripheral blood. 
• EBV transformation of B-cells from RA patients to generate clones that secrete ACPA 
which can be used as a positive control.   
A novel CD24-CD84-CD95+LAIR1- memory B-cell subset was identified to be relatively 
expanded in RA patients relapsing post-rituximab which was not seen in other instances of B-
cell depletion for non-autoimmune conditions  suggestive of a direct role in RA pathogenesis.  
This exact phenotype was not detected in vitro or other lymphoid organs or sites of 
inflammation. The functional significance of this expanded memory B-cell subset prior to relapse 
still remains incompletely understood. This can be evaluated further by: 
• Clinical samples collected longitudinally from patients undergoing BCDT to validate the 
data obtained from the initial dataset. 
• Secretion of IgG, TNFα and ACPA by this subset by ELISpot with improved flow sorting 
techniques and availability of positive control for ACPA secreting cells. 
• Gene expression profiling of relapse-associated memory B-cells, the usual dominant 
memory B-cells and plasmablasts. 
• Evaluation of RA synovial B-cells obtained by synovial biopsy during relapse and 
remission to understand whether the skewing of memory B-cell subsets is due to spill 
over from or recruitment into the synovium. 
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The performance of gene expression profiling could be limited by the low frequency of these 
cells in peripheral blood. This can be circumvented by using highly sensitive amplification base 
methods, as used for single cells, or if required, by pooling of samples from clinically similar RA 
patients. Since this subset is also seen in healthy volunteers, using leukapheresis samples from 
blood donors would allow conclusions relating to the general functional properties of these cells 
if not their inflammatory associations.  
The closest phenotype in vitro to this relapse associated subset was the activated B-cell stage 
during which the cells secrete pro-inflammatory mediators and are in the process of 
differentiating to plasmablasts and the synovial fluid B-cells also exhibit similar expression levels 
for most of the markers. The secretion of proinflammatory mediators could be studied further by 
multiplex analysis of the supernatants from RA B-cell cultures from different clinical groups and 
controls.  
TIM3 was expressed in vitro during the stage of B-cell differentiation when they secrete 
inflammatory mediators. The assays to delineate the functional role of TIM3 in B-cells were 
largely unsuccessful. TIM3 has not been studied on B-lineage cells so far and this could be of 
potential relevance to RA, other B-cell mediated autoimmune disorders, B-cell neoplasms and 
normal B-cell biology. This can be addressed by: 
• Confirming the presence of TIM3 protein with different antibody clones and different 
techniques such as western blot, and RNA by real-time PCR. 
• Confirming the presence of TIM3 expression on B-lineage cells in vivo by 
immunohistochemistry. 
• Repeat evaluation of the role of galectin-9 by sourcing the protein from different labs on 
B-cell life span and differentiation in vitro. 
Long-lived plasma cells are likely to be CD19Neg as shown by delay in reconstitution in vivo and 
slower decay of CD19Neg PCs during long-term in vitro culture. The in vitro findings were 
suggestive of the CD19Neg PCs being generated early and independent of CD19Pos PCs and 
there was also some evidence that CD19Neg PBs could be generated early in vivo during a 
controlled immune response. It would be important to extend these studies to: 
• Prove the longevity of CD19Neg PCs by detecting vaccine-specific cells within this subset 
by ELISpot. 
    277 
 
 
• Confirm the generation of CD19Neg PBs early during an immune response by assessing 
their antigen specificity and also assessing for their presence in lymphoid organs. 
• Gene expression profiling of CD19Neg and CD19Pos PCs to identify differential expression 
of survival factors and possible targets on short and long-lived PCs. 
• Confirm the lack of CD19 in the in vitro CD19Neg PCs by time-lapse confocal microscopy 
and western blot of cytoplasmic and membrane fractions. 
 
There was an unexpected finding of B-cell mediated contact-dependant upregulation of NK cells 
that has not been studied in detail before. Although this was beyond the scope of the project, it 
has potential relevance in various fields including cancer biology, autoimmunity, 
immunodeficiency and basic B&NK-cell biology. There was also a suggestion of NK cell 
mediated death of B-lineage cells which needs further confirmation with functional NK cell 
cytotoxicity assays. There is a potential role for EBV in this interaction which could be studied 
further by preselecting EBV negative B-cells for differentiation with NK cells. This interesting 
topic can be further evaluated by 
• Analysis of NK cell activation markers and markers of degranulation such as LAMP1 as 
well as supernatants for the presence of NK cell secreted cytokines such as IFNγ and 
TNFα.  
• Evaluation of the cytotoxicity of the in vitro expanding NK cells on B-cell lines. 
• Confirmation of the presence of EBV RNA by real-time PCR and proteins by western 
blot. 
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14 Appendices 
14.1 Supplementary Data 
14.1.1 Expansion of non-B lineage cells is operator independent 
The culture conditions are changed on day 6 which includes adding 3 different cytokines at 
specific concentrations and 3 different nutrients on top of a stromal cell layer. To exclude the 
possibility of operator dependent variability causing the expansion, on day 6 the cells were 
cultured with media made by self and media prepared by an independent experienced operator. 
There was a similar expansion with both sets of media with the non-B lineage cells expanding 
from less than half a percent on day 6 to more than 40 percent in both cases by day 13. 
 
 
Figure  14.1-1Operator independent expansion of non-B lineage cells 
The proportion and absolute count of non-B lineage cells on the days specified with media 
prepared by self (Std) and media prepared by an experienced operator (Alt). 
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14.1.2 Expansion of non-B lineage cells is not due to dilution of the 
initial seeding concentration of cells  
To assess whether the dilution in the initial seeding concentration is responsible for the noted 
expansion between days 6 and 13, B-cells were differentiated from 2 volunteers at standard and 
one-fifth concentrations. The higher starting dilution did not cause increased expansion as seen 
in Figure  14.1-2. In fact the higher starting concentration yielded more expansion between day 6 
and day 13. This suggests that cell density is a significant determinant of CD19 negative cells 
expansion, possibly consistent with a cell contact mediated effect.  
 
 
Figure  14.1-2 Effect of standard and 1/5th Initial seeding concentrations on non-B lineage 
cell expansion  
Percentage of non-B lineage cell expansion with standard and 1/5th starting cell 
concentrations from 2 donors is shown. 
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14.1.3 Expansion of non-B lineage cells is worse with a 48 well plate 
compared to 24 well plate. 
The other variation from the standard protocol for differentiating RA B-cells was to use 48 well 
plates instead of 24 well plates to try and reduce the volume of blood needed to be collected 
from patients. The initial seeding concentration was reduced by half for a 48 well plate to 
account for the difference in surface area of the 24 well plate. Although the increase in absolute 
numbers of non-B lineage cells was not dramatic, when the fold expansion of the non-B cells 
from day 0 and day 6 is compared between the two conditions, it becomes clear that the 
expansion is favoured by the 48 well plate.  
 
Figure  14.1-3 Favourable expansion of non-B lineage cells when differentiated on a 48 
well plate 
B-cells from 2 donors were differentiated in parallel on a 24 and 48 well plate and the 
change in number of non-B lineage cells is shown in the first graph. Fold increase from 
day 0 shown in the second graph was calculated as: (Number of cells on day 10 or 6 from 
a single day 0 well) / (Number of cells that started in a single day 0 well) 
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14.1.4 Expansion of non-B lineage cells can be reduced by swapping 
from 48 to 24 well plate between day 6 to day 10 
Since there was increased expansion of non-B lineage cells with a 48 well plate between day 6 
and day 10, the possibility of overcoming this effect by swapping the plates on day 6 was 
evaluated. Cells differentiated in 24 and 48 wells in parallel were either continued on the same 
sized plate or swapped to the alternative plate. There was more expansion of the non-B lineage 
cells when the cells were swapped from 24 well plate to a 48 well plate on day 6 as evidenced 
by the comparison of fold increase in non-B cells from day 0 to day 10 when they were grown in 
24 well plate throughout. It is not as evident in the donor who started with much lower number of 
non-B cells on day 0. Conversely the expansion could be reduced by swapping from a 48 well 
plate to a 24 well plate in both donors. 
 
 
Figure  14.1-4 Reduction in Expansion of non-B lineage cells by swapping to a 24 well 
plate on day 6 
Expansion of non B-lineage cells when they are cultured throughout on 24 or 48 well 
plates compared with swapping plates on day 6. The numbers shown in tables are fold 
expansion on day 10 from day 0 calculated as (Number of CD19 negative cells on day 10 
from a single day 0 well) / (Number of CD19 negative cells that started in a single day 0 
well) 
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14.1.5 Summary 
The above experiments show that non-B lineage cell expansion is unlikely to be an operator 
dependent issue and not due to seeding the cells at a lower concentration. However, it is made 
worse by using smaller sized wells for the culture and therefore subsequent experiments were 
performed in a 24 well plate. 
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14.2 Appendix A – Reagents used 
Reagent Source Constituents 
Lymphoprep Axis-Shield Sodium diatrizoate - 9.1% (w/v) 
Polysaccharide – 5.7% (w/v) 
Ammonium Chloride Sigma-
Aldrich 
8.6g/l in distilled water 
FACSflow  BD 
Biosciences 
 
Bovine Serum Albumin Sigma 
Aldrich 
0.5% in FACSflow 
Human Memory B-cell 
Isolation Kit  
Miltenyi 
Biotec 
Biotin Antibody cocktail- Biotinylated mAb 
against CD2,CD14, CD43, CD16, CD36, Anti-
IgE,CD235a 
Microbead conjugated to monoclonal antibiotin 
antibodies 
 
Human NK cell Isolation KIt Miltenyi 
Biotec 
NK cell biotin antibody cocktail 
NK cell microbead cocktail 
IMDM (Iscove's Modified 
Dulbecco's Medium) 
 
GIBCO Glycine 30 mg/L 
L-Alanine 25 mg/L 
L-Alanyl-L-Glutamine 812 mg/L 
L-Arginine hydrochloride 84 mg/L 
L-Asparagine (freebase) 28.4 mg/L 
L-Aspartic acid 30 mg/L 
L-Cystine 70 mg/L 
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L-Glutamic Acid 75 mg/L 
L-Histidine hydrochloride-H2O 42 mg/L 
L-Isoleucine 105 mg/L 
L-Leucine 105 mg/L 
L-Lysine hydrochloride 146 mg/L 
L-Methionine 30 mg/L 
L-Phenylalanine 66 mg/L 
L-Proline 40 mg/L 
L-Serine 42 mg/L 
L-Threonine 95 mg/L 
L-Tryptophan 16 mg/L 
L-Tyrosine disodium salt 104 mg/L 
L-Valine 94 mg/L 
Biotin 0.013 mg/L 
Choline chloride 4 mg/L 
D-Calcium pantothenate 4 mg/L 
Folic Acid 4 mg/L 
Niacinamide 4 mg/L 
Pyridoxal hydrochloride 4 mg/L 
Riboflavin 0.4 mg/L 
Thiamine hydrochloride 4 mg/L 
Vitamin B12 0.013 mg/L 
i-Inositol 7.2 mg/L 
Calcium Chloride (CaCl2-2H2O) 219 mg/L 
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Magnesium Sulfate (MgSO4-7H2O) 200 mg/L 
Potassium Chloride (KCl) 330 mg/L 
Potassium Nitrate (KNO3) 0.076 mg/L 
Sodium Bicarbonate (NaHCO3) 3024 mg/L 
Sodium Chloride (NaCl) 4500 mg/L 
Sodium Phosphate monobasic (NaH2PO4-
2H2O) 141 mg/L 
Sodium Selenite (Na2SeO3-5H20) 0.017 mg/L 
D-Glucose (Dextrose) 4500 mg/L 
HEPES 5958 mg/L 
Phenol Red 15 mg/L 
Sodium Pyruvate 110 mg/L 
Penicillin Streptomycin Invitrogen Penicillin 5000 units 
Streptomycin 5000 μg/ml 
Trypsin-EDTA 
 
Invitrogen 
 
Trypsin      2.5 g/L  
EDTA      0.38 g/L 
Flow Cytometry Absolute 
Count Standard 
Invitrogen 
Countbright 
Beads 
0.49 - 0.51 X 105 particles/50µL 
Blocking Buffer In-house FACS Buffer 933 µL 
Normal Mouse Serum 50 µL  
Human IgG 16.7 µL 
Human IgG Sigma-
Aldrich 
Human IgG >95% 4.7 mg/ml 
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Normal Mouse Serum Invitrogen  
Hybridomax Gentaur DMEM/F12 base, HEPES buffer, Insulin, 
Transferrin, Testosterone, Sodium selenite, 
Ethanolamine, saturated and unsaturated fatty 
acids and stabilising proteins 
Lipid Mixture 1, Chemically 
defined 
Sigma 
Aldrich 
Arachidonic acid   2 μg/ml  
Linoleic acid    10 μg/ml 
Linolenic acid    10 μg/ml 
Myristic acid   10 μg/ml 
Oleic acid   10 μg/ml 
Palmitic acid   10 μg/ml 
Stearic acid   10 μg/ml 
Cholesterol    0.22 mg/ml 
Tween-80   2.2 mg/ml 
Tocopherol acetate  70 μg/ml 
Pluronic F-68    100 mg/ml 
MEM Amino Acids (50X) 
Solution 
Sigma 
Aldrich 
L-Arginine.Hcl   6.32 g/L 
L-Cystine.2Hcl  1.564 g/L 
L-Histidine.Hcl.H20  2.1 g/L 
L-Isoleucine   2.625 g/L 
L-Leucine   2.62 g/L 
L-Lysine.Hcl   3.625 g/L 
L-Methionine   0.755 g/L 
L-Phenylalanine  1.65 g/L 
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L-Threonine    2.38 g/L 
L-Tryptophan   0.51 g/L 
L-Tyrosine    1.8 g/L 
L-Valine   2.34 g/L 
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14.3 Appendix B – Details of Antibodies used for flow cytometry  
Antigen Fluorochrome 
Volume Per 
Test (µL) 
Clone Manufacturer Isotype 
BCL2 FITC 2 124 Dako Cytomation IgG1 
CD10 PE 1 HI10a BD Biosciences IgG1 
CD117 PE-Cy7 5 104D2 BD Biosciences IgG1 
CD11c APC 1 B-ly6 BD Pharmingen IgG1 
CD126 Alexa Fluor 647 5 BL-126 Biolegend IgG1 
CD126 PE 5 M91 Immunotech IgG1 
CD13 PE 5 L138 BD Biosciences IgG1 
CD130 PE 5 AM64 BD Pharmingen IgG1 
CD137 APC 5 4B4-1 Biolegend IgG1 
CD137 LEAF  4B4-1 Bolegend IgG1 
CD137 Unconjugated  BBK-2 Thermo Scientific IgG1 
CD137L PE 5 5F4 Biolegend IgG1 
CD138 APC 1 B_B4 Miltenyi IgG1 
CD14 FITC 5 M5E2 BD Pharmingen IgG2a 
CD15 FITC 5 C3D-1 Dako IgM 
CD150 PE 5 A12 BD Pharmingen IgG1 
CD152 PE 5 BNI3 BD Pharmingen IgG2a 
CD16 PE 0.1 3G8 BD Pharmingen IgG1 
CD16 V500 5 3G8 BD Horizon IgG1 
CD184 PE 5 12G5 BD Pharmingen IgG2a 
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Antigen Fluorochrome 
Volume Per 
Test (µL) 
Clone Manufacturer Isotype 
CD19 BV421 1 HIB19 Biolegend IgG1 
CD19 PE 2 LT19 Miltenyi IgG1 
CD19 PE-Cy7 1 SJ225C1 BD Biosciences IgG1 
CD19 PerCP-Cy5.5 2.5 SJ225C1 BD Biosciences IgG1 
CD19 V500 5 HIB19 BD Horizon IgG1 
CD196 Alexa Fluor 647 5 11A9 BD Pharmingen IgG1 
CD2 LEAF  RPA-2.10 Biolegend IgG1 
CD2 PE-Cy7 1 RPA2.10 BD Biosciences IgG1 
CD20 APC-H7 2.5 L27 BD Biosciences IgG1 
CD20 efluor450 2.5 2H7 eBioscience IgG2b 
CD20 Pacific Blue 5 B9E9 IOTest IgG2a 
CD200 APC 5 OX104 Biolegend IgG1 
CD200 APC 5 OX104 eBioscience IgG1 
CD21 FITC 5 LB21 Serotec IgG1 
CD22 APC 1 S-HCL-1 BD Biosciences IgG2b 
CD23 APC 5 EBVCS-5 BD Biosciences IgG1 
CD24 FITC 5 ML5 BD Pharmingen IgG2a 
CD25 APC 5 2A3 BD Biosciences IgG1 
CD25 PE 5 2A3 BD Biosciences IgG1 
CD261 FITC 5 DR-4-02 Exbio IgG1 
CD27 AF 647 5 LT27 AbD Serotec IgG2a 
CD27 BV605 2.5 O323 Biolegend IgG1 
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Antigen Fluorochrome 
Volume Per 
Test (µL) 
Clone Manufacturer Isotype 
CD27 CF594 1 M-T271 BD Horizon IgG1 
CD27 FITC 5 M-T271 BD Pharmingen IgG1 
CD27 PE-Cy7 2.5 M-T271 BD Pharmingen IgG1 
CD27 Qdot605 2.5 CLB-27/1 Invitrogen IgG2b 
CD28 PE 5 L293 BD Biosciences IgG1 
CD3 APC 1 SK7 BD Biosciences IgG1 
CD3 APC-H7 2.5 SK7 BD Biosciences IgG1 
CD3 PE-Cy7 1 SK7 BD Biosciences IgG1 
CD307d APC 5 413D12 Biolegend IgG2b 
CD31 FITC 5 WM59 BD Pharmingen IgG1 
CD319 PE 5 162.1 Biolegend IgG2b 
CD34 APC 0.5 8G12 BD Biosciences IgG1 
CD37 FITC 5 M-B371 BD Pharmingen IgG1 
CD38 AF700 2.5 HIT2 Biolegend IgG1 
CD38 CF594 1 HIT2 BD Horizon IgG1 
CD38 PE 1 HB7 BD Biosciences IgG1 
CD38 PE-Cy7 0.1 HB7 BD Biosciences IgG1 
CD38 PerCP-Cy5.5 0.5 HIT2 BD Pharmingen IgG1 
CD39 FITC 5 A1 AbD Serotec IgG1 
CD4 PerCP-Cy5.5 5 SK3 BD Biosciences IgG1 
CD43 FITC 5 1G10 BD Pharmingen IgG1 
CD45 APC-H7 2.5 2D1 BD Biosciences IgG1 
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Antigen Fluorochrome 
Volume Per 
Test (µL) 
Clone Manufacturer Isotype 
CD45 V500 5 HI30 BD Horizon IgG1 
CD48 FITC 5 TU145 BD Pharmingen IgM 
CD49d FITC 5 44H6 AbD Serotec IgG1 
CD5 PerCP-Cy5.5 5 L17F12 BD Biosciences IgG2a 
CD54 APC 5 HA58 BD Pharmingen IgG1 
CD56 BV605 1 HCD56 Biolegend IgG1 
CD56 PE 5 NCAM16.2 BD Biosciences IgG2b 
CD56 PE-Cy7 2.5 NCAM16.2 BD Biosciences IgG2b 
CD56 V450 5 B159 BD Horizon IgG1 
CD57 FITC 5 HNK-1 BD Biosciences IgM 
CD58 PE 5 L306.4 BD Biosciences IgG2a 
CD58 LEAF  TS2/9 Biolegend IgG1 
CD61 APC 5 CLB-thromb/1 Caltag IgG1 
CD62L FITC 5 DREG-56 BD Pharmingen IgG1 
CD63 PE 5 H5C56 BD Pharmingen IgG1 
CD69 APC 5 L78 BD Biosciences IgG1 
CD73 PE 5 AD2 BD Pharmingen IgG1 
CD79b PE 5 CB3-1 IOTest IgG1 
CD8 APC 0.5 SK1 BD Biosciences IgG1 
CD80 PE 5 L307.4 BD Pharmingen IgG1 
CD81 FITC 5 JS81 BD Pharmingen IgG1 
CD84 PE 5 CD84.1.21 Biolegend IgG2a 
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Antigen Fluorochrome 
Volume Per 
Test (µL) 
Clone Manufacturer Isotype 
CD85j FITC 5 GHI/75 BD Pharmingen IgG2b 
CD86 APC 5 2331 (FUN-1) BD Pharmingen IgG1 
CD94 PE 5 HP-3D9 BD Pharmingen IgG1 
CD95 BV421 1 DX2 Biolegend IgG1 
CD95 Pacific Blue 5 LT95 Exbio IgG1 
CD95 PE 5 DX2 BD Pharmingen IgG1 
CXCR5 Alexa Fluor 647 5 RF8B2 BD Pharmingen IgG2b 
FCRL4 APC 5 580810 R&D Systems IgG1 
Galectin-9 LEAF  9M1-3 Biolegend IgG1 
HLA-DR FITC 5 G46-6 BD Biosciences IgG2a 
IgA FITC 5 Polyclonal Dako Fab2 
IgD PE 5 IA6-2 BD Pharmingen IgG2a 
IgD AF700 5 IA6-2 BD Pharmingen IgG2a 
IgG FITC 5 G18-145 BD Pharmingen IgG1 
IgM APC 5 G20-127 BD Pharmingen IgG1 
IRF4 Unconjugated 1 M-17 Santa Cruz Goat IgG 
Goat IgG AF488 1 Polyclonal Invitrogen Donkey IgG 
Kappa Pacific Blue 1 A8B5 Exbio IgG1 
Ki67 FITC 5 B56 BD Pharmingen IgG1 
LAIR1 Alexa Fluor 647 1 NKTA255 Biolegend IgG1 
LAIR1 Biotin 1.5 NKTA255 Abcam/Serotec IgG1 
LAIR1 PE 5 DX26 BD Pharmingen IgG1 
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Antigen Fluorochrome 
Volume Per 
Test (µL) 
Clone Manufacturer Isotype 
Lambda FITC 5 1-155-2 BD Biosciences IgG1 
TIM3 PE / LEAF 5 F38-2E2 Biolegend IgG1 
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14.4  Ethical Approval Forms and Consent Forms 
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